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SUMMARY
The aim of this thesis was to characterise the 
abnormalities of plasma lipoprotein metabolism which occur 
in the nephrotic syndrome in man.
Both quantitative and qualitative changes in plasma 
lipoproteins were documented in a series of 45 consecutive 
patients with heavy proteinuria. Patients with proteinuria 
less than the nephrotic range(<3g/24 hours) did not have 
any significant elevations in cholesterol concentrations 
compared to controls but there was a relationship between 
urinary albumin loss and blood cholesterol. Primary 
hyperlipidaemia was not associated with increased urinary 
albumin losses.
The duration and magnitude of postprandial lipaemia 
following an oral fat load were not significantly greater 
in a group of nephrotic subjects compared to controls. 
However, both groups showed a high degree of inter­
individual variation. The lipoproteins isolated in the 
d<1.006g/mL fraction following an oral fat load did not 
differ in composition between the two groups. Post-heparin 
lipase activities were not significantly different.
The transfer of apolipoprotein B along the delipidation 
cascade from very low to low density lipoproteins was
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investigated using radioiodinated lipoproteins. Overall, 
apoB synthesis in nephrotic syndrome was not greater than 
in controls although the range in the nephrotic group was 
wide(up to four times normal). There was a significant 
increase in the production of apoB into the smaller, 
triglyceride-poor VLDL^ density interval. Both VLDL^ and 
VLDL2 were cleared from the plasma at slower rates in the 
nephrotic syndrome. There was a modest increase in apoB 
transfer to LDL.
Studies of LDL metabolism revealed a consistent defect in 
fractional catabolism of LDL by the receptor-mediated 
pathway. LDL production was closely related to proteinuria 
and only rose when this exceeded lOg/day.
Inhibition of cholesterol synthesis with simvastatin 
produced dramatic falls in total and LDL-cholesterol in 
these subjects. Metabolic studies revealed a heterogeneous 
response with a majority of patients demonstrating 
increased catabolism of LDL but some showing reduced 
synthesis. Two serious and potentially worrying adverse 
events were witnessed during simvastatin therapy.
Particles corresponding to both HDL and LDL were isolated 
form urine collected from nephrotic subjects. The 
significance of this is uncertain but justified the 
corrections made for urinary LDL losses in the metabolic
18
studies and gives credence to the suggestion that filterd 
lipoproteins may be nephrotoxic.
The results of these studies are compared with the 
relatively few previous reports of lipoprotein metabolism 
in human nephrotic syndrome and the extensive literature on 
animal work. In man, catabolic defects appear to be at 
least as important as increases in lipoprotein production 
in the genesis of the hyperlipidaemia. However, some of 
the data is difficult to reconcile. Reasons for 
conflicting observations are discussed and areas requiring 
further research are highlighted.
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CHAPTER 1 INTRODUCTION
1.1 Background
Hyperlipidaemia has been recognised as a complication of 
renal disease since the 19th century(1). Epstein, however, 
was the first to report the specific association between 
the nephrotic syndrome and hyperlipidaemia(2). Despite 
extensive clinical and animal research, the precise 
disturbances of lipid metabolism which initiate and 
maintain the hyperlipidaemia in human nephrotic syndrome 
have not been clearly elucidated(3).
An understanding of the changes in lipoprotein metabolism 
is important for several reasons. Firstly, investigation 
of dyslipidaemias may lead to important advances in our 
knowledge of both normal and abnormal lipoprotein 
metabolism. This is well illustrated by the example of 
familial hypercholesterolaemia. Secondly, there is now 
considerable epidemiological, experimental and clinical 
evidence that hyperlipidaemia plays an important role in 
the evolution of coronary artery disease in the general 
population. Although the role of hyperlipidaemia in the 
pathogenesis of coronary disease in nephrotic syndrome is 
debated, a substantial proportion of patients with renal 
disease die of cardiac disease. There is a general 
consensus that, in subjects with unremitting nephrotic
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syndrome, hyperlipidaemia may accelerate atherosclerotic 
disease. Furthermore, recent experimental work suggests 
hyperlipidaemia may be implicated in the progression of 
renal failure. Finally, identification of the underlying 
metabolic defects permits therapy to be chosen on a 
rational basis thereby increasing efficacy and reducing the 
risk of adverse reactions.
The main aim of this thesis is to characterise the 
metabolism of apolipoprotein B-containing lipoproteins in 
human nephrotic syndrome. The fate of lipoproteins in the 
circulation has been investigated by labelling these 
particles and following their disappearance from the 
plasma. Application of multicompartmental modelling 
analysis generates a number of parameters describing the 
kinetic behaviour of lipoprotein subfractions. This 
permits comparisons with control subjects. In addition, a 
number of other related issues are considered including the 
relationships between proteinuria and lipid disturbances; 
treatment of nephrotic hyperlipidaemia; the effects of 
therapy on lipoprotein structure and metabolism; and 
urinary excretion of lipoproteins.
1.2 Lipoproteins - classification
Lipids are used by cells for a wide range of functions 
including membrane synthesis, hormone production and energy
21
requirements. The liver and intestine are the main sites 
of lipid synthesis and a directed and efficient transport 
mechanism has evolved in man and other species for their 
dispersion to other tissues. Neutral lipids(cholesterol 
esters, triglycerides) are hydrophobic and can only be 
transferred through the aqueous environment of plasma in 
macromolecular complexes containing protein 
(apolipoproteins) and more polar lipids(phospholipids). 
These "lipoproteins" form a spectrum of particles which can 
be divided into a number of classes according to differing 
physical and/or chemical properties.
The basic structure of a lipoprotein is shown in figure 
1.1. It consists of a hydrophobic core of neutral lipids 
surrounded by a surface monolayer of protein and 
phospholipid. The polar regions of the latter are directed 
to the surface of the particle and facilitate its 
solubilisation in plasma. The more hydrophobic regions 
abut on the core lipid. Free cholesterol molecules occupy 
a position intermediate between these two parts of the 
micellar structure.
A number of classifications have been proposed for 
lipoproteins. The most common is that based on hydrated 
density and ultracentrifugal characteristics. This 
approach was developed during the 1950's by Gofman,
Lindgren and co-workers(reviewed in 4) who identified
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several discrete classes using a step-wise increase in 
background density to float lipoproteins in the
ultracentrifuge. The procedure is still widely used today
for preparative work although it is slow, labour-intensive 
and may result in apolipoprotein losses during 
centrifugation. Five main lipoprotein classes were 
recognised - chylomicrons, very low density(VLDL), 
intermediate density(IDL), low density(LDL) and high 
density(HDL) lipoproteins. The chemical composition and 
physical characteristics of particles within these 
subgroups are shown in tables 1.1 and 1.2. In recent 
years, the application of increasingly sophisticated 
techniques has led to the identification of structurally
discrete subgroups within these classes.
Lipoprotein particles may also be defined by their
flotation rates in the analytical centrifuge at a fixed
background density. Lower density lipoproteins are
separated by this method at a background density of
1.063g/mL; a density of 1.210g/mL is used for high density
lipoproteins. The flotation rates are measured in Svedberg
-13units(cm/sec/dyne/g x 10 ) and the rates corresponding to
the various lipoprotein classes are given in table 1.1.
From these initial methods, a number of developments have 
led to quicker and more accurate means of isolating intact 
lipoproteins, particularly for preparative work. The use
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of swing-out bucket instead of fixed angle rotors reduces 
errors in separation due to lipoproteins impacting on the 
tube wall. The centrifugal force is generated along, 
rather than at an angle to, the long axis of the tube. 
Patsch(5) developed the technique of rate zonal 
ultracentrifugation where a linear gradient of increasing 
density(continuous or step-wise) is produced in a large 
capacity bowl rotor using a pump. This permits rapid and 
sensitive resolution of lipoproteins for both analytical 
and preparative purposes. Similarly, the use of pre­
determined density gradients in swing-out rotor centrifuge 
tubes has been used to isolate rapidly lipoproteins from 
small quantities of plasma(density gradient 
ultracentrifugation - DGUC). Both of these techniques are 
used in this thesis and are described in more detail in 
methods.
Other chemical and physical properties have been used to 
separate and classify lipoprotein particles.
Electrophoresis has been employed for more than 60 years to 
separate particles according to differences in size:charge 
ratio using a variety of matrix supports(paper, agarose, 
polyacrylamide). Three classes are identifiable by agarose 
gel electrophoresis(alpha, beta and pre-beta) which 
correspond approximately to HDL, LDL(including IDL) and 
VLDL. Chylomicrons are excluded from the gel by their large 
size and remain at the origin. This was the technique used
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by Fredrickson et al.(6) to classify the common 
dyslipidaemias(table 1.3). This classification has many 
limitations which have been highlighted by advances in 
molecular biology. The lipoprotein patterns described do 
not represent homogeneous groups but rather the phenotypic 
expression of a number of genetically- and environmentally- 
determined defects which cannot be differentiated by 
electrophoretic methods. Fredrickson's classification is 
still widely used to describe lipoprotein patterns and, 
until further progress is made on the underlying metabolic 
defects of hyperlipoproteinaemias, it is unlikely to be 
superseded.
Particle size alone may be used to differentiate the plasma 
lipoproteins using molecular sieve gels of different pore 
size(7). Although this method is sensitive and has 
excellent resolution, it is not easily adapted for routine 
analysis of samples. Similarly, electron microscopy of 
negatively-stained lipoprotein samples allows direct 
visualisation of particles and measurement of sizes but is 
time-consuming, technically difficult and therefore not 
suitable for widespread use.
Gustafson and Alaupovic(8) were the first to propose a 
classification of the lipoproteins on the basis of their 
constituent apolipoproteins in the 1960's. The merit of 
this approach is that it emphasises the relationship
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between lipoprotein structure and metabolism/function. The 
protein content of particles plays a crucial role in 
regulating lipoprotein metabolism in vivo.
1.3 Lipoproteins - physical and chemical characterisitics
Chylomicrons are the largest lipoprotein particles varying 
in diameter from 35 to >200nm. In normal individuals, 
chylomicrons are virtually absent in the fasting state.
They are formed in the intestinal epithelial cells and 
their main lipid content, triglyceride, is synthesised from 
re-esterification of dietary monoglycerides and fatty 
acids. Triglycerides represent 90% by weight of 
chylomicrons. Protein accounts for 1-2% of the mass and 
the remainder is composed of phospholipid, cholesterol 
ester and free cholesterol in decreasing proportion. They 
contain apolipoproteins B48, A-I, A-IV and C initially. 
Other apoC's and apoE are acquired from HDL or VLDL 
particles in the lymphatic or systemic circulation.
Very low density lipoproteins are similar to chylomicrons 
with triglyceride as the main lipid constituent. These 
particles are secreted by hepatocytes and range in size 
from 35-75nm with a hydrated density <1.006g/mL. 
Apolipoproteins B-100, CII, CIII and E are the main protein 
constituents and have important regulatory roles in the 
catabolism of these particles.
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Intermediate density lipoproteins(d=l.006-1.019g/mL) 
represent a transition from VLDL to LDL particles as a 
result of delipidation of the triglyceride moiety. They 
represent a small proportion of the circulating lipoprotein 
mass.
Low density lipoproteins are the main cholesterol-carrying 
lipoprotein in man and account for 70% of circulating 
cholesterol. They play a crucial role in cholesterol 
transport but are also associated with an increased risk of 
coronary artery disease when present in excess. Plasma 
levels of LDL are much higher in humans than comparable 
mammals and it has been postulated that this is the reason 
for our propensity to atherosclerosis. Apolipoprotein B100 
is the main protein constituent accounting for 25-30% of 
particle mass. Recent evidence suggests that particles in 
the LDL density range(d=l.019-1.063g/mL) exist as several 
species with distinct structural and possibly metabolic 
characteristics(9) .
High density lipoproteins are the most abundant lipoprotein 
particles(10) in human plasma although they only carry 
approximately 2 0% of circulating cholesterol. 
Epidemiological evidence suggests that HDL-cholesterol 
levels are inversely correlated with coronary heart 
disease. These particles are small and dense compared to 
other lipoproteins(d=l.063-1.210g/mL; particle size
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5.5-12.Onm). A number of different species have been 
identified but in man HDL2 (d=l.063-1.125g/mL) and 
HDL^(d=l.125-1.210g/mL) are the commonly recognised 
subclasses. Phospholipid and cholesterol ester are the 
main lipid constituents which are complexed with 
apolipoproteins AI and All. Small amounts of other 
apolipoproteins(CI-III, D and E) may also be present.
1.4 The apolipoproteins
Because of their crucial role in maintaining the integrity 
and solubility of lipoproteins and regulating their 
metabolism, the apolipoproteins will be considered in some 
detail. The physicochemical properties and known 
physiological roles of these proteins are listed in table 
1.4.
Apolipoprotein B in man exists in two forms designated B48 
and B100. B100 is the predominant form. Its complete
amino acid sequence has recently been reported(11). In 
plasma, it exists as a glycoprotein with a molecular weight 
of approximately 555000 daltons which is close to that 
calculated from its sequence - 512937 daltons. ApoB is 
highly insoluble in aqueous solution which has considerably 
hindered investigations into its biochemistry and function. 
B100 is secreted by the liver in VLDL particles on a 
one-to-one molar basis and transferred along the
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delipidation cascade(see below) to LDL. In contrast to 
other apolipoproteins, it does not participate in exchanges 
between plasma lipoproteins. This unique property has been 
utilised to investigate the metabolism of apoB-containing 
lipoproteins in tracer experiments. ApoBlOO acts as a 
ligand for the apoB/E receptor. Recent evidence suggests 
that variants of apoBlOO which are poorly bound by 
receptors may be an important cause of hyperlipidaemia in 
the population(12).
ApoB48 in man is synthesised by intestinal cells and 
incorporated into chylomicrons. It is antigenically 
related to apoBlOO although it does not bind to apoB/E 
receptors. It represents a truncated form of B100 which 
arises as a result of post-transcriptional editing of 
apoB mRNA(13).
ApoAI, the predominant protein of HDL, is produced by 
hepatic and intestinal cells and accounts for 70% of the 
protein content of HDL. Its main metabolic roles are as a 
co-factor for the enzyme, lecithin cholesterol acyl- 
transferase(LCAT), and in promoting cholesterol efflux 
from tissues. A number of defective apoAI variants have 
been described and some of these appear to be functionally 
less effective(e.g. as activators of LCAT). ApoAII is the 
second commonest protein in HDL. No physiological role for 
apoAII has been determined in man. ApoAIV was originally
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identified in the rat but has been found in human plasma, 
mostly as free apolipoprotein, and in the intestinal 
mucosa.
The C class of apolipoproteins contains three forms - Cl, 
CII and CIII. These are present in small quantities in 
VLDL and HDL particles. CII has an important role as a 
co-factor for lipoprotein lipase. No definite role for 
apoCI has yet been established. ApoCIII is a glycoprotein 
with a variable content of sialic acid residues which 
permits resolution into three subclasses by isoelectric 
focusing. Both in vitro and in vivo apoCIII inhibits 
lipoprotein and hepatic triglyceride lipase(14).
Much attention has been focused in recent years on apoE 
with the discovery of three common isoforms in the 
population. Isoelectric focusing has been used to 
identify E2, E3 and E4(15). Each is the product of a 
single gene which has three common alleles. The result is 
the appearance of six phenotypes which are, in decreasing 
order of frequency, E3/3, E4/3, E3/2, E4/2, E4/4 and E2/2. 
ApoE is an important ligand for both the B/E receptor and 
the putative chylomicron remnant receptor. It has a much 
higher affinity for the B/E receptor compared to apoB.
This is attributed to interactions occurring at multiple 
binding sites between these molecules. The isoforms of 
apoE differ in their in vitro binding to apoB/E receptors
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and this influences in vivo VLDL -> LDL transfer(see 
below). ApoE is present in VLDL and HDL. It is mainly 
synthesised in liver although many organs have been 
documented to produce small quantities.
Apolipoprotein(a) is a recently identified protein which is 
not strictly an apolipoprotein but is the characteristic 
component of a discrete group of lipoprotein particles 
known as Lp(a). These are apoB-containing lipoproteins 
which float at a density varying between 1.050-1.082g/mL 
and exhibit pre-beta mobility on electrophoresis. Recent 
studies have revealed that Lp(a) is an LDL-type particle 
with an extra glycoprotein molecule(apo(a)) linked to the 
apoB moiety by a disulphide bridge(16). Apo(a) shows 
considerable sequence homology with plasminogen(16). 
Plasminogen consists of a number of protein units known as 
kringles and an active protease site for cleaving 
fibrinogen. Apo(a) is now known to consist of an inactive 
protease region linked to a kringle 5 unit of plasminogen 
with a variable number of kringle 4 units attached. Recent 
studies have shown that apo(a) exists as a number of 
isoforms in man and that these appear to influence the 
plasma concentration(see below). High plasma apo(a) 
concentrations are associated with an increased incidence 
of cardiovascular disease(17). However, much remains to be 
discovered regarding the metabolism of Lp(a) and its 
importance and potential for modification in
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atherosclerotic disease.
1.5 Lipoprotein metabolism
The control of lipoprotein metabolism in man is complex and 
not fully understood. The wide variation in lipid and 
lipoprotein levels within and between populations suggests 
that the homeostatic mechanisms regulating plasma 
lipoprotein levels are not under tight control. Many 
factors may disturb "normal" levels. Common genetic 
polymorphisms of proteins which modulate lipoprotein 
metabolism and diet are thought to be the most important 
factors. This variation is illustrated by the elevated 
cholesterol and triglyceride levels in the Western 
populations compared with Japan and third world countries. 
Countries such as Scotland and Finland with the highest 
mean levels have the highest incidence of cardiovascular 
mortality and morbidity(18). Until recently it has proved 
difficult to dissect out the precise pathophysiological 
disturbances responsible for the majority of primary and 
secondary hyperlipidaemias. With new developments in 
molecular biology and use of radioactive and stable 
isotope trace-labelled lipoproteins in kinetic studies, 
rapid advances are being made. This section attempts to 
summarise some of the current theories regarding the 
production and catabolism of the various lipoprotein 
subfractions. Where appropriate, examples of
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dyslipidaemias due to specific genetic disorders or 
acquired conditions with known metabolic defects are used 
to illustrate the importance of these factors in 
maintaining normolipidaemia.
The two main pathways for lipid transport in man are termed 
the exogenous and endogenous pathways according to the 
source of the main lipid constituent(19). The liver acts 
as the central coordinator of these two pathways and is 
intimately involved in the secretion and removal of plasma 
lipoproteins. These two transport systems will be 
considered separately. In addition, a number of enzymes 
play important roles in plasma lipoprotein metabolism.
These are listed in table 1.5.
1.5.1 Exogenous lipid transport
Dietary fat, glycerides and cholesterol, is transported in 
the exogenous pathway initially as chylomicrons which are 
synthesised in the intestinal villi. Synthesis of these 
lipoproteins is dependent both on the supply of exogenous 
fat from the intestinal lumen and on production of apoB48. 
In the rare condition of abetalipoproteinaemia, 
chylomicrons(and other apoB-containing lipoproteins) are 
absent from plasma and fat droplets accumulate in 
enterocytes(2 0). Chylomicrons are secreted both into the 
portal blood stream and the intestinal lymphatics. They
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acquire apoE and apoC's in the interstitial fluid or 
circulation and these are important in their further 
metabolism. These particles bind to endothelial-bound 
lipoprotein lipase(LPL) in tissues, especially adipose 
tissue and skeletal muscle, and are rapidly hydrolysed with 
the release of free fatty acids. This reaction requires 
apoCII as a co-factor. Other apolipoprotein constituents 
of chylomicrons may inhibit this enzyme. The importance of 
this lipolytic enzyme is illustrated by familial LPL 
deficiency which is characterised by severe 
hyperchylomicronaemia with opalescent plasma even after a 
prolonged fast(21). Surface components(phospholipid, free 
cholesterol and some triglyceride) are transferred during 
lipolysis to HDL particles. The particles remaining are 
smaller, denser and contain a larger proportion of protein 
and cholesterol. Further hydrolysis occurs in the liver 
under the influence of hepatic triglyceride lipase(HTGL). 
The remnant particles formed are rich in apoE and are 
thought to be removed by receptor-mediated endocytosis in 
the liver. For some time the existence of a specific 
chylomicron receptor recognising apoE has been postulated 
and, recently, a candidate receptor protein(the LDL related 
protein) has been described(22).
The exogenous pathway is completed by the excretion of 
cholesterol as bile salts. This represents the only route 
by which significant quantities of cholesterol can be
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ultimately excreted by the body. Small amounts may be lost 
as a result of desquamation of epithelial cells and as 
degraded sterol hormones in the urine. The production of 
bile acids from cholesterol is dependent on the activity of 
the rate-limiting enzyme, 7-alpha-hydroxylase. The 
activity of this varies inversely with the activity of 
3-hydroxy-3-methylglutaryl coenzyme A reductase(HMG CoA 
reductase) which controls de novo cholesterol synthesis.
In this way, cholesterol and bile acid synthesis are 
coordinated in an attempt to conserve intra-hepatic 
cholesterol pools although the precise relationship between 
these two pathways is not clear(19).
1.5.2 Endogenous lipid transport
These pathways are responsible for the redistribution of 
lipids to and from the liver. The metabolism of the 
various subfractions will be considered separately although 
it should be stressed that there is constant interchange 
between these particles which are in a dynamic equilibrium 
with each other and tissue lipids.
VLDL/IDL metabolism
Lipids arriving in the liver from the portal and systemic 
circulation or synthesised de novo must be packaged into 
lipoproteins to allow their transport through the plasma.
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This is initiated by the assembly and secretion of very low 
density lipoproteins(VLDL). The secretion of these 
triglyceride-rich lipoproteins(like chylomicrons) is a 
function of the availability of fatty acids. Triglycerides 
are synthesised from either dietary fat delivered in 
chylomicrons or hepatic glucose and fatty acids stores.
ApoB production is also essential for the secretion of 
these lipoproteins as shown by their absence in 
abetalipoproteinaemia(20). The relative importance of 
triglyceride and apolipoprotein synthesis in the control of 
VLDL secretion is unclear but it appears that increased 
triglyceride production is associated with a rise in both 
the number and size of VLDL particles(23). The latter 
reflects an increase in the triglyceride to protein ratio. 
Hormones, such as insulin, also influence the rate of 
secretion. Patients with poorly controlled non-insulin- 
dependent diabetes mellitus have an elevated level of 
triglyceride-rich lipoproteins due to increased hepatic 
secretion(24). This can be reversed by insulin therapy.
VLDL is secreted by the liver and carried to the periphery 
where, like chylomicrons, triglycerides and phospholipids 
are hydrolysed by lipoprotein lipase(LPL). This is 
facilitated by the acquisition of apoCII from HDL particles 
in the circulation. The larger VLDL particles(Sf 60-400) 
are preferentially hydrolysed by lipoprotein lipase while 
smaller VLDL and IDL remnant particles are substrates for
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hepatic triglyceride lipase. This has been confirmed both 
by studies of hepatic clearance of these lipoproteins and 
by apoB kinetic investigations in rare cases of hepatic 
triglyceride lipase deficiency(25).
Considerable interchange of lipids also occurs between 
lipoproteins in the circulation. Triglyceride-rich 
particles acquire cholesterol ester from HDL2 through 
the action of cholesterol ester transfer proteins.
Lipolysis of the triglyceride component leads to a 
reduction in size and alteration in composition of these 
particles. ApoC and phopholipids are transferred to HDL in 
exchange for apoE with the formation of remnant 
particles(or IDL) in the density range 1.006-1.019g/mL. 
These are analagous to chylomicron remnants. Further 
remodelling results in the bulk of the particles passing to 
the LDL density range. Some of the remnant material is 
removed directly by hepatic B/E receptors. Recent 
evidence(25) suggests that there may be metabolic 
heterogeneity among subfractions of VLDL of differing 
densities. It is now clear that significant quantities of 
VLDL apoB are removed directly from this density range and 
are not transformed to LDL particles. ApoB kinetic studies 
have demonstrated that there is input and removal of these 
subfractions at a variety of points in the delipidation 
cascade. The precise metabolic fate may be determined by 
the initial particle size.
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Another factor influencing the metabolism of VLDL particles 
is the common polymorphisms of apoE(15). The E2 
polymorphism has a reduced affinity for the chylomicron and 
B/E receptor resulting in reduced clearance of remnant 
particles. Homozygosity for E2 gives rise to a specific 
dyslipidaemia which is accompanied by frank hyperlipidaemia 
in type III hyperlipidaemia(familial 
dysbetalipoproteinaemia). Affected individuals have 
fasting hypertriglyceridaemia and hypercholesterolaemia, 
high VLDL cholesterol: plasma triglyceride ratio, remnant 
accumulation and variable LDL levels. However, since 1% of 
the population are homozygous for the E2/E2 polymorphism 
and only 1/5000-10000 have type III hyperlipidaemia, 
another factor(e.g. obesity, alcohol excess) must co-exist 
with the E2/E2 phenotype for the full expression of this 
condition.
LDL metabolism
The majority of LDL particles are formed as the end-product 
of lipolysis of VLDL. A small part of the LDL pool may be 
secreted directly by the liver or as a very rapidly 
metabolised subfraction of VLDL which is difficult to 
detect by tracer experiments(27,28). The nature of this 
LDL production is still controversial. To date, there is 
no evidence of direct LDL-like particle secretion in
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hepatic perfusion studies in a number of animals(29) 
although direct LDL synthesis may be quantitatively 
important in some types of hyperlipidaemia in man e.g. 
familial hypercholesterolaemia(27,28,30). In general, the 
production of LDL is linked to the catabolism of VLDL. The 
delipidation of the triglyceride content and the transfer 
of redundant surface material(phospholipid and free 
cholesterol) to HDL leads to the formation of smaller, 
denser particles within the LDL density range (d=1.019- 
1.063mg/L).
The mechanisms for removal of LDL from the plasma have been 
extensively investigated. A substantial proportion 
(approximately 50-70%) is cleared by the specific LDL 
receptor. This is a membrane-bound receptor found on most 
cells which recognises apoB and apoE, binds and 
internalises lipoprotein particles. These are then rapidly 
hydrolysed in lysozymes. The identification of the LDL(apo 
B/E) receptor and its role in cholesterol homeostasis(31) 
was recognised by the award of the Nobel prize to Goldstein 
and Brown in 1985 for work spanning more than a decade. 
Control of cellular cholesterol requirements is achieved by 
feedback regulation of the number of LDL receptors and of 
the production of 3-hydroxy-3-methyl-glutaryl coenzyme A 
reductase which controls de novo cholesterol synthesis from 
acetate. The overriding requirement is to deliver adequate 
amounts of cholesterol to cells for membrane synthesis and
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repair or sterol hormone production. Intracellular free 
cholesterol(or an oxidised derivative) controls the 
intracellular concentration by its effect on three crucial 
proteins - 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMG CoA reductase), acyl-CoA cholesterol acyltransferase 
(ACAT) and the LDL receptor. When intracellular supplies 
of free cholesterol are adequate, the number of LDL 
receptors expressed on the cell membrane is decreased as is 
HMG CoA reductase activity. Cholesterol is converted to 
cholesterol ester in the cell by ACAT for later use. If 
the intracellular cholesterol pool decreases, the opposite 
effects occur - LDL receptor numbers and HMG CoA reductase 
activity increases. These homeostatic mechanisms appear to 
be regulated by the effect of oxidised derivatives of free 
cholesterol on transcription and degradation of these 
proteins(32).
The alternative route(s) for catabolism of plasma LDL is 
poorly characterised but probably involves phagocytic 
cells. These "scavenger" pathways are thought to 
preferentially remove physiologically-altered LDL. This 
route for LDL removal appears to be unregulated and can 
lead to massive accumulation of cholesterol ester in smooth 
muscle and macrophage cells in atherosclerotic plaques. It 
has been postulated that modified LDL taken up by pathways 
independent of the LDL receptor leads to an increased risk 
of atherosclerosis(31). In vitro. acetylated LDL has been
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shown to bind to a receptor on mouse macrophages(33). 
Another receptor identified in vitro on mouse macrophages 
binds and internalises beta-VLDL(cholesterol enriched) with 
the formation of foam cells. As yet, there is no clear 
evidence that similar pathways exist in vivo in mice or in 
man. The putative role of modified LDL, particularly 
oxidised LDL, in atherosclerosis has recently been 
reviewed(34).
The crucial role played by the LDL receptor in the control 
of plasma LDL is illustrated by the classical condition of 
familial hypercholesterolaemia(35). The clinical and 
genetic characteristics of this autosomal co-dominant 
condition have been well described. The diagnosis is based 
on a family history of premature coronary artery disease, 
tendon xanthomata and hypercholesterolaemia due to elevated 
plasma LDL-cholesterol and is associated with the onset of 
features of coronary insufficiency usually in the fourth or 
fifth decade. One in five hundred of the population have 
familial hypercholesterolaemia and there is a gene dose
g
effect with homozygotes(frequency 1/10 ) more severely 
affected. The latter often die from ischaemic heart 
disease before the age of twenty. Heterozygotes have only 
half of the normal number of functional LDL receptors 
resulting in a doubling of the plasma cholesterol; 
homozygotes have virtually no functional receptors and 
severe hypercholesterolaemia(3-4x normal). The rise in
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plasma cholesterol levels permits sufficient cholesterol 
uptake by hormone-synthesising and actively dividing cells 
but at the expense of massive, unregulated uptake by 
alternative pathways which lack regulatory feedback. The 
changes in plasma cholesterol in this disease indicate the 
importance of LDL receptor activity in regulating plasma 
LDL levels. However, LDL synthesis can also affect the 
plasma level and kinetic studies of patients with familial 
hypercholesterolaemia indicate that many have an increased 
rate of LDL production. It is now recognised that the 
apoB/E receptor removes apoB-containing lipoproteins other 
than LDL(e.g. small VLDL and IDL) and the increased LDL 
production rate in familial hypercholesterolaemia may be 
due to increased availability of IDL for delipidation when 
its direct removal is impaired. In an unselected 
population, LDL-cholesterol levels have been correlated 
with both synthetic and catabolic rates suggesting that 
both play a role in determining the steady state level(36).
HDL metabolism
HDL metabolism is complex, poorly understood and 
inextricably linked to the metabolism of other 
lipoproteins. HDL is thought to play a critical role in 
preventing tissue accumulation of cholesterol. Nascent HDL 
is secreted by the liver(and probably other organs) as 
disc-like particles of phospholipid, free cholesterol and
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protein(apoAI). These may also be produced from surface 
components of triglyceride-rich lipoproteins or by 
association of free phospholipid and apolipoprotein in 
plasma. These discs are not detected in plasma as they are 
rapidly converted to spherical particles as a result of the 
action of lecithin cholesterol acyltransferase(LCAT). 
Phospholipid and triglyceride are acquired from lower 
density lipoproteins and the HDL^ particles formed 
(d=l.125-1.210g/mL) are thought to have a crucial role in 
"reverse cholesterol transfer"(10). Cholesterol from 
peripheral cells is transferred to these particles and 
esterified by LCAT. HDL particles enriched by cholesterol 
ester(HDL2 d=l.063-1.125g/mL) have been shown to bind to 
hepatic membranes and other sterol-requiring cells by 
receptor-mediated mechanisms. Both apoAI and apoE may be 
ligands. As the liver is the only organ that can excrete 
significant amounts of cholesterol in the form of bile 
acids, this provides an important means of reducing tissue 
cholesterol levels. Cholesterol ester may also be 
transferred between HDL and lower density lipoproteins via 
cholesterol ester transfer proteins in the plasma.
HDL levels are linked to the metabolism of other 
lipoproteins. Measures of VLDL catabolism and 
apolipoprotein AI turnover show close correlations.
Exchange of apolipoproteins between HDL and VLDL regulates 
the activity of lipoprotein lipase. The precise importance
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of this and many other aspects of HDL metabolism have not 
been fully established.
1.6 Nephrotic syndrome - definition, causes and 
complications
The nephrotic syndrome is a clinical and biochemical 
syndrome rather than a single disease. A large number of 
pathological conditions may cause the syndrome which is 
arbitrarily defined as the presence of oedema, proteinuria 
in excess of 3.5g/day and hypoalbuminaemia(usually <3 0g/L). 
Although there is a broad correlation between these three 
features, some subjects maintain a normal serum albumin 
despite heavy proteinuria while others develop 
hypoalbuminaemia with smaller measured urinary losses. 
Treatment such as diuretics, albumin infusions and dietary 
intervention may modify the clinical picture. Since 
proteinuria is thought to be the primary manifestation 
leading to many other features of the syndrome, the 
nephrotic syndrome is often empirically defined on the 
basis of guantitative proteinuria alone. Although a useful 
practical approach, this value may vary considerably from 
day to day as a result of both intra-individual variation 
and the imprecision of urinary protein measurements.
In normal man, up to 150mg of protein is excreted in the 
urine per day. This represents the balance of protein
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filtered in the glomeruli and reabsorbed in the tubules. A 
small amount of protein is also secreted by the tubules.
In most cases, pathological elevation of urinary protein 
results from changes in the glomerular capillary wall 
(GCW). Rarely, proteinuria is secondary to excessive 
plasma proteins(e.g. light chain myeloma), decreased 
tubular absorption or lower urinary tract disease. It is 
unusual for any of these(with the possible exception of 
light chain myeloma where a number of these pathological 
mechanisms are operative) to give rise to proteinuria in 
the nephrotic range.
The GCW, consisting of the endothelial cell, basement 
membrane and the epithelial cell, restricts the passage of 
molecules into the urinary space on the basis of molecular 
size, configuration and electrical charge. Experimental 
studies, based on the differential clearance of dextran 
molecules over a range of sizes, have suggested that this 
barrier constitutes a series of cylindrical pores(37). The 
precise size and distribution of these theoretical pores 
remains controversial. The GCW also contains a fixed 
negative electrical charge which hinders the passage of 
anionic molecules such as proteins. Damage to the GCW may 
result in a change in the number and size of pores or a 
loss of negative charge leading to a marked increase in 
glomerular permeability. Opinions vary as to which of 
these defects is most important and this may differ between
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diseases.
Many disorders can impair the integrity of the glomerular 
barrier and result in the clinical syndrome of proteinuria. 
Both primary glomerular diseases or systemic diseases with 
renal involvement may present in this way. The commonest 
causes in adults in the United Kingdom are listed in table 
1.6. In many countries, infectious diseases(e.g. malaria, 
syphilis or hepatitis) account for the majority of cases. 
Light negative(or minimal change) nephropathy is the 
commonest cause of nephrosis in children in the UK.
Although the diagnosis may on occasion be reached from the 
history and examination, the majority of cases will require 
renal biopsy for precise histological classification. This 
often has prognostic and, occasionally, therapeutic 
importance.
For many years, it has been widely held that the clinical 
syndrome and laboratory features of the nephrotic syndrome 
are initiated by the urinary loss of protein and modified 
by a number of compensatory mechanisms. However, there are 
still many unanswered questions regarding the metabolic 
changes which occur. Albumim homeostasis may be deranged 
by relatively small urinary losses. This has led some 
workers to invoke extensive tubular catabolism of filtered 
albumin. Increased albumin synthesis in response to 
proteinuria is not a universal finding. Studies have shown
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that nephrotic patients on a low protein diet have albumin 
synthetic rates similar to controls(38). Although 
augmenting protein intake increases the rate of albumin 
synthesis, serum albumin levels do not rise and proteinuria 
increases. These findings have, in part, been confirmed by 
others(39). Since increasing proteinuria is associated 
with a poorer prognosis, clinicians are now reassessing the 
role of the traditional high protein diet in these 
patients. These examples illustrate our relative ignorance 
of many basic physiological and metabolic processes in this 
disease.
The nephrotic syndrome is accompanied by a wide range of 
disturbances of normal physiology(40). Hyperlipidaemia is 
a well-recognised association and will be considered in 
detail below. In addition, an increased incidence of 
thrombo-embolic events has been associated with changes in 
coagulation parameters(both activators and inhibitors of 
coagulation) and platelet function. A variety of 
disturbances of calcium homeostasis have been described 
including low ionised calcium and vitamin D deficiency. 
Osteodystrophy only develops in association with declining 
renal function. Infection has been a major cause of 
mortality and morbidity in nephrotic syndrome and this 
reflects an immunocompromised state. Immunoglobulin 
losses in the urine may be compounded by decreased 
synthesis and/or increased catabolism resulting in low IgG
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and IgA levels. IgM levels are often high. Changes in 
cell-mediated immunity and in macrophage function have also 
been reported. Many other abnormalities including trace 
element deficiencies and altered thyroid status have been 
described. A comprehensive discussion of all these is 
outwith the scope of this thesis.
1.7 Hyperlipidaemia in nephrotic syndrome
1.7.1 Lipid and lipoprotein abnormalities
The association between renal disease and elevated blood 
lipids was first described by Blackall as long ago as 
1813(1). Other workers subsequently confirmed his 
observations specifically in relation to glomerular 
disease(2,41). Despite the efforts of many investigators 
over the years, both the precise nature of the 
pathophysiological disturbances responsible for this 
phenomenon and the clinical importance remain uncertain.
The spectrum of lipid abnormalities found in nephrosis, 
involving both quantitative and qualitative changes in 
plasma lipoproteins, has been fairly well-characterised. 
However, the prevalence of abnormalities is not well 
documented and many studies have failed to control for 
other factors which may perturb lipid metabolism. Many 
early series included subjects with systemic diseases,
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advanced renal failure or on treatment with 
corticosteroids. Diuretics and anti-hypertensive drugs are 
frequently needed in nephrotic subjects and the effects of 
these are difficult to avoid. All of these factors have 
independently been associated with alterations in plasma 
lipid levels.
Plasma cholesterol concentrations, both free and 
esterified, are consistently increased as are 
phospholipids. Triglyceride levels are much more variable. 
Baxter et al.(41) emphasised this wide variation with 
plasma triglyceride concentrations ranging from 76 to 
3820mg/dL(0.9-43.3mmol/L). In this series, both 
triglyceride and cholesterol levels showed an inverse 
relationship with serum albumin although in more severe 
cases the ratio of cholesterol to triglyceride fell 
dramatically. At very low levels of serum albumin, lipid 
levels rose exponentially. The patients in this study were 
severely hypoalbuminaemic with 42 of 58 plasma lipid 
measurements associated with serum albumin <15g/L.
Changes in apoB-containing lipoproteins reflect the changes 
in neutral lipid levels with increases in LDL- and VLDL- 
cholesterol which in general show a positive relationship 
with the severity of the condition. Gherardi et al. (42) 
quantified the changes in plasma lipoproteins in a group of 
nephrotic children. They noted relationships between
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serum albumin and three lipoprotein fractions. LDL2 
(d=l.019-1.063g/mL) was negatively correlated while HDL2 
(d=l.063-1.125g/mL) showed a positive correlation. Plasma 
VLDL-cholesterol(del.006g/mL) increased exponentially as 
serum albumin fell to 15g/L - a finding similar to Baxter's 
observations on triglycerides(41). Qualitative changes in 
the lipoprotein particles also occur with increased 
cholesterol ester and phospholipid content of both LDL and 
VLDL and a reduced protein content. A larger study of 59 
children in relapse and remission of minimal change 
nephrotic syndrome confirmed the elevation of LDL- 
cholesterol concentrations(>95th centile for age) in 81% of 
patients but VLDL-cholesterol was only elevated in 60%(43). 
There was only a poor correlation with serum albumin and a 
significant number of patients had persistent lipid 
abnormalities in remission. However, another study, while 
confirming the elevated lipid levels in relapse, reported 
normalisation of all parameters including apolipoprotein 
concentrations within 7 weeks of remission(44).
In adults, there are few large studies of uncomplicated 
nephrotic syndrome which have clearly documented the 
prevalence and severity of hyperlipoproteinaemia using the 
current standard methods of preparative ultracentrifugation 
and precipitation of apoB-containing lipoproteins for 
measuring cholesterol content of plasma lipoproteins. An 
early study(45) reported hyperlipidaemia in only 17 of 33
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patients with nephrotic syndrome but 13 of these patients 
were in remission at the time of the study and all 7 who 
were actively nephrotic(serum albumin <30g/l; proteinuria 
>3g/day) had abnormal lipoprotein profiles. One third of 
the patients were on corticosteroids. These factors and 
the method of lipoprotein analysis make interpretation of 
this report difficult. Newmark et al.(46) have reported 
the largest series in a retrospective review of 96 cases of 
hyperlipidaemia in nephrosis caused by a variety of 
glomerular diseases including diabetes mellitus and 
systemic lupus erythematosus. Significant inverse 
associations were found between serum albumin and both 
total cholesterol and triglyceride. Although serum albumin 
was inversely related to urinary protein loss, no 
relationship was demonstrated between proteinuria and 
plasma lipid levels. Lipoprotein phenotypes were mainly 
classified as Ila, lib or V. No clear differences between 
patients with primary or secondary glomerular disease were 
seen. However, as only patients with hyperlipidaemia were 
studied, this may not reflect the prevalence of 
hyperlipidaemia in an unselected nephrotic population. A 
study(47) of 2 0 consecutive patients with heavy proteinuria 
(>3g/day) demonstrated total cholesterol concentrations 
greater than the 95th centile for the population in 70% 
with figures of 55% and 3 0% for LDL- and VLDL-cholesterol, 
respectively. Total cholesterol concentration showed an 
inverse correlation with plasma albumin and oncotic
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pressure. Joven et al. have also recently reported a 
series of 57 patients with nephrotic syndrome(48).
Compared with published data, 33% had increased 
LDL-cholesterol with normal VLDL-cholesterol, 60% had 
increased levels of both and 7% had elevated VLDL- 
cholesterol alone. Plasma cholesterol, triglyceride, 
phospholipid and LDL-cholesterol were all inversely 
correlated with serum albumin but no association with 
proteinuia was observed.
HDL concentrations have been recorded as normal(44,48,49) 
or low(41,42,50) by most investigators although increased 
levels have also been found(51,52). HDL has been 
quantified in the urine in nephrotic patients but the 
urinary losses do not appear to be related to plasma levels 
although as with other proteins(e.g. albumin) the effect 
of tubular catabolism of filtered lipoprotein is uncertain. 
Changes in the composition of urinary HDL have been 
ascribed to this(53).
In general, changes in plasma apolipoprotein levels in man 
parallel the changes in lipoproteins. ApoB levels are 
invariably increased and apoAI reflect HDL-cholesterol 
levels. Levels of all three apoC's are increased although 
there is no change in the C-II/C-III ratio(44).
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1.7.2 Altered lipoprotein metabolism
The metabolic changes resulting in the hyperlipidaemia in 
nephrotic syndrome are complex. Theoretically, 
hyperlipoproteinaemia may develop due to increased 
lipoprotein production, decreased catabolism or a 
combination of these mechanisms. Changes in both lipid and 
apolipoprotein metabolism occur. In both normal and 
abnormal lipoprotein metabolism, it is uncertain how the 
production of lipids and apolipoproteins is coordinated 
with the assembly and secretion of lipoprotein particles.
In nephrotic syndrome, the primary defect is generally 
considered to be increased hepatic secretion of 
lipoproteins. However, a number of catabolic defects have 
also been described. Much of the evidence for increased 
hepatic synthesis and secretion of lipoproteins is based on 
the work of Marsh and colleagues(54). Over a number of 
years, they have performed a series of experiments on 
animal models of nephrotic syndrome and consistently shown 
increased production of lipids, lipoproteins and 
apolipoproteins in intact animals and isolated perfused 
livers of nephrotic rats. These results have been 
confirmed by other workers by measuring the incorporation 
of labelled precursors into lipoproteins and 
apolipoproteins(55-58) and lipids(59—60). However, not 
all studies have reached this conclusion(61).
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An alternative approach involving studies of the clearance
of exogenously-labelled lipoprotein particles in nephrotic
animals has demonstrated the presence of catabolic defects.
Clearance of both HDL(62) and VLDL(63,64) particles appears
125to be reduced. A recent report on the fate of I- 
labelled LDL particles in rats rendered nephrotic with 
puromycin aminonucleoside showed no difference in the 
fractional catabolic rate compare to controls(65). The 
elevated plasma LDL concentrations were ascribed to 
increased synthesis although this was only significant when 
compared on a mg/kg/day basis and was influenced by the 
failure of the nephrotic group to gain weight.
How far these results can be extrapolated to man is 
uncertain for a number of reasons. Firstly, the two main 
rat models of nephrotic syndrome which have been studied 
are induced by anti-kidney serum and puromycin 
aminonucleoside. Both experimental models have features 
which might perturb lipid and lipoprotein metabolism 
independent of proteinuria. Anti-kidney serum causes renal 
failure while puromycin is a general cytotoxin which is 
associated with hepatic toxicity. Secondly, lipoprotein 
metabolism shows marked inter-species differences. Man has 
an almost unique plasma lipoprotein profile with a greatly 
expanded LDL pool compared to other mammals. The main 
cholesterol carrying particle in plasma of most other 
species is HDL. Therefore, although the use of animal
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models of nephrotic syndrome is convenient and has 
permitted some insights into abnormal lipoprotein 
metabolism, the results should be interpreted with caution. 
Confirmatory studies in man are required to validate the 
conclusions reached.
Similar techniques have been utilised in human nephrotic 
syndrome but on a relatively small scale compared to the 
extensive literature on animal work. Gitlin(66) 
performed pioneering studies on the use of radiolabelled 
lipoproteins to trace lipoprotein metabolism in vivo. Some 
of the earliest studies were performed on nephrotic 
children. The clearance of lipoproteins S^ 3-9, 10-200 and 
alpha-1ipoproteins was investigated. It was concluded that 
S^ 3-9 lipoproteins were catabolised at a slightly faster 
rate in nephrosis but that there was a defect in conversion 
of less dense lipoproteins to this fraction. Alpha- 
lipoproteins were more rapidly removed from the circulation 
even when corrections were made for urinary losses.
Similar studies of the metabolism of trace-labelled low 
density lipoproteins by Scott et al.(67) in the late 1960's 
showed a small but statistically insignificant decrease in 
the fractional catabolic rate of this lipoprotein fraction. 
They postulated that the increased LDL levels commonly 
found must be due to increased synthesis. A similar 
conclusion has recently been reached by other groups of 
investigators in studies of small numbers of nephrotic
55
subjects(48,68-70). The total number of nephrotic patients 
studied using these techniques is relatively small.
Other workers have looked at whole body lipid turnover by 
measuring the incorporation of radiolabelled precursors 
into triglyceride and cholesterol ester respectively. This 
is useful for assessing total lipid turnover but is unable 
to determine the metabolism of lipoprotein fractions 
because of lipid transfer between particles in the 
circulation. Using labelled glycerol and mevalonic acid, 
McKenzie and Nestel(71) demonstrated a reduction in the 
fractional clearance of both triglyceride and esterified 
cholesterol in nephrotic syndrome. However, there was a 
disproportionate increase in the lipid pool size suggesting 
that changes in both synthetic and catabolic mechanisms 
contribute to the hyperlipidaemia. Similar results were 
found for triglycerides by another group(72).
The stimuli to increased lipid and lipoprotein synthesis is 
uncertain. Cholesterol production may be increased due to 
disturbances of the metabolism of mevalonate, an important 
precursor of cholesterol biosynthesis. Mevalonate is both 
excreted by filtration and oxidised by the kidney.
Clearance by both routes is reduced in nephrotic rats and 
increased substrate availability could enhance hepatic 
cholesterol production(73). However, the same mechanism 
could also account for decreased catabolism of low
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density lipoproteins by its effect on intrahepatic sterol 
pools and, secondarily, on apo B/E receptor activity. 
Increased substrate availability has also been postulated 
as a cause of increased triglyceride synthesis. Fatty 
acids released by hydrolysis of triglycerides are normally 
bound to albumin. Hypoalbuminaemia increases plasma levels 
of free fatty acids which may be taken up by the liver and 
stimulate triglyceride synthesis(72).
Precisely how the changes in lipoprotein and apolipoprotein 
metabolism are mediated is not clear. Many workers have 
emphasised the central role of hypoalbuminaemia. Evidence 
for the importance of hypoalbuminaemia derives from studies 
in both animal models and man where amelioration of 
nephrotic hyperlipidaemia was achieved by infusion of large 
quantities of albumin or other oncotic agents(74,75). 
Furthermore, hyperlipidaemia accompanies the rare syndrome 
of analbuminaemia in man(76) and there is a broad inverse 
relationship between the degree of hypoalbuminaemia and 
hyperlipidaemia. Appel(47) also correlated the lipid 
abnormalities with plasma oncotic pressure. Early theories 
suggested that albumin and lipoproteins shared a common 
biosynthetic pathway and that a general increase in hepatic 
protein synthesis resulted in hyperlipoproteinaemia. 
However, the evidence for this is unconvincing. Increased 
albumin synthesis has not been consistently found in 
nephrotic syndrome and, recently, hypercholesterolaemia has
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been demonstrated in a group of nephrotic patients 
maintained on a low protein diet who had normal albumin 
synthetic rates(38). Other factors must be involved since 
some patients develop hyperlipidaemia despite a normal 
serum albumin and hyperlipidaemia precedes hypoalbuminaemia 
in some animal models.
1.7.3 Enzymes involved in lipid and lipoprotein 
metabolism
Lipoprotein metabolism is dependent on a number of key 
enzymes and regulatory proteins(e.g. receptors and 
apolipoproteins). Defects in the concentrations or 
functional activities of some of these enzymes have been 
found in nephrotic syndrome in experimental animal models 
and in man.
Decreased post-heparin lipase activity has been recorded by 
a number of groups(63,77-79) and this has been localised to 
the lipoprotein lipase fraction(79). However, this is not 
a universal finding(51,80,81). Decreased lipase activity 
would explain the decreased catabolism of lighter 
lipoproteins found by Gitlin(66) and the marginally reduced 
capacity of nephrotic subjects to clear an intravenous fat 
load(82). Since apolipoprotein CII is a co-factor for this 
enzyme, increased urinary losses might result in decreased 
enzyme activity. Low plasma levels of apoCII have not been
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found(44,83) although it has been suggested that the VLDL- 
associated apoCII may be relatively reduced(83). Staprans 
(84) found another lipase cofactor in the urine of 
nephrotic subjects which was identified as a 
glycosaminoglycan, heparan or chondroitin sulphate.
Similarly, lecithin cholesterol acyltransferase activity 
has been found to be decreased in nephrosis(85). Animal 
studies have confirmed this and related it to the degree of 
hypoalbuminaema(86).
Hypoalbuminaemia has also been implicated in the decreased 
activities of these enzymes. Albumin is an important 
acceptor of the products of these reactions(lysolecithin 
and free fatty acids, respectively) and accumulation of 
unbound products may limit the activities of the enzymes.
In summary, the nephrotic syndrome is associated with a 
complex series of changes in metabolism involving increased 
synthesis of lipids and apolipoproteins, catabolic defects 
of VLDL and HDL and altered activities of regulatory 
enzymes. However, many of these observations have been 
made in experimental nephrotic syndrome in contrast to the 
paucity of data in man. The factors which induce these 
changes and their relative importance in man have not been 
clearly determined.
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1.7.4 Lipid abnormalities in other renal diseases
Abnormalities of plasma lipids and lipoproteins are also 
found in other renal diseases and these are considered 
briefly.
Renal failure
The lipid and lipoprotein changes in renal failure are 
distinct from those seen in the nephrotic syndrome.
However, where the nephrotic syndrome is accompanied by 
reduced glomerular filtration a complex picture may result. 
Abnormalities of triglycerides have been reported when 
glomerular filtration rates decrease by 50% (87) - before 
most of the other clinical and biochemical features of 
renal failure develop. Although most of the studies of 
hyperlipidaemia in renal failure have been on maintenance 
dialysis patients, it is now clear that these precede 
end-stage renal failure.
The advent of dialysis therapy may accentuate 
hyperlipidaemia. Maintenance haemodialysis is associated 
with hypertriglyceridaemia, low HDL-cholesterol and normal 
total cholesterol concentrations. Many theories have been 
advanced to explain this. There appears to be a 
significant reduction in lipoprotein lipase activity. 
Reduced catabolism of VLDL leads to a reduction of HDL.
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During the lipolysis of VLDL, excess surface material is 
transferred to HDL^ particles which under the influence of 
lecithin cholesterol acyltransferase are converted to HDL2. 
Failure of this mechanism is often associated with a fall 
in HDL-cholesterol concentration. Decreased LPL activity 
has been attributed to the repeated adminstration of 
heparin as an anticoagulant during regular dialysis.
Heparin releases endothelial-bound lipoprotein lipase into 
the circulation and may lead to chronic exhaustion of the 
enzyme. However, lipase activity has been shown to be 
decreased in patients with impaired renal function before 
dialysis is required(88). Uraemic serum inhibits lipase 
activity in vitro(89).
In the dialysis population, other mechanisms have been 
implicated in the hypertriglyceridaemia. These include 
disturbances of carbohydrate metabolism due to insulin 
resistance, excessive dietary carbohydrate in low protein 
diets and acetate loading from dialysate. Carnitine 
deficiency has also been postulated as a cause. The precise 
mechanisms underlying the lipid abnormalities of chronic 
renal failure remain uncertain.
Organ transplantation
Hyperlipidaemia following organ transplantation is thought 
to be related to immunosuppressive therapy.
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Corticosteroids, particularly in the larger doses used in 
the pre-cyclosporin era, cause insulin resistance and 
stimulate VLDL secretion. More recently, the advent of 
cyclosporin has been associated with a rise in cholesterol 
levels(90).
1.8 Hyperlipidaemia and atherosclerosis in the nephrotic 
syndrome
Over the last 20 years, substantial evidence has 
accumulated to implicate a causal role for primary 
hyperlipidaemia in premature coronary artery disease. 
Whether these findings can be extrapolated to other forms 
of hyperlipidaemia is less certain. It is often stated 
that the risk of cardiovascular events is increased in the 
nephrotic syndrome. However, this is based almost entirely 
on anecdotal or uncontrolled reports and has been 
challenged by some authorities. This controversy remains 
unresolved.
There are two main questions
1 . Is the nephrotic syndrome associated with an increased 
risk of cardiovascular disease?
2. If so, what is the contribution of the 
hyperlipidaemia?
Reports of small series of nephrotic subjects have 
suggested an increased incidence of cardiovascular events,
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usually myocardial infarction(91,92). Coronary artery 
disease has been documented at a very young age in 
corticosteroid-refractory nephrotic syndrome(93). The 
only autopsy study of the coronary artery status of 
patients with this condition found an increase in the 
degree of coronary atherosclerosis compared to a group of 
matched controls(94). However, this study only included 3 
patients with idiopathic glomerular disease. Thirteen had 
lupus nephropathy and 4 had diabetes mellitus. Both of 
these conditions may accelerate atherosclerosis 
independently. The prevailing opinion that the nephrotic 
syndrome confers an increased risk was challenged by Wass 
and colleagues(95). In what remains the largest 
epidemiological study of vascular disease in nephrosis, 
they followed a group of 159 consecutive adult nephrotics 
for a mean period of 5 years. When compared to a cohort of 
1005 Greater London Council employeees, they were unable to 
detect an excess of deaths, morbid vascular events or 
electrocardiographic changes. A number of criticisms of 
this study have been made. Twenty-nine of 49 deaths were 
ascribed to terminal renal failure only 5 of whom received 
renal replacement therapy. Many of these deaths may have 
been due to cardiovascular disease rather than uraemia. 
Similarly, nearly half of the survivors had only a single 
short episode of proteinuria which may be a more benign 
condition. Separate analysis of those with persistent 
proteinuria showed a slight excess of cardiovascular
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findings although this did not reach statistical 
signifigance. In contrast, a recent preliminary report of 
a similar large series has documented an increased 
incidence of ischaemic heart disease(96).
This controversy was highlighted by the juxtaposition in 
one journal of editorials supporting opposite opinions in 
1981(97,98). However, some unanimity was reached over 
patients with persistent nephrosis with an unfavourably 
high LDL:HDL-cholesterol ratio who were considered to be at 
increased risk. A recent retrospective study of membranous 
glomerulopathy in the West of Scotland(99) found a 
significant increase in both arterial and venous thrombosis 
compared to a matched group with IgA nephropathy. The 
membranous group were characterised by heavy proteinura 
which is uncommon in IgA nephropathy. In summary, current 
opinion holds that those patients with a persistent 
nephrotic state are more likely to develop features of 
cardiovascular disease, particularly coronary artery 
obstruction.
Assuming this is true, how important is the hyperlipidaemia 
in accelerating atherosclerosis? The nephrotic syndrome 
may complicate other systemic disease and is often 
accompanied by a number of features which may increase 
cardiovascular risk. Hypertension and a hypercoagulable 
state(often manifesting as venous thrombosis) are perhaps
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the most important. The preponderance of males with 
nephrotic syndrome, progressive renal failure and 
haemoconcentration due to over-vigorous diuretic therapy 
may also be relevant. However, the quantitative and 
qualitative changes in plasma lipoproteins documented in 
nephrosis are of a type commonly associated with an 
increased risk of coronary events in the general population 
(i.e. increased LDL-cholesterol, low or normal HDL- 
cholesterol and increased total and LDL:HDL-cholesterol 
ratio). Convincing experimental(100) and epidemiological 
(101) evidence exists causally implicating these 
abnormalities in the development of premature coronary 
heart disease. Recent studies(102,103) have shown that 
reductions in total and LDL-cholesterol are associated with 
a decreased incidence of cardiovascular events. It would 
seem reasonable to extrapolate these results to nephrotic 
syndrome where the calculated overall cardiovascular risk 
may be greater. However, the benefits of lipid lowering in 
nephrotic syndrome specifically have not been proven by the 
appropriate controlled trials.
1.9 The role of lipids and lipoproteins in progressive 
renal disease
Renal diseases are characterised by their progressive 
nature. Following renal injury and loss of filtration 
capacity, there is often a slow decline in the remaining
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renal function even where the original process is 
apparently no longer active. For an individual, this 
decline is predictable with a linear fall in glomerular 
filtration with time. Work on animal models of renal 
failure led to the hypothesis that loss of renal excretory 
capacity was accompanied by glomerular hypertrophy and 
hyperfiltration in surviving nephrons(104). This 
protective response leads to further nephron loss by 
unexplained mechanisms although increased intraglomerular 
pressure has been implicated. Both systemic hypertension 
and protein load have been suggested as mediators of these 
glomerular changes. There is fairly convincing evidence 
that control of hypertension can at least retard the 
progression of renal failure both in experimental animal 
models and in man(105). Despite intensive study, the role 
of dietary protein restriction has not been conclusively 
prpven(106) and many nephrologists do not prescribe low 
protein diets. Accumulation of inorganic salts(e.g. 
phosphate, calcium and urate) in the renal interstitium may 
accelerate renal failure by interfering with tubular 
function.
Recently, evidence has emerged to suggest that 
hyperlipidaemia may play a role in the progressive loss of 
renal function. This was first hypothesised in a 
comprehensive fashion by Moorhead in 1982(107). The 
evidence for this is based on a number of clinical and
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pathological observations in man and in experimental models 
of renal disease. Glomerulosclerosis with mesangial 
expansion, foam cell accumulation and deposition of 
amorphous hyaline material is the common histological 
finding in many progressive renal diseases. For many years 
histologists have noted accumulation of lipid droplets in 
glomerular cells giving the cytoplasm a "foamy" appearance. 
These mesangial foam cells bear many similarities in terms 
of morphometry, contractility and histochemistry to the 
foam cells derived from macrophages and smooth muscle cells 
of atherosclerotic streaks(108). An autopsy study has 
correlated the presence of glomerular changes of ageing 
with atherosclerosis(109) raising the possibility of a 
common pathogenesis. Progressive renal disease in the rare 
familial lecithin cholesterol acyltransferase deficiency 
where cholesterol esters accumulate in peripheral tissues 
(110) anecdotally supports the concept of lipid 
nephrotoxicity.
The effect of manipulation of plasma lipids on the course 
of glomerulosclerosis, proteinuria and renal failure has 
been investigated in a number of normal species and models 
of renal injury. In early reports, dietary-induced 
hypercholesterolaemia was shown to promote 
glomerulosclerosis in the guinea pig(111) and this was 
confirmed in rats(112). Hypercholesterolaemia(dietary- 
induced or endogenous) in rats has been shown to accelerate
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proteinuria, renal failure and renal histological 
abnormalities in obese Zucker rats, a remnant-kidney model 
(113) and puromycin aminonucleoside-induced nephrosis(114). 
These effects can be ameliorated, at least partially, by 
reducing the hyperlipidaemia with clofibrate or cholesterol 
synthesis inhibitors and are independent of changes in 
glomerular haemodynamics(113-115). As yet, no comparable 
data on the effects of lipid-lowering therapy on the course 
of chronic renal disease in man is available although an 
anecdotal report suggests that long term lipid-lowering 
with simvastatin may reduce proteinuria significantly(117).
The precise mechanisms whereby hyperlipidaemia may be 
nephrotoxic have been reviewed by Moorhead(107,116). Low 
density lipoproteins have cytotoxic effects on both 
endothelial and mesangial cells at high concentrations. 
Mesangial cell growth and expansion may be stimulated at 
lower concentrations(118). Although LDL carries an overall 
negative charge(pi 5.7), it contains positively charged 
domains which are essential for binding to the apoB/E 
receptor. In vitro, these can combine with negatively 
charged glycosaminoglycans. A similar occurence in vivo 
could lead to the neutralisation of the anionic sites of 
the glomerular capillary barrier and increase flux of 
anionic molecules. The role of filtered lipoproteins may 
also be important. Lipoproteins of all densities have been 
isolated from nephrotic urine(119) although HDL3 (5.5-9.5nm)
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has been most commonly reported. Extensive tubular 
catabolism of filtered proteins and lipoproteins is thought 
to occur and direct or indirect effects on tubular cell 
function and viability may result. Further work is 
required to determine the precise role of hyperlipidaemia 
in progressive renal disease.
1.10 Treatment of hyperlipidaemia in the nephrotic 
syndrome
The rationale for treatment of hyperlipidaemia of nephrotic 
syndrome is that by reducing plasma lipid levels morbidity 
and mortality from cardiovascular disease will fall and, 
more contentiously, that the rate of progression of renal 
failure may be retarded. However, both of these 
propositions remain unproven. Where specific therapy is 
available for the nephrotic syndrome, remission of 
proteinuria will in most cases normalise the lipid profile. 
Alternative approaches to reducing proteinuria involving 
non-steroidal inflammatory agents, angiotensin converting 
enzyme inhibitors or protein restriction are available but 
there is little information on the effect of these 
interventions on plasma lipids and lipoproteins. In 
chronic, unremitting nephrotic syndrome, many physicians 
will actively treat hyperlipidaemia. The following section 
aims to summarise the published work on the hypolipidaemic 
measures employed in refractory nephrotic syndrome.
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Few studies have looked at the effect of dietary 
restriction of cholesterol, saturated fat or calories alone 
in nephrotic hyperlipidaemia. Most drug studies, however, 
have incorporated some form of lipid lowering diet into the 
regimen. The precise importance of this is uncertain 
although, considering the degree of hyperlipidaemia in 
nephrotic syndrome, it is unlikely that dietary 
manipulation alone would reduce plasma lipids to 
"normal"levels.
In the last 2 0 years, a number of reports of 
pharmacological treatment have appeared. Edwards(12 0) 
performed a series of animal experiments demonstrating the 
efficacy of a wide range of agents in the hyperlipidaemia 
of experimental nephrosis and was one of the first to 
advocate a more aggressive approach to the problem in man. 
Enthusiasm for this was dampened by the experience of 
Bridgeman and co-workers who reported symptoms of muscle 
toxicity in 5 of 6 patients treated with clofibrate(121). 
Pharmacokinetic studies indicated that there was a greater 
proportion of free drug in plasma of nephrotic patients due 
to reduced protein binding and that the ratio of conjugated 
to unconjugated drug in the urine was lower. These 
differences would have led to a relative overdose of active 
drug. Recent experience with a newer fibric acid 
derivative, gemfibrozil, has shown that this group of drugs
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can produce significant improvements in lipid parameters, 
especially triglyceride, without adverse effects(122,123).
Bile acid binding resins, which are still the mainstay of 
treatment of hypercholesterolaemia in the general 
population, have been used relatively infrequently in 
published studies of nephrotic syndrome although anecdotal 
experience suggests that they are poorly tolerated. In a 
placebo-controlled trial, colestipol reduced plasma and 
LDL-cholesterol in 6 out of 7 patients with average 
reductions of 20% and 32% respectively(124). The drug was 
generally well tolerated although others have reported 
problems with this group of drugs(123,125). Concern has 
been expressed that reduced absorption of vitamin D, which 
is already impaired in nephrotic syndrome, may precipitate 
osteomalacia.
Conflicting evidence has been reported on the efficacy of 
probucol in nephrosis(124,126) and experience with 
nicotinic acid derivatives is limited.
The advent of a new group of drugs which lower plasma 
cholesterol by inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A reductase, the rate limiting enzyme in 
cholesterol biosynthesis, has stimulated new interest in 
the field of cholesterol-lowering therapy(127). Reductions 
of 3 0-40% in total and LDL-cholesterol have been achieved
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and the drugs appear to be well tolerated although long 
term experience is limited. Early reports(69,125,128,129) 
of their use in the nephrotic syndrome have been 
encouraging with reductions of total cholesterol of 35% and 
of LDL-cholesterol of >40%. The magnitude of reduction 
and the lack of side effects to date suggest this group of 
drugs may be eminently suitable for reducing 
hypercholesterolaemia in nephrotic syndrome.
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TABLE 1.1 - PHYSICAL CHARACTERISTICS OF LIPOPROTEINS
density Sf
(g/ml) value3
chylomicrons <0.93 >400
VLDL 0.93-1.006 20-400
IDL 1.009-1.016 12-20
LDL 1.019-1.063 0-12
HDL2 1.063-1.125 3.5-20
h d l 3 1.125-1.210 0-3.5
particle molecular EP*3
size(nm) weight mobility
(daltons)
75-1200 400 x 106 origin
30-80 10-80 X 106 pre-beta
25-35 5-10 x 106 slow pre-beta
18-25 2.3 x 106 beta
9-12 3.6 x 105 alpha
5-9 1.8 x 105 alpha
a - Flotation rate in Svedberg units. ApoB-containing lipoproteins measured at d=1.063g/mL; 
HDL measured at d=1.210g/mL 
b - electrophoresis on agarose gel
TABLE 1.2 - MEAN PERCENTAGE COMPOSITION OF LIPOPROTEIN CLASSES
free cholesterol triglyceride phospho- 
cholesterol ester lipid
protein
chylomicrons
VLDL
IDL
LDL
HDL2
HDL3
5
12
23
38
16
12
2
7
8 
10 
6 
3
84
55
32
9
4
4
7
18
21
22
30
26
2
8
16
21
44
55
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TABLE 1.6 - CAUSES OF NEPHROTIC SYNDROME
PRIMARY GLOMERULAR DISEASES SECONDARY GLOMERULAR DISEASES
minimal change 
focal glomerulosclerosis 
membranous idiopathic 
secondary 
mesangiocapillary type I & II 
mesangial IgA
other mesangioproliferative GN 
hereditary GN(Alport's, nail-patella) 
congenital nephrosis
VASCULAR
renal vein thrombosis/arterial stenosis
hypertension
INFLAMMATORY
systemic vasculitides incl. SLE
anti-GBM disease
INFECTION
post-streptococcal
hepatitis B
bacterial endocarditis/shunt nephritis 
NEOPLASTIC
myeloma/light chain nephropathy
MISCELLANEOUS
diabetes mellitus
amyloidosis
pregnancy-associated
transplant rejection
severe right heart failure
Note: Primary glomerular diseases are diagnosed by histopathological features and the 
exclusion of systemic disorders which cause similar appearances.
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CHAPTER 2 GENERAL METHODS
2.1 Materials and methods
All biochemical parameters were measured in the routine 
laboratories of the Institute of Biochemistry, Glasgow 
Royal Infirmary. Measurements of cholesterol and 
triglyceride were performed by automated enzymatic assays 
(source: Boehringer Mannheim, East Lewes, Sussex, UK) on a 
Hitachi 704 analyser(source: Hitachi Ltd., Tokyo, Japan). 
Subfractionation of total plasma cholesterol was performed 
by "beta-quantification"(13 0). Very low density 
lipoproteins(d<l.006g/mL) were separated from 5mL of 
plasma by ultracentrifugation. Low density lipoproteins 
were precipitated from the d>1.006g/mL fraction with 
heparin/manganese. The precipitate was separated by 
centrifugation and HDL-cholesterol measured in the 
supernatant solution. LDL-cholesterol was calculated as 
the difference between total cholesterol and the sum of 
VLDL- and HDL-cholesterol.
The composition of lipoprotein subfractions was analysed 
using the previously described assays for total cholesterol 
and triglyceride. Free cholesterol was measured by a 
similar colorometric method omitting the cholesterol 
esterase step. Phospholipid was also assayed by an 
enzymatic method involving phospholipase(source: Boehringer
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Mannheim, East Lewes, Sussex, UK). Protein content of 
isolated lipoproteins was measured by Lowry's method(131). 
Where samples were turbid, sodium dodecylsulphate(lmg/mL) 
was added to the copper alkali solution to disperse large, 
triglyceride-rich particles. Results were converted into 
mg/dL to calculate the total lipoprotein concentrations in 
plasma and the percentage composition by weight of each 
subfraction.
Apolipoprotein AI and B levels were measured by an 
automated immunoturbidometric method using commercially 
available kits(source: Orion Diagnostica, Espoo, Finland). 
Lipoprotein(a) was assayed using an enzyme linked immuno­
sorbent assay(source: Immuno AG, Vienna, Austria). High 
density lipoprotein subfractions(HDL2 and HDL3) were 
measured by analytical ultracentrifugation(132). 
Apolipoprotein E phenotypes were defined by isoelectric 
focusing(13 3).
Serum electrolytes, urea, creatinine and proteins were 
assayed in the routine biochemistry laboratory using a 
multi-channel analyser. Urinary creatinine was measured by 
the Jaffe reaction on a Hitachi 717 autoanalyser(source: 
Hitachi Ltd, Tokyo, Japan). Total urinary protein was 
measured by the Ponceau-S dye-binding method(134) and 
urinary albumin concentration by a specific 
radioimmunoassay(135).
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All chemicals and reagents used were obtained from Sigma 
(Poole, Dorset, UK) or BDH chemicals(Poole, Dorset, UK) 
except where otherwise indicated in the text. Ultra­
centrifugation procedures were performed on L8-60 or L5 
machines(source: Beckman, Palo Alto, California, USA) using 
Beckman rotors as detailed in individual methods.
Statistical tests are detailed in the text.
2.2 Patients
In an attempt to limit the effect of factors other than 
proteinuria/hypoalbuminaemia on plasma lipids and 
lipoproteins, these studies were restricted to patients(age 
18-70years) who fulfilled the following criteria
- primary glomerular disease
- quantitative proteinuria >3g/day on two consecutive 
visits
- serum creatinine <400umol/L
Subjects with the following diagnoses were excluded 
diabetes mellitus, amyloid, systemic lupus erythematosus, 
malignant disease, immunosuppressive therapy and pregnancy. 
All of these conditions may independently perturb lipid 
metabolism.
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Between 1st October,1988 - 1st October,1990, data was 
collected on 45 patients who fulfilled the above criteria. 
Over this period, a total of 242 patients with proteinuria 
in excess of 3g/day on at least one occasion were recorded 
on the renal unit computer base at Glasgow Royal Infirmary. 
One hundred and forty nine patients were excluded because 
of renal failure, interstitial renal disease or other 
systemic disease. The rest were excluded by other 
criteria, failed to attend when invited or had been lost to 
follow-up. These 45 subjects formed the population base 
for the subsequent studies. Fasting lipids and lipoprotein 
cholesterol concentrations were determined in all patients. 
Subfractionation of apoB-containing lipoproteins, 
apolipoprotein AI and B and lipoprotein(a) concentrations 
were performed in the majority of subjects.
Patients with hypercholesterolaemia(>7mmol/L) were invited 
to take part in the metabolic and drug studies to 
investigate the mechanisms responsible for hyperlipidaemia 
in the nephrotic syndrome and the response to treatment. 
Controls were recruited from laboratory and clinical 
personnel, from coronary screening projects in the Glasgow 
area and from patients attending the renal unit at Glasgow 
Royal Infirmary with minor renal disease. All subjects 
were studied as outpatients and asked to continue their 
normal diets except where indicated. For the metabolic 
studies, steady state conditions of lipoprotein metabolism
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were confirmed by at least 3 measurements of plasma lipid 
and lipoprotein levels over the study period. The 
coefficient of variation for each patient's plasma 
cholesterol level was <10%. The figure for plasma 
triglyceride ranged up to 20%.
Participants in the metabolic investigations were given a 
personal explanation of the nature and aims of these 
studies and many were also given a pamphlet repeating this 
explanation. Written consent was obtained. Potassium 
iodate was administered orally for three days before each 
study and continued for four weeks to prevent thyroidal 
sequestration of radioiodide. All studies were approved by 
the Ethics Committee of Glasgow Royal Infirmary. Professor 
J Shepherd of the Institute of Biochemistry is licensed to 
administer radioactively labelled lipoproteins to human 
volunteers for the investigation of lipoprotein metabolism 
by the Adminstration of Radioactive Substances Advisory 
Committee of the Department of Health.
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2.3 Lipoprotein kinetics - theory, modelling and 
computing
Over the last thirty years considerable information 
regarding normal and abnormal lipoprotein metabolism has 
accumulated from in vivo tracer studies using labelled 
lipoprotein particles. For a full consideration of the 
available techniques, readers are referred to Berman(136). 
The discussion here will be limited to the techniques used 
in this thesis including their theoretical basis, 
underlying assumptions and limitations and the analysis of 
experimental data.
The apoB-containing lipoproteins contain one molecule of 
apoB per particle. ApoB is integral to the structure of 
these particles, remains with them throughout their 
lifetime in the circulation and is removed with the 
particle from the plasma compartment. Therefore, by 
labelling apoB and following its metabolic fate in the 
plasma, the metabolism of these lipoprotein particles can 
be investigated. ApoB may be labelled endogenously by the 
intravenous administration of isotopically-labelled amino 
acids(e.g. [ 7 5 S e ] selenomethionine or tritiated leucine) or
exogenously with radioiodide. The former involves 
relatively large doses of radioactivity, labels all plasma 
proteins and is complicated by the re-cycling of tracer 
from rapidly catabolised proteins. However, it does
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eliminate the possibility that artefacts introduced during 
ex vivo labelling alter the behaviour of the tracer and 
destroy tracer-tracee equivalence. In contrast, radio- 
iodination of lipoproteins involves relatively small doses 
of radioactivity and the free iodotyrosine released during 
catabolism is rapidly cleared via the renal tract with 
negligible re-cycling. The principal disadvantages are 
that only catabolism is examined directly and concern has 
been expressed that tracer damage may occur during the 
labelling process or that iodination may change the 
chemical properties of the apolipoprotein and interfere 
with its metabolism(137). However, studies in rabbits have 
shown that radiolabelled tracers, screened in vivo for 24 
hours then re-isolated, decay at the same rate as newly 
labelled lipoproteins(138).
Radioiodinated lipoproteins were first used in tracer 
experiments in the 1950's(66) but their potential was not 
fully realised until Langer(139) reported a reduction in 
the fractional catabolic rate(FCR) of radioiodinated LDL in 
patients with familial hypercholesterolaemia. This 
observation laid the groundwork for the identification of 
the metabolic block in this condition. Subsequently, apoB 
metabolism has been extensively investigated in a range of 
dyslipidaemic states.
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The protein moiety of lipoprotein particles is 
radioiodinated by the iodine monochloride method(140,141). 
The apolipoprotein content of LDL particles is 90-95% apoB 
and previous work(141) has shown that nearly all the 
radioactivity is associated with the protein moiety. 
Following intravenous injection, the radioactivity remains 
in the LDL fraction(figure 2.1) and the plasma 
radioactivity decay provides an estimate of the catabolic 
rate of LDL apolipoprotein(apoLDL). Free radioiodide 
released from LDL is rapidly cleared from the circulation.
When VLDL is labelled with radioiodide, significant 
quantities of label will be associated with other 
apolipoproteins(C and E) and lipids. In vivo. the apoB is 
transferred by progressive delipidation of VLDL particles 
to lipoproteins of higher density(i.e. IDL and LDL). To 
follow the metabolism of apoB, it is necessary to 
subfractionate(see chapter 3) the apoB-containing 
lipoproteins and measure the specific activity of apoB 
(counts per minute/mg apoB) in each fraction. This permits 
investigation of precursor-product relationships among 
these lipoprotein fractions(see chapter 6 methodology).
Studies with labelled lipoproteins generate data in the 
form of plasma total or specific radioactivity curves. 
Lipoprotein pool sizes are measured separately. These data 
can be analysed in a number of ways but the application of
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multicompartmenta1 modelling generates a number of 
kinetic parameters which quantitatively describe the 
metabolism of the lipoprotein fractions. These are useful 
for comparisons with normal or other disease states; for 
generating and testing quantitative hypotheses of 
lipoprotein metabolism in vivo; and for planning further 
experiments to help validate the model. In the modelling 
process, each apoB-containing lipoprotein fraction is 
considered to comprise a number of discrete metabolic 
compartments. In the steady state, the size of each 
compartment is stable i.e. transfer rates in and out are 
equal. The transfer between compartments is assumed to 
follow first order kinetics and can therefore be described 
by a linear function:-
R(i,j) = L(i,j) x M(j)
R(i,j) is the flux from compartment j to i in mg apoB/day 
L(i,j) is the rate constant for this flux in pools/day 
M(j) is the mass of apoB in compartment j in mg 
The shape of the plasma decay/appearance curves determines 
the number of exponentials which are required to explain 
the experimental data. The flux from a compartment is 
equal to the sum of the individual rate constants 
multiplied by the mass i.e.:-
R(x,j) = [L(i1#j)+L(i2,j)+L(in ,j)+----] x M(j)
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The series of differential equations thus generated can be 
solved simultaneously for the experimental data given 
initial estimates of the distribution of the tracer between 
the compartments in the pools. Fixed standard deviations 
of 5% were used for each data point. The modelling was 
done using the SAAM(simulated analysis and modelling) 
programme in its interactive mode(CONSAM) run on the VMS 
system of the Glasgow University computer network(142,143).
The SAAM programme generates a solution from the observed 
data by a least squares fit procedure and plots calculated 
plasma radioactivity curves for each compartment. These 
curves can then be "hand-fitted" i.e. the individual rate 
constants altered to approximate the observed and 
calculated data sets. When the sum of squares of the 
differences between these values is reduced below an 
arbitrary level, an automated iterative procedure is 
employed in which a series of changes in parameters is 
tested with the aim of reducing the overall sum of squares 
to a minimum value. Weighting of data points allows the 
operator to minimise the effect of outlying data points on 
the solution. Both radioactivity and mass data are used to 
provide a single solution containing rate constants, 
calculated pool sizes and synthetic inputs.
The compartmental models used in the kinetic studies of 
VLDL and LDL are described under methods for these sections
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(chapters 5 and 6, respectively) but the general principles 
are applicable to both.
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CHAPTER 3 THE RELATIONSHIP BETWEEN HYPERLIPIDAEMIA AND 
PROTEINURIA
3.1 PREVALENCE OF LIPID AND LIPOPROTEIN ABNORMALITIES IN 
NEPHROTIC SYNDROME/PROTEINURIA
3.1.1 Introduction
Few studies have documented the prevalence of lipid and 
lipoprotein abnormalities in an unselected population of 
subjects with idiopathic nephrotic syndrome. The patients 
identified by the methods in section 2.2 formed the 
population base for subsequent studies. In this section, 
the abnormalities of lipid and lipoprotein are 
characterised and related to severity of disease.
3.1.2 Patients and methods
Subjects were contacted either at routine clinic visits or 
by post and invited to attend with a view to participating 
in these studies. Fasting blood was drawn for plasma 
lipids, beta-quantification of lipoprotein cholesterol, 
apolipoprotein E phenotype and lipoprotein(a) measurements. 
Twenty four hour urine collections and serum for creatinine 
and albumin were collected at the same time. A group of 
192 patients selected from the data base of a coronary 
screening project(described below) were used as controls
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for comparisons of plasma lipid and lipoprotein cholesterol 
concentrations. The assays were performed in the same 
laboratory. However, there was an interval of 
approximately 2-4 years between the periods of data 
collection and, in the control group, LDL-cholesterol 
levels were calculated by the Friedewald formula(144) 
rather than measured directly. The use of this formula has 
been validated up to a triglyceride concentration of 
5mmol/L and all the control group had plasma concentrations 
below this value.
In a sub-group of patients, the apo B-containing 
lipoproteins were separated into VLDL1 (Sf 60-400), VLDL2 
(Sf 20-60), IDL(Sf 12-20) and LDL(Sf 0-12) by cumulatative 
flotation ultracentrifugation on a density gradient(see 
chapter 5 methods). Seven millilitres of fresh fasting 
plasma was adjusted to a density of 1.118g/mL by the 
addition of 1.194g of solid NaCl. Three x 2mL aliquots 
were then layered onto 0.5mL of a solution of d=1.182g/mL 
in a Beckman SW40 tube using a peristaltic pump. The 
density gradient was then layered on top as shown in figure 
3.1. The four lipoprotein fractions were recovered by 
sequential ultracentrifugation using the protocol shown 
in the same figure. All runs were performed at 23°C and 
decelerated with the brake off to minimise disruption of 
the gradient. The time of each run was corrected for 
acceleration and deceleration. VLDL^ was recovered by
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careful aspiration of the top lmL of each tube which was 
then replaced by lmL of d=l.0588g/mL. VLDL2 and IDL were 
recovered in 0.5mL and LDL in lmL fractions. These were 
analysed for lipid and protein by the methods described 
above and the plasma concentrations and compositions 
calculated.
These data were used to estimate the prevalence and 
nature of lipid and lipoprotein abnormalities and the 
relationship with serum albumin and proteinuria.
Preliminary frequency plots were used to judge whether the 
data were normally distributed. Plasma triglyceride and 
lipoprotein(a) both showed a highly skewed distribution but 
became Gaussian on log transformation of the data. Two 
sample t tests were used to compare data between groups 
except for the subfraction concentrations which 
demonstrated a wide variance and were analysed by 
distribution-free methods(Mann Whitney test). Least squares 
linear regression was used to explore the relationships 
between lipid values and proteinuria/hypoalbuminaemia.
2These are summarised as coefficients of determination(r 
values) and the signifigance assessed by analysis of 
variance.
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3.1.3 Results
Over a two year period, data on plasma lipids and 
lipoproteins were collected on 45 patients who fulfilled 
the criteria listed in chapter 2. The mean age was 45 
years(range 17-68) and there was a preponderance of 
males(M:F=32:13). The period of follow-up(taken from 
time of renal biopsy) varied greatly from a minimum of 1 
month to over 25 years in the case of one patient with 
membranous nephropathy, persistent proteinuria and very 
slowly declining renal function. The median time from 
diagnosis was 33 months.
All patients had an established histological diagnosis of 
primary glomerular disease. The main categories were 
idiopathic membranous nephropathy(27), minimal change(5), 
mesangiocapillary glomerulonephritis(4) and IgA nephropathy 
(3) . There were two subjects with poorly defined 
mesangioproliferative lesions and single cases of focal 
glomerulosclerosis, glomerulosclerosis related to 
hypertension, nail patella syndrome and probable hereditary 
nephropathy. The average serum creatinine was 159umol/L(sd 
83) and proteinuria ranged from 3.0-24.2g/day(mean 9.0). 
Mean serum albumin was 31g/L(sd 6).
The plasma lipid and lipoprotein cholesterol values and 
physical characteristics of the nephrotic and control
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groups are compared in table 3.1. As expected, there were 
considerable increases in plasma cholesterol, triglyceride 
and LDL-cholesterol in the nephrotic group. HDL- 
cholesterol were decreased compared to controls. 89% of 
subjects had total cholesterol >6.5mmol/L - a level at 
which a number of authorities strongly recommend positive 
lipid-lowering measures in the general population(145). 
34/45 patients had severe hypercholesterolaemia(i.e. 
>7.8mmol/L). A smaller number(84%) had LDL-cholesterol 
values greater than 4mmol/L. Elevated fasting triglyceride 
concentrations(>2mmol/L) were present in 66% with 5 
patients exhibiting severe hypertriglyceridaemia 
(>6.5mmol/L). No patients had hypertriglyceridaemia and 
plasma cholesterol <6.5mmol/L.
Relationships between the severity of nephrotic syndrome 
and hyperlipidaemia were sought using quantitative 
proteinuria and serum albumin as explanatory variables.
The coefficients of determination and the signifigance of 
the slopes of the regression lines determined by analysis 
of variance are listed in table 3.2. The strongest 
association was an inverse relationship between 
LDL-cholesterol and serum albumin. Serum albumin 
correlated only weakly with total cholesterol and not at 
all with triglyceride. In contrast, proteinuria showed 
some association with all three lipid measurements.
However, there were significant inter-individual
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variations. The subject with the highest LDL-cholesterol 
(16.3mmol/L) had only modest hypoalbuminaemia(29g/L). No 
relationships could be demonstrated between HDL-cholesterol 
and these parameters. Body mass index, age or length of 
follow up did not show any significant associations with 
lipid values.
Lipoprotein(a) concentrations were measured in 30 subjects. 
Values ranged from undetectable in one patient to 320mg/dL. 
The median value was 32mg/dL i.e. 50% of subjects had a 
plasma concentration greater than the level(3 0mg/dL) that 
has been postulated as indicating an increased risk of 
atherosclerosis(17). There was a significant correlation
between the log transformed Lp(a) concentrations and serum
2
albumin(r =35.9%, p=0.001) although there was no such 
association with proteinuria(figure 3.2).
Table 3.3 lists the plasma concentrations and composition 
of the four apoB-containing lipoprotein subfractions 
separated by density gradient ultracentrifugation in 33 
nephrotic subjects and a group of 21 normolipidaemic 
controls. There were marked increases in the plasma 
concentrations(calculated from the sum of the masses of 
lipids and protein) in all four subfractions. The free 
cholesterol content of VLDL1, VLDL2 and IDL was increased 
in the nephrotic group but LDL isolated by this method had 
a normal composition.
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3.1.4 Discussion
Plasma lipids and lipoprotein-cholesterol
These results broadly reflect the changes reported in the 
main published series on hyperlipidaemia in the nephrotic 
syndrome(41,46,48). In these studies, however, it is 
unclear whether all patients with nephrotic syndrome were 
screened for lipoprotein abnormalities. Thus, the 
occurrence of hyperlipidaemia in 100% of subjects may be a 
result of patient selection. In a smaller study of 20 
consecutive patients with nephrotic syndrome, Appel et 
al.(47) recorded elevated plasma cholesterol in "most" 
patients with 70% lying above the 95th centile for age and 
sex. The paper does not give the individual lipid values 
but some patients were not considered
hypercholesterolaemic. The data presented here and other 
studies confirm that hyperlipidaemia is a very common but 
not invariable complication of heavy proteinuria.
Differences between study populations may influence the 
nature and prevalence of lipid abnormalities even when 
other factors(e.g. diabetes mellitus, systemic lupus 
erythematosus, renal failure, corticosteroid therapy) are 
excluded. In both this study and Appel's(47), proteinuria 
alone was used to define the nephrotic syndrome while 
others have only included those with reduced serum albumin
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- usually <30g/L. In Baxter's study(41), the subjects were 
severely hypoalbuminaemic with all but 15/58 lipid 
measurements taken when serum albumin was <20g/L. Only one 
subject in the current study had serum albumin <20g/L.
This may reflect poorer nutrition thirty years ago, 
improvements in accuracy of albumin assays or simply that 
the study populations are truly different. In this study, 
only one patient with plasma cholesterol <6.5mmol/L had 
serum albumin <3 0g/L. A few months after diagnosis this 
patient died and, at autopsy, was found to have bronchial 
carcinoma. This may have been the underlying cause of his 
glomerular disease and may have modified the changes in 
lipoproteim metabolism produced by nephrosis.
Hyperlipidaemia and severity of nephrosis
In the current study, the association between severity of 
disease and hyperlipidaemia is best illustrated by the 
negative correlation between LDL-cholesterol and serum 
albumin. Proteinuria also correlated with total and 
LDL-cholesterol concentrations. More severe disease with 
heavier proteinuria and falling serum albumin was 
associated with an exponential rise in plasma 
triglycerides.
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Lipoprotein(a)
Significant elevations of lipoprotein(a) were found in the 
group of thirty patients tested. A similar finding has 
recently been reported by Karadi et al.(146). The 
concentrations of Lp(a) in some patients were very high - 
up to 320mg/dL. The mechanism of the rise in Lp(a) in this 
condition is not known. The concentration of Lp(a) is 
markedly influenced by phenotypic variation in Lp(a) 
isoforms(147) and the interaction of these and nephrosis 
may be important in determining the final plasma 
concentration. Studies of Lp(a) metabolism in both normal 
and nephrotic subjects are required to elucidate the 
pathophysiology of these changes.
Apolipoprotein B-containing subfractions
The increases in plasma lipids in nephrotic syndrome are 
reflected in the substantial rises in all apoB-containing 
lipoprotein subfractions although the magnitude of these 
changes were very variable. VLDL^ VLDL2 and IDL were all 
enriched in free cholesterol. This conclusion is only 
tentative for VLDL1 due to the very low content of free 
cholesterol in the controls which in some cases was below 
the limit of detection. However, the increased free 
cholesterol content in both VLDL2 and IDL supports this 
finding. This could be explained by reduced LCAT activity
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(86,87). The composition of LDL isolated by DGUC was not 
significantly different from controls. There are 
relatively few previous studies of lipoprotein composition 
in human nephrotic syndrome but in one report Gherardi et 
al. (42) found an increase in cholesterol ester and 
phospholipid content of VLDL and IDL at the expense of free 
cholesterol. Again, interpretation of this discrepancy is 
complicated by differences in the populations since 
Gherardi's study was on children.
In conclusion, these results emphasise that both 
guantitative and qualitative changes occur in the plasma 
lipoproteins in the nephrotic syndrome. The previously 
documented relationships between severity of nephrotic 
syndrome and hyperlipidaemia were confirmed. Lipoprotein(a) 
concentrations were elevated and significant changes in the 
concentration and composition of apoB-containing 
lipoprotein subfractions were found.
3.2 THE EFFECT OF NON-NEPHROTIC(<3.5g/day) PROTEINURIA ON 
BLOOD CHOLESTEROL
3.2.1 Introduction
Although the relationship between heavy proteinuria and 
hyperlipidaemia has been extensively reported, there is 
surprisingly little information on the effects of lower
9 3
levels of proteinuria on plasma lipids. This issue was 
addressed in a study looking at the relationship between 
urinary albumin excretion and blood cholesterol 
concentrations in an outpatient population attending a 
glomerulonephritis clinic.
3.2.2 Method and subj ects
Aliquots of routine 24 hour urine collections and 
non-fasting serum were obtained from patients attending a 
renal outpatient clinic. Only patients with primary 
glomerular disease and well-maintained renal function(serum 
creatinine <200umol/L) were included. Those with other 
diseases known to effect lipoprotein levels were 
excluded(see chapter 2). Over a period of 9 months, 
samples were collected from 100 patients and urinary 
albumin excretion rates(AER) and serum cholesterol and 
albumin were measured.
Cholesterol measurements were compared with age, sex and 
weight matched controls. For each subject two controls 
were selected from a database of 10,000 subjects who 
participated in a coronary screening project between 1983 
and 1985(148). Controls were selected in groups of ten 
taken from blocks of 500 participants and were matched for 
sex, age within 5 years and weight within 10%. The average 
values of the two controls were used for comparisons with
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the groups defined by albuminuria(see below) and for 
investigating the relationship between cholesterol and both 
AER and serum albumin. Controls were not located for five 
patients <18 or >65years and these subjects were excluded.
Paired t tests were used to compare cholesterol values in 
the albuminuric and control groups. Both cholesterol and 
albumin excretion rate were negatively skewed in the 
patient group but became Gaussian on log transformation 
of the data. Linear regression of the log transformed 
values was used to examine the relationship between AER and 
serum cholesterol.
3.2.3 Results
The patient group contained patients with a range of 
primary glomerular disease(minimal change 19, mesangio- 
proliferative glomerulonephritis with IgA or IgM deposits 
38, membranous nephropathy 27, mesangiocapillary glomerulo­
nephritis 6, focal glomerulosclerosis 2, other 8). No 
account was taken of those whose disease was judged to be 
in remission since the end-point was the relationship 
between cholesterol and albumin excretion. The group 
encompassed a very wide range of AER from 1.6 to 
15420mg/day(median 257). Serum cholesterol was also 
distributed over a wide range from 3.6 to 14.Ommol/1(median 
6.6). The group were split into 4 subgroups according to
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the rate of albumin excretion
1. <30mg/day i.e. normal(n=29)
2. 30-300mg/day - equivalent to a rate used to predict 
overt nephropathy in diabetes mellitus(n=21)
3. 300-3000mg/day - clinically significant proteinuria
but less than nephrotic range(n=31)
4. >3000mg/day - nephrotic-range proteinuria(n=14)
Plasma cholesterol in each of these groups was compared
with the values in the appropriate control subjects(table
3.4). The only group where there was a significantly
increased cholesterol was the nephrotic group. However,
when all 100 subjects were considered there was an increase
in the plasma cholesterol concentrations in the proteinuric
group and a relationship between serum cholesterol and
albuminuria after log transformation(figure 3.3). This
relationship persisted even when those subjects with
albuminuria in excess of 3000mg/day were excluded although
2
the association was predictably weaker(r =7.1%, p<0.02). 
When albumin losses increased to >5g/day, cholesterol rose 
exponentially.
3.2.4 Conclusion
There is little data available on the relationship of blood 
cholesterol with lower levels(i.e. non—nephrotic) of
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urinary protein loss. By limiting this study to otherwise 
healthy patients with well-documented primary glomerular 
pathology, the effect of glomerular permeability alone on 
serum cholesterol was sought.
As expected those subjects with heavy proteinuria had 
raised cholesterol concentrations although in two subjects 
plasma cholesterol concentrations were <4mmol/L despite an 
AER >3000mg/day. In the other groups, there were no 
significant differences between the subjects and matched 
controls but overall there was a relationship between log 
albumin excretion and cholesterol suggesting that even at 
lower(i.e. non-nephrotic) rates of protein loss, serum 
cholesterol may be adversely effected. This may be of 
importance in the light of recent reports that 
microalbuminuria is a predictor of vascular disease in 
non-diabetic subjects(149,150) and of increased lipids in 
diabetics with microalbuminuria compared to well-matched 
diabetics without renal involvement(151). However, other 
factors such as hypertension may also be important in 
linking increased glomerular permeability to an increased 
risk of vascular disease.
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3.3 URINARY ALBUMIN EXCRETION IN PATIENTS WITH PRIMARY 
HYPERLIPIDAEMIA
3.3.1 Introduction
Despite the evidence that hyperlipoproteinaemia may be 
nephrotoxic (116), there are no published studies of renal 
function in patients with primary hyperlipidaemia. In this 
section, urinary albumin excretion was used as a sensitive 
measure of renal dysfunction in patients with primary 
hyperlipidaemias.
3.3.2 Methods and subjects
Fasting plasma and random urine samples were collected from 
patients routinely attending the lipoprotein clinic at 
Glasgow Royal Infirmary. Patients with the following 
conditions were excluded:- diabetes mellitus, known renal 
disease or serum creatinine >120umol/L, hypertension or BP 
>170/95, malignancy, thyroid disease, connective tissue 
diseases, treatment with non-steroidal anti-inflammatory 
drugs. Over a period of 3 months, 141 samples were 
collected. Cholesterol and triglycerides were measured on 
plasma samples and albumin and creatinine on the urine 
samples. The results were compared with published data on 
albumin excretion rates. The relationship between 
albuminuria and hyperlipidaemia was tested by linear
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regression after log transformation of the albumin and 
triglyceride data and by comparing AER's between the upper 
and lower quartiles of the cholesterol distribution.
3.3.3 Results
The plasma cholesterol in this group of 141 patients with 
primary hyperlipidaemia averaged 7.73mmol/L; range 4.15 to 
13.3mmol/L. Urinary albumin concentrations and albumin: 
creatinine ratios demonstrated a negatively skewed 
distribution as shown in figure 3.4. These values are 
similar to those reported by Watts(152) for random urine 
samples in normal ambulant subjects. In this study, the 
upper 95% confidence limit was 29.6mg/L for albumin 
concentration and 2.3mg/mmol for albumin:creatinine ratio. 
Only 1.4% and 4.4% respectively of the results recorded in 
this study lie above these cut-off points.
There was no relationship between plasma cholesterol and 
either urinary albumin concentration(figure 3.5a) or 
albumin:creatinine ratio. A weak association was seen 
within the group between the log transformed plasma 
triglyceride concentration and urinary albumin 
concentration(figure 3.5b; r^=3.1%, p<0.05). There was no 
difference between the mean values for albumin 
concentration between the upper and lower quartiles of the 
cholesterol distribution(0.735 sd 0.374 v 0.802 sd 0.286;
99
p = 0 . 4 )  .
3.3.4 Conclusion
There was no evidence from this study that primary 
hyperlipidaemia per se can cause renal dysfunction as 
assessed by urinary albumin excretion. Although there is 
accumulating evidence for a role of hyperlipidaemia in the 
progression of renal disease(mainly based on experimental 
animal models), this may only be a secondary phenomenon 
following a primary renal insult. This contention is 
supported by the absence of reports of renal disease in 
homozygous familial hypercholesterolaemia or in the animal 
model of this disease, the Watanabe rabbit. However, 
glomerulosclerosis can be induced by cholesterol feeding 
alone in some animals(111) and is a recognised feature of 
the rare familial lecithin cholesterol acyltransferase 
deficiency in man(110).
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TABLE 3.1 - PHYSICAL CHARACTERISTICS AND LIPID PARAMETERS FOR CONTROL
AND NEPHROTIC GROUPS
n
sex(M:F) 
age(years) 
BMI(kg/m2) 
plasma cholesterol 
plasma triglyceride 
LDL-cholesterol 
HDL-cholesterol
CONTROL NEPHROTIC signifigance 
(two sample t test)
192 45
120:72 32:13 nsa
44(11) 45(14) ns
26.1(4.1) 25.6(3.6) ns
5.9(1.2) 10.5(4.6) <0.0001
1.7(1.4) 3.9(3.8) <0.0001b
3.75(1.03) 6.79(3.25) <0.0001
1.43(0.38) 1.18(0.35) 0.0001
Figures in parenthesis are standard deviations. Lipid values are in mmol/L 
a - chi-square test b - comparing log transformed values
TABLE 3.2 - CORRELATIONS BETWEEN LIPID PARAMETERS AND INDICES OF
DISEASE SEVERITY
n explanatory response r2(%) signifigan
variable variable
42 albumin LDL-chol 29.4 <0.001
44 albumin plasma chol 9.2 0.05
43 albumin plasma trig(log) 0 0.89
43 proteinuria LDL-chol 17.9 0.005
45 proteinuria plasma chol 14.4 0.01
44 proteinuria plasma trig(log) 10.1 0.04
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TABLE 3.4 - SERUM CHOLESTEROL CONCENTRATIONS IN RELATION TO ALBUMIN
EXCRETION RATE
ALBUMIN CHOLESTEROL(mmol/L) paired
EXCRETION RATE t test
(mg/day) n albuminuric control p
<30 29 5.9(1.3) 5.7(0.9) ns
30-300 21 6.2(1.7) 5.7(1.0) ns
300-3000 .31 6.5(1.3) 6.0(0.9) ns
>3000 14 8.5(2.4) 6.2(0.6) <0.02
Cholesterol values are shown as means and standard deviations
FIGURE 3.1 DENSITY GRADIENT FOR SEPARATION OF 
apoB-CONTAINING LIPOPROTEINS
density(g/ml) Yolume(ml)
1.0588 2
1.0641 2
1.0722 2
1.0790 2
1.0860 1
1.0988 1
1.1180 PLASMA 2
1.1820 L J 0.5
FRACTION SPIN SPEED SPIN TIME 
(Sf) (rpm) (hours:min)
INCREMENT
W2t(x1011)
TOTAL
W2t(x101
VLDLi (60-400) 39000 1:38 1.03 1.03
VLDL2(20-60) 18500 15:41 2.12 3.15
IDL(12-20) 39000 2:35 0.63 4.78
LDL(0-12) 30000 21:10 7.52 12.30
W - radians/sec(rpm/60x2TT); t -  time(sec)
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FIGURE 3.2a
RELATIONSHIP BETWEEN QUANTITATIVE PROTEINURIA AND Lp(a)
6
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FIGURE 3.2b
RELATIONSHIP BETWEEN SERUM ALBUMIN AND Lp(a)
6
r = 35.9%, p=0.001
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FIGURE 3.3
RELATIONSHIP BETWEEN ALBUMIN EXCRETION RATE AND SERUM CHOLESTEROL
r =21%, p<0.001
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FIGURE 3.4
URINARY ALBUMIN CONCENTRATIONS IN SUBJECTS WITH PRIMARY HYPERLIPIDAEMIA
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FIGURE 3.5a - RELATIONSHIP BETWEEN PLASMA CHOLESTEROL 
AND URINARY ALBUMIN CONCENTRATION
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FIGURE 3.5b - RELATIONSHIP BETWEEN PLASMA TRIGLYCERIDE 
AND URINARY ALBUMIN CONCENTRATION
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CHAPTER 4 POST-PRANDIAL LIPOPROTEIN METABOLISM IN NEPHROTIC 
SYNDROME
4.1 Introduction
The epidemiological, experimental and intervention studies 
which have examined the relationship between lipoproteins 
and ischaemic heart disease have focused on the association 
between atherosclerosis and hyperlipidaemia in the fasting 
state. However, the major part of our lives is spent in 
the post-prandial state. Abnormal metabolism of post­
prandial lipoproteins(i.e. chylomicrons) may predispose to 
atherosclerosis(153). The metabolism of these 
triglyceride-rich lipoproteins is inextricably linked to 
that of other lipoproteins more commonly associated with 
atherosclerosis. Lipolysis of chylomicrons leads to a 
reduction in size and an increase in density of these 
particles with excess surface material(phospholipid and 
apolipoproteins AI and C) transferred to nascent HDL 
particles. LDL metabolism may be influenced by the 
delivery of intestinally-derived cholesterol to the liver. 
Although chylomicrons contain only a small percentage by 
weight of cholesterol ester(derived from the diet or 
incorporated by exchange with other lipoproteins in the 
plasma), they may contribute significantly to cholesterol 
flux to the liver due to their rapid turnover. Increasing 
intrahepatic sterol pools will reduce LDL receptor numbers.
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The metabolism of post-prandial lipoproteins may be 
investigated by following the concentration of triglyceride 
and retinyl palmitate in the d<1.006g/mL fraction of plasma 
after a standardised oral fat load containing vitamin A 
(154) . This fat-soluble vitamin is esterified, mainly as 
retinyl palmitate, and incorporated into chylomicron cores 
in the intestinal epithelium. The retinyl ester remains in 
the core of the chylomicron during progressive delipidation 
(mediated by endothelial-bound lipases) and is removed from 
this fraction when chylomicron remnant particles are taken 
up in the liver. Subsequently, retinol is re-secreted from 
the liver bound to retinol-binding protein which is not 
present in the d<1.006g/mL fraction of plasma. The 
concentration of retinyl palmitate in this fraction has 
been used as an indirect measure of circulating chylomicron 
remnants(154,155).
This method has been used to investigate chylomicron 
clearance in a number of disorders over the last 15 
years. Delayed clearance of post-prandial lipoproteins has 
been reported in type III and type IV hyperlipidaemias 
(156,157), patients heterozygous for the E2 allele(158), 
chronic renal failure(159) and in older subjects(160). 
Recently, the potential role of these particles in 
atherogenesis has been supported by the observation that 
subjects with coronary artery disease have slower clearance 
rates(161). There are no published studies of post-
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prandial lipoprotein metabolism in human nephrotic syndrome 
although a number of workers have addressed this question 
in experimental models. The aim of this study was to 
assess and quantify post-prandial lipaemia in human 
nephrotic syndrome.
4.2 Patients and methods
Subjects attended after a 12 hour fast and blood was drawn
for fasting lipids and routine biochemistry. A
standardised fat meal was then administered(161) . 280mL of
fresh double cream, 2 0g sucrose, 20g dried milk powder,
20mL flavoured syrup and 3 00,OOOunits(equivalent to 150mg
of retinol) of aqueous retinyl palmitate(RO-A-Vit - source:
Roche Products, Welwyn Garden City, UK) was made up to a
volume of 500mL with water. This emulsion contained
approximately 137g fat, 11.4g protein, 50.3g carbohydrate
and 400mg cholesterol(total calorie content 1480kcal). A
2
volume equivalent to 65g fat/m was consumed over ten 
minutes. Body surface area was calculated from a nomogram 
based on Du Bois' formula(162). The majority of subjects 
tolerated this well although a few reported some gastric 
fullness and mild nausea. One nephrotic patient, with 
probable irritable bowel syndrome, had moderately severe 
diarrhoea and has been excluded from the analysis. No 
other bowel symptom were reported. In previous studies, 
fat absorption with this test meal has been shown to be
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almost complete(155) although this was not specifically 
determined in this study.
Subjects fasted for the first ten hours after the fat load 
with free access to water and a maximum of two cups of 
black tea or coffee. After ten hours, they were allowed a 
low fat, low vitamin A meal and then fasted until the final 
blood sample. Blood samples were taken at 2 hour intervals 
over the first ten hours and then at 14 and 24 hours.
Plasma was separated at low speed centrifugation and stored 
at 4°C protected from light. When all eight samples were 
collected, the d<1.006g/mL fraction was recovered from 4mL 
of plasma by overlaying with 2mL sodium chloride solution 
(d=l. 006g/mL). Ultracentrifugation was performed for 
16hours at 39000rpm(4°C) in a Ti50.3 or Ti40.3 rotor. The 
d<1.006g/mL fraction containing chylomicrons, chylomicron 
remnants and hepatic VLDL was recovered in the top 2-3mL. 
Cholesterol and triglyceride were measured in plasma and 
this fraction. HDL2 and HDL3 were measured at 0, 6 and 24 
hours and plasma from each of these time points was 
subjected to sequential ultracentrifugation at increasing 
densities of 1.019, 1.063, 1.125 and 1.210g/mL to obtain 
fractions corresponding to IDL, LDL, HDL^ and HDL^ 
respectively. After the final blood sample, subjects were 
given an intravenous bolus of heparin(7OlU/kg) to assess 
heparin—releasable lipase activity. Plasma was obtained 
after 10 minutes, immediately separated at 4 C and then
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frozen at -20°C till assayed.
Retinyl palmitate was measured in the d<1.006g/mL fraction 
from each time point by high pressure liquid chromotography 
(HPLC) - (161). 0.5mL of this fraction was diluted 1:1
with sodium chloride solution(d=l.006g/mL) and 50uL of 10% 
glacial acetic acid added. Fifty uL of retinyl acetate 
(lOug/mL) was added as an internal standard. Neutral 
lipids were extracted twice with diethyl ether. The lipid 
extract was blown down under nitrogen and kept protected 
from light at -20°c till analysed(within 7-14 days). In 
some subjects, retinyl palmitate was also measured in the 
IDL and LDL fractions from the 6 and 24 hour samples to 
assess lipid transfer between lipoprotein fractions in the 
plasma. No retinyl palmitate was found in HDL 
subfractions.
Reverse phase HPLC was performed on a Brownlee aquapore 
RP300 column(source: Brownlee Laboratories, Santa Clara, 
California, USA) using acetonitrile and water as the mobile 
phase. Samples were dissolved in 250-500uL of isopropanol 
and loaded onto the column via an automatic injection 
loop(source: Rheodyne, Cotacti, California, USA). Peaks 
were detected at 345nm using a Holochrome monitor(source: 
Gilson, Middleton, Wisconsin, USA) and integrated 
electronically by a Hewlett-Packard integrator(source: 
Hewlett-Packard, Avondale, Philadelphia, USA). The area
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under the curve was used to calculate the concentration of 
retinyl palmitate by comparison with standards. This was 
corrected for recovery(70-100%) of the retinyl acetate 
internal standard. At a plasma concentration of 1.5mg/dL, 
the intra-assay coefficient of variation(CV) was 5.6%(n=8) 
and the inter-assay CV was 14.5%(n=6). Previous studies 
have shown that a linear relationship exists between 
retinyl palmitate concentrations in a serially diluted 
plasma sample and the value obtained by this method(164).
Plasma triglyceride and d<1.006g/mL retinyl palmitate 
concentration were plotted against time for both nephrotic 
and control subjects. The area under the curve was 
calculated by the "trapezium" method(164) for both using 
the values at 0 hours as the baseline.
Post-heparin lipase activity was measured in vitro by
estimating the rate of lipolysis of a triglyceride
14emulsion. Briefly, plasma was incubated with a C- 
labelled triglyceride/gum arabic emulsion. Released free 
fatty acids were bound to albumin in the reaction mixture 
and extracted with solvents(165). Pooled normal plasma 
was added as a souce of apoCII activator. Selective 
measurement of lipoprotein lipase(LPL) was performed by 
inhibiting hepatic triglyceride lipase(HTGL) with sodium 
dodecylsulphate. HTGL was assayed in 1M NaCl which 
inactivates LPL.
106
Patients were selected according to the criteria in 
chapter 2 with the exception that two patients with more 
advanced renal failure were included in the nephrotic 
group. Control subjects with only minor renal disease(i.e. 
minor proteinuria and serum creatinine <250umol/L) were 
recruited from the renal outpatient clinic to assess the 
effect of heavy proteinuria alone on the lipaemic response. 
The characterisics of the two groups of subjects studied 
are compared in table 4.1. The groups were well-matched 
for age, sex, body mass index and smoking habits. There 
was no statistical difference between the mean serum 
creatinine concentrations. The nephrotic group had the 
anticipated elevations of fasting plasma cholesterol and 
triglyceride.
Statistical analysis
The purpose of this study was to compare the lipaemic 
response to a fat load measured by changes in triglyceride 
and retinyl palmitate concentrations in the d<1.006g/mL 
fraction of plasma in nephrotic subjects and controls. The 
main outcome measures were the peak and increments in 
triglyceride and retinyl palmitate concentrations; the 
areas under the concentration versus time curves for these 
two parameters; and post-heparin lipase activities. These 
were compared by two sample t tests. The relationships 
between the lipaemic response, fasting triglyceride
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concentration, lipase activities and HDL subfraction levels 
for all 2 0 subjects were explored by linear regression 
although no firm conclusions were drawn from any observed 
associations as these were not the primary end-points. 
Stepwise multiple regression was used to determine if the 
lipaemic response(i.e. area under curve for triglyceride or 
retinyl palmitate) could be predicted from a combination of 
fasting triglyceride, HDL subfraction concentrations or 
lipase actvities.
4.3 Results
The most striking feature was the marked inter-individual 
variability within both nephrotic and control as 
demonstrated by the time course of plots of plasma 
concentration of both triglyceride and retinyl palmitate in 
the d<1.006g/mL fraction(figures 4.1 and 4.2). This 
heterogeneity of response is well-recognised although 
previous studies have shown that the response is generally 
reproducible within an individual(155,163) . The mean 
triglyceride and retinyl palmitate concentrations in the 
d<l.006g/mL fraction are plotted in figures 4.3 for both 
groups. These parameters rose to a peak at 6 hrs and then 
declined to near basal values by ten hours in both 
nephrotics and controls. The shape of both curves is 
similar. Although the nephrotic group start with a higher 
basal triglyceride v a l u e (d<l.006g/mL concentration -
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control 0.89mmol/L sd 0.45 v nephrotic 1.58 sd 0.81; 
p<0. 05) , the average increments(2.17mmol/L sd 1.07 v 2.73 
sd 1.28) were the same as were the time to peak and return 
to baseline. One patient in the nephrotic group had a 
markedly decreased clearance rate of retinyl palmitate with 
persistently high levels at 14 hours and significant 
quantities present at 24 hours. This subject had the 
highest fasting plasma triglyceride level(4.45mmol/L) and 
the largest area under the curve for both triglyceride and 
retinyl palmitate in the del.006g/mL fraction. Two further 
patients(one in each group), who possessed one E2 allele, 
had an unusually high level of d<1.006g/mL retinyl 
palmitate at 24 hours. There were no differences between 
the areas under the curve from 0-24 hours for triglyceride 
(nephrotic 15.56mmol.hr/L sd 13.24 v control 12.59 sd 6.63) 
or retinyl palmitate in the d<1.006g/mL fraction 
(7.14mg.hr/dL sd 6.44 v 6.11 sd 4.05).
When data from all twenty subjects were considered, there
was an association between fasting triglyceride levels and
both the rise in triglyceride(r2=0.56, p=0.016) and the
2
area described by the triglyceride curve(r =0.37, p=0.004). 
A similar but weaker association was seen between 
triglyceride concentrations and the area under the retinyl 
palmitate curves(r2=0.22, p=0.035) and peak retinyl 
palmitate concentrations(r =0.20, p=0.046).
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Measurement of retinyl palmitate in IDL and LDL fractions 
revealed a small and variable transfer of retinyl ester
into these higher density lipoproteins in both groups. In
IDL, this amounted to an average of 5.1% of the d<1.006g/mL 
concentration at 6 hours and only 1.3% in LDL. Small
quantities were also found at 24 hours in LDL. There were
no differences between the controls and nephrotic subjects.
There were small but significant differences between the 
concentrations of HDL subfractions between the two groups 
with reductions in both HDL2 (controls 84mg/dL sd 47 v 
nephrotic 45 sd 28; p<0.05) and HDL^(253mg/dL sd 61 v 201 
sd 45; p<0.05) in nephrotic sydrome. However, this 
difference was no longer significant when the two patients 
with advanced renal failure who had the lowest HDL 
concentrations were excluded. There was a modest fall in 
HDL3 concentrations at 6 hours(mean 21mg/dL sd 40; paired t 
test p=0.035). This had returned to normal by 24 hours and 
was seen in both groups. HDL2 levels did not alter 
significantly.
The composition of particles in the d<1.006g/mL fraction at 
0 and 6 hours were compared. At both time-points, there 
were small increases in the free and esterified cholesterol 
with a slightly reduced triglyceride content of these 
particles in the nephrotic group. These relatively small 
changes may reflect the higher circulating cholesterol in
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the nephrotic group creating a concentration gradient for 
net movement of cholesterol to triglyceride—rich 
lipoproteins. The ratio of cholesterol:phospholipid 
(mmol/mg) was increased in the baseline sample(0.026 sd 
0.004 v 0.021 sd 0.004, p<0.01) but was not significantly 
different at the 6 hour sample.
There were no differences in lipoprotein lipase, hepatic
triglyceride lipase or total heparin-releasable lipase
activity between the two groups(table 4.2). There was a
weak relationship between LPL activity and del.006-
triglyceride area under the curve following a fat load 
2(r =0.21, p<0.05). HTGL activity may be important in the 
clearance of "remnant" particles formed by delipidation of 
triglyceride-rich lipoproteins(156) but no relationship 
was demonstrated between retinyl palmitate clearance(area 
under the curve) and HTGL activity.
When all these factors(fasting triglyceridaemia, lipase 
activities, HDL subfraction concentrations) were 
considered, fasting triglyceride remained the most powerful 
predictor of post-prandial lipaemia although still 
accounting for only 36.2% of the variability in this 
response. The predictive value could not be improved using 
any combination of HDL subfractions or lipase activities.
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4.4 Discussion
Altough defective catabolism of triglyceride-rich 
lipoproteins is well-described in nephrotic syndrome, 
chylomicron metabolism has not been extensively 
investigated in human nephrotic syndrome. Studies in 
experimental nephrotic syndrome(166-168) have demonstrated 
an increased half-life of labelled chylomicrons. This 
could be reversed by heparin/albumin infusions(166) or by 
intravenous heparan sulphate isolated from nephrotic rat 
urine(167). Levy(168) attributed this defect partly to a 
3 5% reduction in lipase activity. However, there was also 
a reduced clearance of homologous nephrotic chylomicrons in 
normal rats. Similar findings were recently reported from 
Japan for VLDL particles(64). Chylomicron synthesis and 
composition may be altered in experimental nephrotic 
syndrome with the production of large lipid-rich particles 
with reduced phospholipid, apo E and apo AI content 
(168,169). These changes may influence the catabolic 
potential of the particles by impairing binding to 
lipoprotein lipase and other proteins involved in the 
catabolism of triglyceride-rich lipoproteins. In human 
nephrotic syndrome, Newmark and colleagues(46) found a high 
incidence of fasting chylomicronaemia although other 
studies have not confirmed this(48).
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In this study, there was no consistent defect in 
chylomicron metabolism assessed by the lipaemic response to 
a standard fat meal in patients with heavy proteinuria 
compared to controls. Although two nephrotic patients had 
significant renal impairment, this would have been 
predicted to increase any differences between the groups 
since renal failure is known to reduce lipolytic capacity 
and increase plasma concentrations of remnant particles 
(88,159). The wide inter-individual variation in both 
groups confirms previous studies. However, the shapes of 
the mean curves for triglyceride and retinyl palmitate and 
the mean areas under the curves are very similar in groups 
who were comparable in age, body weight, sex distribution 
and smoking habits. Inspection of the individual curves 
suggest that at least three subjects(two patients with 
nephrotic syndrome and one control) had a defect in the 
clearance of retinyl esters consistent with impaired 
removal of remnant particles. In two subjects, this may be 
attributed to the presence of an E2 isoform(158) but one of 
the nephrotic subjects demonstrating this pattern possessed 
an E4/E3 phenotype. The delayed clearance in this subject 
was associated with the highest peak triglyceride and the 
largest area under the curve although the precise reason 
for this is not clear. Lipoprotein lipase activity in this 
patient was 2.60umol FFA/mL/hour compared to a mean value 
for the nephrotic group of 3.71. The explanation for this 
response is not known.
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The areas under the curves of triglyceride and retinyl 
palmitate in the d<1.006g/mL fraction are influenced by a 
number of factors other than removal rates. Absorption of 
dietary fat, synthesis and secretion of chylomicrons in the 
intestine and rate of lymphatic flow will effect the 
appearance of lipids in the blood after a fat load. None 
of these were measured directly in this study. However, 
the similarity in the rate of rise of both triglyceride and 
retinyl palmitate curves suggests that these factors are 
not significantly altered in human nephrotic syndrome.
The appearance of retinyl palmitate in IDL and LDL 
fractions has recently been reviewed in a re-assessment of 
this type of study for investigating the clearance of 
chylomicron remnants(160) . However, the isolation of 
subfractions of lipoproteins prior to assay avoids the 
limitations of plasma retinyl ester measurements for this 
purpose. The quantity of retinyl ester found in 
lipoproteins of d>1.006g/mL is small although at 24 hours 
plasma retinyl palmitate concentration may overestimate the 
concentration in the d<1.006g/mL fraction. This probably 
represents transfer of retinyl esters between triglyceride- 
rich and low density lipoproteins mediated by circulating 
lipid transfer proteins. However, other possibilities are 
degradation of intestinally-derived lipoproteins to this 
density interval, contamination of the IDL/LDL fractions by 
remnant particles or re-secretion of retinyl esters in VLDL
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by the liver.
The conflicting conclusions of previous studies on the 
activities of lipases in experimental and human nephrotic 
syndrome have been considered in chapter 1. Using 
specific assays for LPL and HTGL, no difference in the 
activities of these enzymes was seen between these two 
groups.
Clearance of triglyceride-rich very low density 
lipoproteins is decreased in nephrotic syndrome. This has 
been demonstrated by studies in experimental nephrotic 
syndrome, reports of reduced lipase activity and of 
impaired removal of VLDL particles in human nephrotic 
syndrome. Therefore, impaired tolerance of an oral fat 
load with a late and prolonged lipaemia might be 
anticipated. These studies do not confirm that such a 
defect is a consistent feature of the nephrotic syndrome 
although individual patients had delayed clearance of 
retinyl esters from the d<1.006g/mL fraction. The results 
of the dynamic studies are consistent with the normal 
post-heparin lipolytic activities and the absence of major 
compositional changes in triglyceride-rich lipoproteins at 
6 hours which might retard their catabolism. The 
variability among all 20 subjects of the lipaemic response 
to a fat meal probably reflects the complexity of the 
mechanisms regulating an everyday metabolic process.
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TABLE 4.1 - POST- PRANDIAL LIPAEMIA - CHARACTERISTICS OF SUBJECTS
CONTROLS NEPHROTIC
number 
age(years) 
sex M:F 
body mass index(kg/m2) 
smokers 
serum creatinine(umol/L) 
quantitative proteinuria(g/day) 
serum albumin(g/L) 
plasma cholesterol(mmol/L) 
plasma triglyceride(mmol/L)
11
49(11)
8:3
26.1(2.1)
2
130(52)
0.15(0.29)
42(1.6)
5.9(0.8) 
1.6(0.8)
9
52(11)
6:3
24.1(2.1)
2
253(192) 
6.3(4.7) 
31(6.3) 
9.6(2.6) 
2.7(1.2)
Values quoted as mean(SD). Note nephrotic group included two subjects with more 
advanced renal failure(serum creatinine 640 and 520umol/L).
TABLE 4.2 - POST-HEPARIN LIPASE ACTIVITIES
CONTROLS NEPHROTIC
lipoprotein lipase 
hepatic triglyceride lipase 
total lipase
5.08(2.75)
19.9(7.2)
25.0(7.3)
3.71(1.22)
20.5(5.0)
24.2(5.0)
Values are mean(SD) expressed as umol free fatty acids/mL/hour
FIGURE 4.1 a - TRIGLYCERIDE IN d<1.006g/mL FRACTION FOLLOWING FAT LOAD
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FIGURE 4.2a - RETINYL PALMITATE IN d<1.006g/mL FOLLOWING FAT LOAD
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FIGURE 4.3a
MEAN TRIGLYCERIDE CONCENTRATION IN d<1.006g/ml FOLLOWING FAT LOAD
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CHAPTER 5 VERY LOW DENSITY LIPOPROTEIN METABOLISM IN 
NEPHROTIC SYNDROME
5.1 Introduction
The metabolism of very low density lipoproteins bears many 
similarities to that of chylomicrons. Both are large 
triglyceride-rich particles originating in the liver and 
intestine, respectively. Endothelial-bound lipases are 
responsible for the hydrolysis of the triglyceride core of 
these particles. Chylomicrons are converted to "remnant1 
particles with subsequent removal by the liver, while VLDL 
is the precursor of IDL and LDL. It is widely held that the 
main cause of the hyperlipidaemia of the nephrotic syndrome 
is increased hepatic apolipoprotein, lipid and lipoprotein 
synthesis and secretion(54). This should be reflected in 
increased hepatic VLDL production. However, this 
hypothesis is based on experimental models of the nephrotic 
syndrome and few studies have investigated this directly 
(i.e. by the incorporation of labelled precursors into 
lipoproteins) in human nephrotic syndrome.
Catabolic processes can be examined by following the 
clearance of labelled tracers from the plasma. The theory 
of using labelled apoB as a tracer for the metabolic fate 
of apoB-containing lipoproteins was considered in chapter 
2. In steady-state systems, information can be inferred
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about synthetic rates from a knowledge of the plasma decay 
of the tracer and the pool size of the tracee. Despite the 
widespread use of apoB kinetic studies to investigate 
various dyslipidaemias, there have been few applications of 
this technique to the study of the mechanisms underlying 
nephrotic hyperlipidaemia. Decreased removal of VLDL 
particles has been described in both experimental models of 
nephrotic syndrome(63) and in man(66,69). These workers 
used tracers isolated in a wide density range and it is now 
recognised that VLDL (d<l.006g/mL) contains a heterogeneous 
mix of particles of differing metabolic origins and 
fates(26). The aim of this study was to compare the 
metabolism of discrete subfractions of VLDL and to follow 
the transfer of apoB from VLDL->IDL->LDL in nephrotic 
subjects and controls.
5.2 Patients and methods
Subjects attended after an overnight(>12 hours) fast and 
approximately 200-250mL of plasma was obtained by 
plasmapheresis. This was done by venesecting 400-500mL of 
blood into a citrated container, immediately separating the 
plasma by centrifugation and re-infusing the red blood 
cell concentrate(diluted in isotonic sterile saline) via 
the indwelling cannula. Total VLDL(d<l.006g/mL) was 
obtained by ultracentrifugation of 150mL(6 x 25mL) of 
plasma in a Beckman Ti60(or Ti50.2) at 39,000rpm at 10 C
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for 18 hours. The floating VLDL was aspirated in the top 
2—4mL and then, if necessary, diluted with isotonic saline 
to achieve an initial plasma triglyceride concentration of 
1.5mmol/L. This minimises carry over of VLDL^ to VLDL2 
during preparative ultracentrifugation. The solution 
density was then raised to 1.118g/mL by the addition of 
solid sodium chloride(0.17lg/mL). Six 2mL aliquots were 
subjected to cumulative flotation ultracentrifugation on a 
discontinuous salt gradient(figure 2.1) in a Beckman SW40 
swinging bucket rotor as adapted from Lindgren(170) .
VLDL1 (S^ 60-400) and VLDL^S^ 20-60) were isolated by this 
method and aliquots(2mL) labelled with 131i and 125i 
respectively by a modification of the iodine monochloride 
method(140,141,171). Free radioiodide and salt were 
removed by gel filtration on a PD10 column (source: 
Pharmacia, Uppsala, Sweden) followed by extensive dialysis 
against 0.15M NaCl, pH 7.4. Three days after the initial 
plasmapheresis subjects returned, having fasted for >12 
hours, and approximately 50uCi of each tracer was 
administered intravenously. The tracers were sterilised by 
passage through a 0.45micron filter(source: Gelman Science, 
Northampton, UK) immediately prior to injection. Blood 
samples were collected at 10 minutes and then frequently 
over the first 10 hours after which a low fat meal was 
allowed. Further samples were taken at 14 and 24 hours and 
then daily fasting samples were obtained for 12 days. Each
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plasma sample was subjected to ultracentrifugation as above 
to isolate four fractions - VLDI^, VLDL^, IDL(Sf 12-20) and 
LDL(Sf 0-12).
ApoB was precipitated(172) from each fraction by the 
addition of an equal volume of freshly-distilled 1,1,3,3- 
tetramethylurea(TMU). The precipitate was then delipidated 
and the specific activity of apoB in the precipitate 
measured after redissolving in 0.5M NaOH. Protein content 
was estimated by a modified Lowry assay(131) where 
standards were dissolved in 0.5M NaOH and radioactivity 
was measured in a twin channel gamma counter(source: 
Canberra Packard, Pangbourne, UK) .
The plasma concentrations(in mg/dL) of VLDL^ VLDL2, IDL 
and LDL were estimated from compositional analysis of each 
fraction isolated from pooled plasma. The total 
cholesterol recovered in the four fractions by cumulative 
flotation ultracentrifugation was compared with the 
cholesterol content of the non-HDL cholesterol measured by 
routine beta-quantification of plasma. Recovery varied 
from 82-92%. The calculated lipoprotein masses were each 
corrected by this factor. This assumes that each fraction 
was lost in similar amounts and that the different 
components of the lipoproteins were also lost in equal 
proportion.
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ApoB concentration was measured in aliquots of each 
fraction by precipitating apoB as above and measuring the 
protein content in the supernatant fluid. ApoB 
concentration was calculated as the difference between 
total protein and TMU-soluble protein. Intravascular pool 
sizes of apoB were obtained from the product of apoB 
concentration and plasma volume derived from the dilution 
of the VLDL2 tracer at ten minutes.
Eight patients with nephrotic syndrome were recruited to 
this study. The characteristics of these subjects are 
listed in tables 5.1 and 5.2. The results of the kinetic 
studies were compared with a group of 5 normolipidaemic 
controls studied in a parallel investigation.
Kinetic Analysis
The radioactivity in apoB in each lipoprotein fraction was 
obtained by multiplying the specific activity(cpm/mg) at 
each time point by the pool size(mg apoB) of the 
appropriate fraction. All radioactivities were then 
expressed as a percentage of the total apoB activity 
present in the 10 minute sample calculated from the sum of 
radioactivity in VLDL^, VLDL2, IDL and LDL. Plasma decay 
curves(examples shown in figure 5.1) and pool sizes were 
then analysed by a multicompartmental model using the 
SAAM/CONSAM 30 programme (142 ,143) . The apoB radioactivity
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curves and. estimated apoB pool sizes were used to derive 
fractional transfer and catabolic rates, flux rates between 
compartments and production rates for apoB in VLDL^, VLDL2 
and, where necessary, LDL. Production and flux rates are 
expressed as mg apoB/kg body weight/day. Fractional 
transfer and catabolic rates are expressed as pools/day.
The model used to analyse apoB metabolism in very low 
density lipoproteins has been described previously 
(173,25,26,30). In summary, it consists of two parallel 
pathways from large and small VLDL through IDL to LDL. The 
transfer of apoB along this chain is thought to be 
dependent on step-wise delipidation mediated by lipoprotein 
and hepatic triglyceride lipase activities. Direct input 
of apoB occurs both at VLDL1 and VLDL2. Where the 
calculated mass in LDL falls significantly short(>10%) of 
the measured mass, direct synthesis of LDL is invoked. 
Removal of apoB occurs at each level of the pathway. 
However, this model did not allow an adequate fit of the 
data from the proteinuric group. The calculated pool mass 
for VLDL1 was underestimated in a number of these subjects 
who had an expanded VLDL^ pool. Several subjects also 
demonstrated a biexponential decay of VLDL^ suggesting the 
presence of an additional component within this fraction 
which was being metabolised at a different rate. A revised 
model was therefore developed(figure 5.2). In this, VLDL^ 
is composed of three compartments with input to and direct
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removal from two parallel pathways. These extra 
compartments (compartments 29 and 26) were not required for 
the analysis of the control subjects.
Statistical analysis
Non-parametric methods were used because of the small 
numbers and the wide spread of results in the nephrotic 
group. Results are shown as medians and ranges.
Differences between nephrotic and control groups were 
tested by the Mann-Whitney U test and correlations by 
Spearman's rank test. The plots comparing the specific 
activities of the two tracers between the groups are shown 
as mean and standard deviations. The compositional data 
for both groups were of comparable variance and were 
analysed by a two-sample t test.
5.3 Results
Baseline data
This group of patients with moderate to heavy proteinuria 
demonstrated varying increments in plasma cholesterol and 
triglyceride(table 5.3). There were no clear relationships 
between plasma lipids and measured urinary protein loss or 
serum albumin using non-parametric analysis. Serum albumin 
was remarkably well maintained even when quantitative
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proteinuria approached lOg/day. LDL—cholesterol was 
moderately elevated in 7 patients with one pateint(JG) 
having a very high level of 10.Ommol/L. VLDL-cholesterol 
was high in 3 patients all of whom demonstrated a high VLDL 
cholesterol/triglyceride ratio suggesting the accumulation 
of VLDL remnant particles. One of these patients(WS) 
possessed an E2 allele of the apoE polymorphism. These 
changes were reflected in the increased plasma 
concentrations of three lipoprotein fractions(VLDL2, IDL, 
LDL) separated by cumulative flotation ultracentrifugation 
as calculated from the sum of compositional analysis (figure 
5.3). In this small group of subjects and in contrast to 
the findings in chapter 3, there were no significant 
differences in the relative composition of all four 
lipoprotein fractions between controls and proteinuric 
subjects(table 5.4).
Kinetic studies
Figures 5.4a-g compare the metabolism of each tracer in 
the four subfractions by plotting the mean fraction of the 
total initial apoB radioactivity at each time point for 
both proteinuric and control groups. The results of the 
kinetic analysis are presented in tables 5.5a-d.
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VLDL1
131
The I VLDL^ apoB tracer was cleared more slowly in the 
nephrotic group than in controls primarily due to a 
consistent reduction in the fractional transfer of VLDL1 
apoB to VLDL2 (median 0.93pools/day;range 0.22-3.33 v 
3 . 66;2.48-5.16, p<0.02 - table 5.5a). Both nephrotic and 
control groups showed wide variation in the fraction of the 
VLDL^ apoB pool which was catabolised directly from the 
plasma compartment. However, in order to fit the data for 
apoB specific activities and pool sizes, it was necessary 
to postulate that some nephrotic subjects produced a 
species of VLDI^ which did not enter the apoB cascade 
(compartment 2 6 - figure 5.2). In the proteinuric group, 
the VLDL^ apoB pool size varied from normal to eight times 
normal and this was related to plasma triglyceride level. 
The calculated rate of apoB flux from the large 
triglyceride-rich VLDL^ to smaller VLDI^ was reduced 
(1.9mg/kg/day;1.1-2.9 v 2.7;1.8-5.1, p<0.05) even in those 
patients with normal pool s i z e s (CF,MD,RG,JG). There was 
wide variation in the secretion of apoB into VLDL^
(2.6-64.8mg/kg/day) in the proteinuric group. Although 
four patients had very high production, there was no 
statistically significant differences between the groups.
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VLDL2
The VLDL2 apoB tracer was also cleared from the plasma of 
the nephrotic group at a slower rate than normal. This was 
seen with both tracers i.e. directly labelled VLDL2 and the 
material transferred from VLDL1 (figures 5.4b and e) .
Again, this was attributable to a reduced delipidation rate 
to IDL(or LDL by pathways 12->21 and 4->20) - table 5.5b. 
Direct removal of VLDL2 apoB from plasma was highly 
variable and not significantly different between the two 
groups. The VLDL2 apoB pool was expanded in the 
proteinuric group(2-3x normal) mainly due to a marked 
increase in de novo synthesis of apoB in VLDL2 
(14.6mg/kg/day;5.1-32.2 v 4.2;2.9-8.8, p<0.02). Reduced 
catabolism made a relatively smaller contribution to the 
expansion of the pool size. The larger VLDL2 pool led to a 
modest increase in the amount of IDL apoB formation 
although this was not statistically significant 
(10.4mg/kg/day;4.4-17.2 v 5.8;2.7-8.7, p=0.12). This 
occurred despite the reduced fractional transfer rate from 
VLDL2 to IDL.
IDL
. . _ 125t , 131t
The mean plasma radioactivity curves for I and I
reach comparable peak values in IDL at similar times for
both groups(figures 5.4c and 5.4f) . Thereafter, the curves
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diverge with the normals showing an initial more rapid 
decay that was due to direct catabolism of the lipoprotein 
(table 5.5c). There was no obvious difference in the rates 
at which both groups of subjects accumulated 125I and 131I 
in LDL apoB indicating a similar degree of IDL to LDL 
conversion (table 5.5c). The expansion of the IDL apoB pool 
in nephrotics was due to a combination of increased 
synthesis from VLDL2 and diminished direct removal. This 
had the net effect of channelling an increased amount of 
apoB from IDL to LDL(table 5.5d).
LDL
' I O C  *1 O  1
The appearance curves for I and I apoB radioactivity 
in LDL are similar for control and nephrotic groups(figures 
5.4d and 5.4g). Peak values are achieved at a later time 
in the latter group but the extent of transfer from VLDL1 
and VLDL2 is approximately the same. Normal subjects have 
a biphasic LDL decay curve consisting of a relatively rapid 
catabolism up to 120 hours and a slower terminal phase. 
Visual inspection of the averaged data from the patients 
with nephrotic syndrome indicated a lack of the early rapid 
phase of LDL degradation.
The observed fractional catabolic rate for LDL should be 
corrected for urinary loss of whole lipoprotein. This is 
not possible to determine from urine collections during a
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VLDL turnover because a high proportion of injected 
radioactivity is present in components other than apoB(i.e. 
apolipoproteins C and E and lipids) . In other studies(see 
chapters 6 and 7) using trace-labelled LDL in nephrotic 
syndrome, the average urinary excretion of undegraded 
lipoprotein was estimated as 7% of total urine 
radioactivity and the values in table 5.5d overestimate the 
true FCR by this proportion. The LDL FCR was subnormal in 
most of the disease group but three subjects (CM, WS and CF) 
had normal or even high values and, overall, there was no 
significant difference from controls even when corrected 
for estimated urinary losses. Likewise, there was a 
variable expansion of the LDL apoB pool. Its size ranged 
from normal to twice normal. The production of LDL from 
VLDL2 and IDL was significantly increased in the nephrotic 
group compared to normal.
5.4 Discussion
Reduced lipoprotein catabolism has been described in 
nephrotic syndrome and several lines of evidence suggest 
that catabolic defects are present along the VLDL->IDL->LDL 
delipidation cascade. Early work by Gitlin et al.(66) 
demonstrated a delay in the catabolism of radioiodinated 
Sf 100-400 lipoproteins. More recently, Vega and Grundy 
(69) have shown reduced clearance of a combined VLDL and 
IDL tracer(d<l.019g/mL) in four nephrotic subjects compared
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to controls. The delipidation of VLDL is catalysed by 
endothelium—bound lipases in hepatic and extra—hepatic 
tissues(skeletal muscle and adipose tissue). Decreased 
activities of these enzymes have been reported in this 
disorder (76-79) although this finding has not been 
confirmed in all studies(51,80,81) . The studies presented 
in chapter 4 failed to show a difference in lipase 
activities between nephrotic and controls and both groups 
had, on average, similar lipaemic responses. These 
contradictory findings led to the present detailed 
investigation of VLDL metabolism in the nephrotic syndrome.
The eight subjects studied had persistent heavy proteinuria 
and had been followed-up for a period varying from 10 
months to 35 years(table 5.1). They had moderate 
hyperlipidaemia except for JG who had a markedly elevated 
LDL-cholesterol level. Plasma triglyceride levels varied 
from low normal(1.2mmol/L) to high(4.5mmol/L) emphasising 
the heterogeneous nature of the study group. In this small 
group, there was no obvious relationship between disease 
severity (proteinuria or hypoalbuminaemia) and plasma lipid 
levels. When apoB-containing lipoproteins were 
fractionated by cumulative flotation ultracentrifugation 
significant increases were seen in plasma levels of VLDL2 , 
IDL and LDL(figure 5.3). The composition of all four 
lipoprotein fractions was not significantly different 
between the two groups. However, there was a trend towards
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an increased free cholesterol content in VLDL subfractions 
as seen in chapter 3. There was no substantial 
accumulation of cholesterol ester-rich VLDL remnants in the 
VLDL2 and IDL density ranges despite high plamsa 
triglyceride/VLDL cholesterol ratios in some patients.
Three significant perturbations of apolipoprotein B 
metabolism were noted in the nephrotic subjects. First, 
the rates of transfer of VLDL1 apoB to VLDL2 and of VLDL2 
apoB to IDL were reduced. This was true even in 
normotriglyceridaemic nephrotic subjects(MD,RG,CF in table 
5.5a) who had normal VLDL1 apoB pool sizes. Thus, the 
delayed clearance cannot be ascribed to saturation of the 
delipidation mechanism. These metabolic steps are believed 
to involve the action of lipoprotein lipase and, to some 
extent, hepatic triglyceride lipase(25) . As noted above, a 
number of studies in both human and experimental nephrotic 
syndrome have examined post-heparin plasma lipase 
activities with contradictory results. Chan and co-workers 
(79), using a substrate-specific method, documented a 
decrease in lipoprotein lipase with normal hepatic 
triglyceride lipase activity. 0etliker(51) could not find 
any significant difference compared to controls for either 
enzyme using a more standard immuno-inhibition method 
although there was an inverse relationship between 
lipoprotein lipase activity and triglyceridaemia. In 
vitro, nephrotic serum may inhibit lipase activity(79) - a
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similar finding has been reported in uraemia(89). However, 
the degree of inhibition in vitro did not correlate with 
reductions in lipase activity in the patients from whom the 
sera were obtained.
Several hypotheses have been advanced to explain the 
possible reduced lipase activity. Apolipoprotein CII, an 
important activator of lipoprotein lipase, has been 
isolated from nephrotic urine. However, total plasma 
concentrations are normal in nephrotic syndrome although 
Kashyap(83) has reported that the absolute amount 
associated with VLDL is reduced. Alterations of the lipid 
and/or apolipoprotein composition of VLDL may alter its 
catabolic potential and account for a recent report that 
VLDL from nephrotic rats has a reduced clearance rate in 
normal animals and is more resistant to lipolysis in 
vitro(64) . The modest increases in free cholesterol 
content of VLDL species seen in the nephrotic subjects may 
affect their metabolic potential.
Two other explanations have been proposed. Staprans and 
co-workers(84) isolated a separate lipase co-factor from 
the urine of nephrotic patients which they identified as a 
glycosaminoglycan and Bernard(40) has reviewed the 
possibility that, in hypoalbuminaemic states, decreased 
removal of free fatty acids which are normally protein- 
bound may impair lipolysis.
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Second, the synthesis of apoB in the density interval of 
VLDL2 was increased several-fold on average. This effect 
was more consistent than the highly variable values seen 
for VLDL^ apoB synthesis in the nephrotic subjects. The 
increased direct synthesis(table 5.5b) more than 
compensated for the reduced flux from VLDL1. This in turn 
led to overproduction of IDL and LDL(tables 5.5c and 5.5d). 
Thus, hepatic oversynthesis of apoB was a feature of this 
group and contributed to the expansion of the VLDL2, IDL 
and LDL pools. As discussed above, hepatic oversynthesis 
of apoB-containing lipoproteins is common in animal models 
of nephrotic syndrome(54-58) and has also been reported in 
man(70). In the latter study, markedly increased rates of 
apoB production were found in a group of severely 
hyperlipidaemic nephrotic patients although the full 
details of these subjects have not been reported. The 
stimulus to overproduction is unclear. In the current 
study, the finding that triglyceride-poor VLDL2 rather than 
VLDL^ is overproduced suggests that increased hepatic apoB 
rather than triglyceride synthesis was responsible for the 
elevation in plasma VLDL. This contrasts with the kinetic 
changes that underly the hypertriglyceridemia of non 
-insulin dependent diabetes mellitus(24) . In this 
condition larger, lipid-rich VLDL^ particles are secreted 
in excessive amounts but insulin therapy results in a 
decrease in VLDL^ production and an increase in VLDL2.
This is thought to reflect limitation of carbohydrate and
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free fatty acid flux to the liver which in the insulin- 
deficient state stimulates hepatic triglyceride synthesis 
and production of VLDI^.
The third abnormality observed in nephrotic subjects was a 
modest increase in the production rate of LDL apoB.
However, unlike Vega and Grundy(69), we did not require to 
invoke a significantly increased level of direct LDL apoB 
synthesis. In most subjects, all of the apoB in LDL of 
nephrotics could be accounted for by delipidation of VLDL 
and IDL. The fractional catabolic rates of LDL were on 
average slightly decreased although the nephrotic group 
covered a wide range and the difference was not 
statistically significant(see chapter 6) .
The signifigance of a separate VLDL species in the 
nephrotic group(compartment 26 - figure 5.2) is uncertain. 
Alterations of hepatic lipid and protein metabolism may 
lead to the production of VLDL sub-species which, because 
of compositional changes, cannot feed into the delipidation 
chain and are removed directly from the circulation. The 
only alternative explanation is that denaturation occurred 
during the preparation of the VLDL^ tracer in some of the 
nephrotic group leading to its rapid clearance from the 
plasma by phagocytic mechanisms. However, there does not 
appear to be any reason for this to be limited to 
nephrotic subjects and this has not been seen in normal and
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other hyperlipidaemic groups which have been studied in 
similar investigations.
The results of this study suggest that increased hepatic 
synthesis of lipoproteins at the level of VLDL2 is a 
feature of the nephrotic syndrome and this, together with a 
diminished capacity in some subjects to catabolise IDL and 
LDL, leads to hypercholesterolaemia. Elevation of plasma 
triglyceride is associated with high concentrations of the 
large triglyceride-rich VLDL^ which derives again from a 
combination of overproduction and a reduced delipidation 
rate. It should be noted that this group of patients was 
atypical in some respects with well-maintained serum 
albumin despite heavy proteinuria. Hypoalbuminaemia has 
been closely correlated with hyperlipidaemia in this 
condition. The absence of severe hypoalbuminaemia in our 
patients is reflected in the relatively modest elevations 
of plasma and LDL-cholesterol and of LDL apoB pools.
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CHAPTER 6 LOW DENSITY LIPOPROTEIN METABOLISM IN NEPHROTIC 
SYNDROME
6.1 Introduction
The potential role of apoB kinetic studies in the 
investigation of lipoprotein metabolism was first fully 
appreciated following the work of Langer et al.(139).
These workers identified a decreased fractional catabolic 
rate of LDL as a consistent feature of familial 
hypercholesterolaemia(type Ila hyperlipoproteinaemia). 
Subsequent work established that this was due to genetic 
defects of the apoB/E receptor and provided a rational 
explanation for the delayed catabolism of LDL. These 
initial studies used LDL prepared by sequential 
ultracentrifugation as the tracer. This approach allows a 
more direct and accurate determination of LDL kinetics 
compared to studies which trace apoB through a series of 
1ipoprotein fractions(chapter 5).
A further advantage of labelling LDL directly is the 
ability to differentiate between the two* pathways for LDL 
catabolism - receptor and non-receptor(36)• Modification 
of the apoB moiety of LDL by 1 ,2-cyciofaexamedioneieifB) 
alters the arginyl residues of the receptor-binding site of 
apoB and abolishes ligand-receptor binding. 'The use of two 
isotopes(12151 and 1311), to label native and chemically-
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Nephrotic subjects are shown by open circles(o); controls by closed 
circles(e)
modified LDL respectively, permits the estimation of total 
and receptor—independent catabolism, the difference being a 
measure of receptor-mediated catabolism. This method has 
been validated in animal studies and in man(138,174) .
The aim of this study was to investigate in more detail the 
metabolism of LDL in nephrotic syndrome and, specifically, 
to determine the relative contributions of these two 
catabolic pathways.
6.2 Subjects and methods
Low density lipoproteins were isolated from approximately
40mL of fasting plasma by rate zonal ultracentrifugation(5)
in a Beckman Til4 rotor using a linear gradient of density
range 1.0-1.3g/mL. The LDL peak was collected in 2-3 x
15mL fractions and concentrated and desalted in a
pressurised Amicon ultrafiltration system(source: Amicon,
Stonehouse, Gloucester, UK) using an XM300 membrane(nominal
MW cut-off 300,OOOd) and 0.15M NaCl/0.01% w/v Na2EDTA/pH
8.1 as buffer. The final concentration of LDL protein was
l-3mg/mL(estimated by absorption of UV light at 280nm
assuming an extinction coefficient of 1.0). Aliquots were
then labelled with and ^^1(140,171) and unbound
iodide and glycine buffer removed by gel filtration on a
131
PDio column (source: Pharmacia, Uppsala, Sweden). The I 
tracer was modified with 1,2-cyclohexanedione(CHD). A
135
freshly prepared solution of CHD(0.15M in 0 .2M borate 
buffer, pH 8.1) was incubated with an equal volume of 
131I-LDL for 2 hours at 35°C. Free CHD was then 
removed by gel filtration on a PD10 column as above.
The radiolabelled tracers were administered intravenously
to their respective donors approximately 8 hours after the
initial blood sample. Immediately before injection, the
labelled LDL was sterilised by membrane filtration through
a 0.22micrometre filter(source: Gelman Science,
Northampton, UK) and the activity in a lOuL sample was
125counted. Each subject received approximately 25uCi I
131LDL and 25-50uCi of I CHD-LDL as an intravenous bolus. 
The precise dose was calculated from the difference in the 
weight of the syringes before and after each injection. A 
blood sample was drawn at ten minutes from the opposite arm 
and then daily fasting samples were obtained between 08:00 
and 09:00 for 14 days. Twenty four hour urine samples were 
collected on a daily basis. Patients were assumed to be in 
a steady state with respect to low density lipoprotein 
metabolism throughout the study and this was confirmed by 
repeated measurements of plasma lipids and lipoprotein 
cholesterol.
LDL was isolated by sequential flotation between 1.019- 
1.063g/mL on 3-4 occasions and the protein content used to 
calculate the plasma apoLDL concentration(>95% apoB). The
136
pool size of apoLDL was calculated as the product of apoLDL 
concentration and plasma volume. The latter was derived
1 OR
from the dilution of the JI-LDL tracer at 10 minutes.
At the end of the study, the radioactivity in 2mL of plasma 
from each time point was measured in a twin-channel gamma 
counter. Previous studies have shown that >95% of the 
plasma radioactivity is in the LDL density range and this 
was confirmed by re-isolating LDL from plasma by rate zonal 
ultracentrifugation (figure 2.1). The distribution of 
radioactivity and protein (measured by absorption at 280nm) 
in the LDL density region are very similar. Correction was
ion 1 O
made for spill over from the I to the I channel. Two 
mL samples of urine were also counted and total urinary 
radioiodide losses calculated from the product of cpm/mL 
and daily urine volume. In proteinuric subjects, 
correction was made for urinary losses of protein-bound 
radioactivity which was assumed to be LDL. Two mL of urine 
were added to 1.33mL of cold 50% trichloroacetic acid(TCA) 
and stood at 4°C for 1 hour. The precipitate was separated 
at low-speed centrifugation, washed once with 2 0% TCA and 
the radioactivity in the precipitate measured. No 
significant protein-bound radioactivity was found in normal 
subj ects.
137
Kinetic analysis
Decay curves of plasma radioactivity versus time were drawn 
for both tracers. The fraction of total radioactivity 
administered which was excreted per day in the urine was 
also plotted against time and the daily urine:plasma 
radioactivity ratio calculated. The data (plasma decay 
curves, urine radioactivities and apoLDL pool sizes) were 
analysed by multicompartmental modelling to obtain 
fractional catabolic rates for both tracers(142,143) . The 
model utilised for this analysis is shown in figure 6.1 
with parallel pathways for native and modified LDL. The 
shape of the plasma decay curves(figure 6.2a) suggests a 
biexponential decay. This is interpreted as a function of 
two LDL pools. One represents the intravascular apoLDL 
pool and tissue spaces in rapid equilibration with this 
pool. The other comprises slowly exchanging material in 
extravascular spaces. LDL is removed only from the plasma 
compartment and the free iodide generated by catabolism of 
LDL is excreted into the urine at a fixed rate of 
2. 5pools/day. The fractional catabolic rates(pools/day) 
for the native and modified LDL are given by rate constants 
L(3,1) and L(7,5) respectively. The difference between the 
fractional catabolic rates represents receptor-mediated 
catabolism. FCR's were adjusted for the urinary losses of 
TCA-precipitable radioactivity. Fractional catabolic rates 
can also be calculated by the daily plasma:urine ratio as
138
shown in figure 6 .2b. Absolute turnover(or production 
rates in a steady-state system) were calculated as the 
product of apoLDL pool size and FCR and are expressed per 
kg body weight (mg apoLDL/kg/day) .
There are a number of underlying assumptions in this 
model:-
(a) Catabolism is assumed to occur from, or close to, the 
intravascular compartment only. This is an over­
simplification although the contribution of extravascular 
routes is probably small.
(b) LDL is considered to be homogeneous and this ignores 
variation due to the presence of specific LDL subfractions 
with differing metabolic fates(175).
(c) Although previous studies have shown that the CHD- 
modified LDL appears to be stable in vivo (138) some 
investigators have questioned this (176).
Nine patients with nephrotic syndrome were studied using 
this technique. The clinical characteristics of this group 
are shown in tables 6.1 and 6.2. Kinetic data were 
compared with a group of eight normal volunteers selected 
from laboratory and clinical staff.
Statistical analysis
Results of compositional analysis and kinetic parameters
139
(fractional catabolic and production rates) were compared 
by two sample t tests. Relationships between plasma 
lipids, production rates of apoLDL and proteinuria and 
hypoalbuminaemia were examined by linear regression.
6.3 Results
Plasma lipid and lipoprotein cholesterol levels
This group of patients illustrated the typical 
abnormalities of lipids and lipoproteins in the nephrotic 
syndrome (table 6.2). Total plasma cholesterol was elevated 
between 7.5 and 16.7mmol/L. This was mainly due to an 
elevation of LDL-cholesterol levels(4.6 to 12.9mmol/L) 
although several patients also had marked increases in 
VLDL-cholesterol (DE,MJ, JB,EA) . This reflected moderate 
hypertriglyceridaemia in these patients with EA also 
demonstrating a very high VLDL-cholesterol: plasma 
triglyceride ratio suggesting accumulation of cholesterol 
ester-rich remnant particles. HDL-cholesterol 
concentrations and were slightly reduced compared to the 
control group. There were significant associations between 
daily protein loss and the three plasma lipid measures - 
total cholesterol (r2=81%, p<0.0005), LDL=cholesterol 
(r2=59%, p<0.002) and triglyceride(r2=52%, p<0.01). No 
such relationships were seen with serum albumin.
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Compositional analysis of LDL(d=l.019-1.063g/mL) isolated 
by sequential ultracentrifugation demonstrated a modest 
decrease in free cholesterol content (nephrotic 6.9% sd 2 .1% 
v control 12.1% sd 1.2%, p<0.001) and a rise in 
triglyceride content (nephrotic 11.4% sd 3.1% v control 7.8% 
sd 1.2%, p<0.01). The plasma apoLDL concentration was 
markedly increased in the nephrotic group with a mean value 
of 251mg/dL(range 118-427) compared to a mean value of 
93mg/dL in the control group.
Kinetic analysis
The results for the kinetic parameters are listed in table 
6.3. In the nephrotic group, there was a significant
reduction in the fractional catabolic rate(FCR) of the
12 5native I-LDL compared to the control group(0.219 sd 
0.061 v 0.384 sd 0.057 pools/day, p<0.001). There was only 
a slight reduction in the clearance of the modified LDL 
(0.169 sd 0.043 v 0.219 sd 0.039, p<0.05). The main 
difference in the clearance rate is therefore due to 
decreased catabolism by the receptor-mediated pathway. The 
mean value was reduced by an average of 70% in the 
nephrotic group. The values for the fractional catabolic 
rates were corrected for the proportion of urinary iodide 
present as protein-bound radioactivity (i.e. TCA- 
precipitable) . This was assumed to be intact LDL as there 
is negligible exchange of radioiodide in plasma and this
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was thought to be unlikely to occur in the urine. This 
figure averaged 6.9% and varied from 1.2-15.7% (calculated 
from the mean daily value for both tracers) . There was 
considerable day—to—day variation within individuals.
There was no difference between urinary losses of native or 
chemically-modified LDL.
The absolute turnover rate(or production rate) was elevated 
in the nephrotic group(20.7mg/kg/day sd 8.3 v 14.2 sd 2 .3, 
p<0.02) but the range was wide. There was a striking 
correlation between quantitative proteinuria and apoLDL 
turnover (figure 6.3) but only where proteinuria exceeded 
lOg/day did turnover exceed normal values.
6.4 Discussion
These results indicate that plasma LDL concentrations are 
elevated in nephrotic syndrome due to a combination of 
decreased catabolism and increased synthesis. There is a 
consistent defect in the removal of apoLDL(and therefore 
LDL particles) from the intravascular compartment in the 
nephrotic syndrome. This was almost entirely due to a 
reduction in the fraction of the apoLDL pool catabolised by 
the receptor-mediated pathway. In contrast, although 
apoLDL turnover rates were slightly raised overall, 
inspection of the individual results and the relationship 
between production rates and quantitative proteinuria
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suggest that synthesis was only increased above normal when 
proteinuria exceeded lOg/day. Thus, the main cause of the 
expanded apoLDL pool is a reduction in catabolism although 
in some subjects increased synthesis also contributes.
The results of this study and those described in the 
previous chapter can be compared. Although there was a 
slight reduction in the FCR for IDL and LDL in the VLDL 
apoB kinetic studies, this was not statistically 
significant. There are three possible explanations. 
Firstly, the fractional catabolic rate for LDL apoB 
derived from VLDL apoB isolated by cumulative flotation 
ultracentrifugation is consistently lower than for apoLDL 
prepared by rate zonal or sequential ultracentrifugation 
and labelled directly (25, 26) . This reflects an 
accumulation of errors in the calculation of LDL kinetics 
in the former studies and the inclusion of IDL particles in 
tracers used in the latter. Nephrotic LDL prepared by 
sequential flotation ultracentrifugation(d=l. 019-1. 063g/mL) 
had a higher triglyceride content (11.4%) compared to that 
isolated by DGUC(6 .8%) - table 5.4. This is due to the 
higher plasma triglyceride concentrations in the study 
group in this chapter and the methodological differences in 
the ultracentrifugation procedures. Secondly, the FCR's in 
chapter 5 were not corrected for urinary lipoprotein loss. 
Finally, and most importantly, the group of patients 
studied in chapter 5 were less severely nephrotic than the
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current group who have lower serum albumin concentrations 
and higher LDL—cholesterol levels. An increase in severity 
of the disease may lead to a greater fall in LDL FCR with a 
further rise in plasma cholesterol.
The relationship between LDL pool size and fractional 
catabolic rate is controversial. The evidence supports the 
contention that apoLDL pool size is a function of the FCR 
and that reduction of FCR in hypercholesterolaemia does not 
simply represent saturation of catabolic pathways. Langer 
et al.(139) first argued this on the basis that familial 
hypercholesterolaemia could not be ascribed to increased 
LDL synthesis since this was normal in their studies. The 
identification of the LDL receptor defect further confirmed 
that the primary metabolic problem was in LDL catabolism. 
The effect of acute reduction in pool size on catabolism of 
apoLDL was studied by Thomson(177) who performed 
plasmapheresis on two subjects (one normal and one 
homozygous FH) during LDL turnover studies. The slope of 
the plasma decay curve and the urine:plasma ratio remained 
constant suggesting the fractional catabolic rate was 
independent of acute changes in pool size. For these 
reasons, the LDL FCR is generally held to be an important 
determinant of the apoLDL pool size which is not influenced 
by acute changes in pool size. However, measures of LDL 
catabolism, even where supplemented by modified LDL tracers 
to quantify receptor-independent catabolism, can only
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indirectly assess LDL receptor activity. More precise 
information regarding receptor numbers and degree of 
saturation can only be obtained by documenting changes in 
FCR following alterations in pool size where receptors 
numbers are kept constant(178). Since most perturbations 
of LDL pool size will automatically alter receptor 
numbers(e.g. treatment with bile acid-binding resins), 
these conditions are difficult to achieve in vivo.
Until recently there have been few published studies on the 
kinetic characteristics of LDL particles in the nephrotic 
syndrome. Early work by Git1in and colleagues(66) showed 
delayed clearance of a "low density lipoprotein". However, 
the tracer used covered a wide density range(S^ 10-100 with 
a preponderance of particles of S^ 20-60) which would now 
be classified as VLDL or IDL particles. In addition, the 
preparation of the tracer, involving dextran precipitation 
of the apoB-containing lipoproteins and their subsequent 
dissociation by centrifugation, may have led to changes 
which could influence tracer-tracee relationships. In 
1970, Scott and colleagues(67) reported LDL FCR's for 
nephrotic subjects which were marginally but not 
significantly lower than controls(mean values - nephrotic 
0.227 pools/day v controls 0.308). These values are 
similar to those reported in this study with the exception 
that the FCR for the control group is lower in Scott's 
series. The reason for this discrepancy is not clear
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although again methodological differences make direct 
comparisons difficult. Scott's tracer, partly prepared by 
precipitation steps, was isolated over a wider density cut 
than in the current investigation and contained a 
relatively high proportion of free iodide (up to 9%). in 
the current study, the young age of the control group may 
have exaggerated the differences between the FCR's of the 
two groups (179) but the mean value of 0.384pools/day is 
similar to the value of 0.371pools/day derived from a 
review of LDL turnover studies in normal subjects(180) .
Two recent studies(48,69) have also examined LDL metabolism 
in the nephrotic syndrome in man. In a group of 4 subjects 
(69) , the mean FCR of LDL apoB was similar to that of a 
group of historical controls (0.28 v 0. 30pools/day) but 
there was a significant increase in the production rate 
(mean values 18.6 v 13.5mg/kg/day - similar to values in 
table 6.3). Joven et al. (48) also found no significant 
reduction in LDL FCR in 6 nephrotic subjects although the 
mean value was lower than control (0.294 v 0.330pools/day) . 
However, LDL production rates were more than twice the 
control values and repeat turnovers in 3 patients following 
remission of proteinuria showed normal LDL apoB pool sizes, 
no change in FCR's and normal production rates. The same 
workers have reported similar results in a rat model of 
nephrotic syndrome induced by puromycin aminonucleoside 
(65) . in contrast, calculation of apoLDL production rate
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by a different technique involving the rate of recovery of 
steady state plasma LDL concentrations after LDL apheresis 
did not show any evidence of increased LDL synthesis (181) .
The differences between these studies and the current 
investigation are difficult to explain. The 
characteristics of the patients studied and the 
methodologies used are similar. None of these studies 
corrected for urinary losses of intact lipoprotein 
particles and, although this may have led to an 
overestimate of the true LDL FCR, this would not be of 
sufficient magnitude to explain the differences. Inter­
individual variation, perhaps due to dietary or genetic 
influences, may account for these differences since even in 
the results reported here there was a wide range of FCR's 
(0.140-0. 325pools/day) in the nephrotic group. However, 
the present investigation is the only study to examine the 
relative contribution of the two LDL catabolic pathways in 
nephrotic syndrome and the consistent reduction in 
receptor-mediated FCR suggests this is a significant factor 
in the genesis of the hypercholesterolaemia in this
condition.
There are several plausible explanations for a reduced LDL 
receptor clearance of LDL in the nephrotic syndrome.
Studies of mevalonate metabolism in nephrotic rats have 
demonstrated reduced clearance of mevalonate through the
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renal shunt mechanism(73). Increased availability of 
mevalonate may stimulate intracellular cholesterol 
synthesis with subsequent down-regulation of LDL receptors. 
A number of studies of experimental nephrotic syndrome have 
documented increased hepatic cholesterol synthesis(55,59). 
Another possibility is an alteration in the characteristics 
of the ligand. In vitro studies of LDL from subjects with 
renal failure have shown decreased binding and degradation 
by normal cultured fibroblasts(182). Although no similar 
studies have been reported for nephrotic subjects, LDL 
isolated from hypertriglyceridaemic patients has been shown 
in vitro to bind less well to LDL receptors(183).
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FIGURE 6.1 - MULTICOMPARTMENTAL MODEL USED FOR 
ANALYSIS OF apoLDL METABOLISM
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FIGURE 6.3 - RELATIONSHIP BETWEEN PROTEINURIA AND apoLDL PRODUCTION RATE
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CHAPTER 7 THE EFFECT OF SIMVASTATIN(AN HMG CoA REDUCTASE 
INHIBITOR) ON PLASMA LIPIDS, LIPOPROTEINS AND LDL 
METABOLISM IN NEPHROTIC SYNDROME
7.1 Introduction
Treatment of hyper1ipidaemia in nephrotic syndrome remains 
controversial. In contrast to primary hyperlipidaemia 
(102,103), the riskibenefit ratio of long-term 
hypolipidaemic therapy has not been quantified. No studies 
have compared the incidence and severity of adverse events 
related to drug therapy with the reductions in morbidity 
and mortality from vascular diseases. The relatively poor 
efficacy and tolerability of drugs such as bile acid- 
binding resins and fibric acid derivatives in nephrotic 
syndrome has not favoured widespread use of lipid-lowering 
agents in this condition. However, a number of recent 
short-term studies(125,128,129) have suggested that a new 
group of drugs, 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors(184), are more effective and better 
tolerated.
These drugs competitively inhibit the rate-limiting enzyme 
in the cholesterol biosynthetic pathway(185) - figure 7.1. 
Whole body cholesterol synthesis is reduced by 
approximately 30%(186,187). This leads to a reduction in 
intrahepatic sterol pools and initiates a number of
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mechanisms to conserve these. The mass of HMG CoA 
reductase increases and hepatocytes express more LDL 
receptors(188,189) thereby increasing uptake from plasma 
and increasing the fractional catabolic rate of LDL(190). 
Since the study described in chapter 6 found a consistent 
reduction in receptor-mediated LDL catabolism in nephrotic 
syndrome, this group of drugs appears to be ideally suited 
to lower plasma cholesterol in this condition.
The aims of this study were to assess:-
(1) short-term efficacy and tolerability of one of these 
drugs(simvastatin) in patients with nephrotic syndrome
(2) changes in LDL metabolism by receptor and non-receptor 
pathways in an attempt to link the putative action of the 
drug with changes in LDL turnover.
7.2 Subj ects and methods
Sixteen subjects with nephrotic syndrome were recruited to 
an open study of the effect of simvastatin on plasma lipids 
and lipoprotein turnover according to the previously 
defined criteria. The characteristics of these subjects 
are listed in table 7.1.
The protocol for this study is illustrated in figure 7.2. 
Patients were seen by a dietitian and instructed on a 
cholesterol-lowering diet. Those of normal body weight
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were given an isocaloric diet containing lOOmg cholesterol 
per 1000 calories/day and a total fat content <35% of diet 
with a polyunsaturated:saturated ratio of >0.5. Subjects 
adjudged to be overweight were also prescribed calorie 
restriction. The diet was continued for at least eight 
weeks including a run-in period of four weeks on placebo 
preparation and plasma lipid values rechecked. Subjects 
whose total cholesterol was still >6.5mmol/L entered the 
active phase of the study. Treatment was started at lOmg 
of simvastatin per day taken with the evening meal.
Patients were seen four weekly when standard biochemical 
and haematological indices were monitored and plasma 
lipids, lipoprotein cholesterol, HDL subfractions and 
apolipoproteins AI and B were measured in fasting plasma. 
The dose of simvastatin was titrated upwards to 20mg then 
40mg according to total plasma cholesterol values. The aim 
was to maintain total plasma cholesterol between 3.5 and 
5.2mmol/L. Patients were asked to keep a three day food 
diary on two occasions during the study to monitor 
adherence to diet. Compliance with drug therapy was 
assessed by tablet counts at each visit. Physical 
examination, electrocardiographs and full ophthalmological 
examination including slit lamp microscopy were performed 
before and at the end of the study.
A subgroup of eight patients(see table 7.1) underwent 
studies of apoLDL turnover as described in chapter 6. The
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first turnover was performed during the placebo phase and 
was repeated in the last two weeks of the study on optimum 
drug therapy. The data from these studies were analysed 
according to the model described in chapter 6. The 
turnover data was supplemented by measures of plasma 
lathosterol by capillary gas chromotography as an index of 
cholesterol biosynthesis(191,192).
Statistical analysis
Paired t tests were used to assess changes in lipid and 
lipoprotein parameters over the active phase(0-12weeks) of 
the study. Kinetic parameters generated from the modelling 
procedure were also compared by paired t tests.
7.3 Results
Plasma lipid and lipoprotein concentrations
Fifteen subjects completed the study. Twelve of these 
required the full dose of 40mg/day and some were still 
significantly hyperlipidaemic. In three subjects, total 
plasma cholesterol fell to <5.3mmol/L on 20 mg/day.
Overall, there were substantial reductions in total and 
LDL-cholesterol with mean falls of 32.9% and 39.5% 
respectively(table 7.2). Plasma triglyceride levels showed 
a modest fall(mean 14.4%) while HDL-cholesterol
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concentrations rose significantly due to an increase in the 
HDI^ subfraction. Apolipoprotein B concentrations in 
plasma fell by an average of 29.7% while there were no 
significant changes in apo AI.
The changes in plasma cholesterol and LDL-cholesterol have 
been plotted for the individual patients in figure 7.3. 
There was a rapid initial fall on lOmg of simvastatin but 
further decreases were observed on both 20 and 40mg doses. 
Total cholesterol concentrations were reduced below 
6.5mmol/L in all but 3 patients. Of these three, one had 
the highest concentration(15mmol/L) at the start of 
active therapy and in another plasma cholesterol level, 
after initially falling on lower doses, rose to the 
starting concentration on 40mg/day simvastatin. The reason 
for this is unclear - on careful questioning the patient 
denied non-compliance and the tablet count was consistent 
with uninterrupted therapy. The results of the third "poor 
responder" are difficult to interpret. This patient had 
been shown to have minimal change histology on two 
occasions. Over the last few years, the nephrotic syndrome 
had been unresponsive to steroids and immunosuppressive 
therapy and proteinuria and severe hypercholesterolaemia 
had been persistently documented. During the study, there 
was a transient spontaneous remission of nephrotic syndrome 
with proteinuria falling to 0.6g/day and serum albumin 
rising to 42g/L. However, a further relapse occurred
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almost immediately and, at the end of the study, 
proteinuria and hypoalbuminaemia were present to a similar 
degree as at the start. Plasma cholesterol at the start of 
the study was 19.1mmol/L but fell to 7.85mmol/L on 40mg/day 
simvastatin.
Renal function, serum albumin and proteinuria
There were no significant changes in renal function as 
judged by serum creatinine and creatinine clearance, 
proteinuria or serum albumin concentrations over the study 
period(table 7.2).
Tolerability
Most subjects tolerated drug therapy well in keeping with 
the reported low incidence of side-effects in other 
dyslipidaemias(127). However, two significant adverse 
events occurred during treatment although their precise 
relationship to the drug is uncertain. One subject 
developed a rapid decline in his visual acuity(from 6/6 to 
6/24) in one eye within 14 days of starting the active 
drug. This was due to the rapid evolution of a pre­
existing minor posterior subcapsular opacity noted at 
baseline ophthalmological examination. This was attributed 
to a course of steroids completed some 4 months earlier. 
This developed into a pronounced opacity involving the
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visual axis. The drug was stopped immediately and, over 
the following year, there was no significant improvement or 
decline in visual acuity or the appearance of the lens. It 
is difficult to say with certainty that this deterioration 
was directly due to the drug therapy. However, a number of 
observations support this contention i.e. the close 
temporal association; the stability over a further year 
after drug withdrawal; the previous reports of cataract 
formation with older inhibitors of cholesterol synthesis 
(e.g. triparanol) and with HMG CoA reductase inhibitors at 
very high doses in dogs. The details of this case have 
been reported to the Committee on the Safety of Medicines.
A second patient had a marked rise in serum creatine 
kinase(CK) activity associated with generalised muscle 
symptoms described as "cramps11. A peak value of 9400IU/L 
(upper limit of normal 150IU/L) was recorded three days 
after the acute symptoms and the time course of the serum 
concentration is plotted in figure 7.4. Drug therapy was 
not interrupted as it was initially thought that her 
symptoms were due to salt and water depletion related to a 
partial remission of proteinuria, hypokalaemia and 
over-vigorous diuretic therapy. When the serum CK level 
was checked a few days after the peak, it was falling 
rapidly and the drug was continued. Serum CK rose again to 
1000IU/L by the end of the study but was not accompanied by 
any symptoms.
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Low density lipoprotein metabolism
In the eight subjects investigated by apoLDL turnover 
studies, there was a consistent fall in the apoLDL pool 
size from a mean value of 5158mg to 3376mg - an average 
decrease of 33.1%(sd 11.6). There was also a relative 
depletion of cholesterol in the LDL particles isolated in 
the density range d=l.019-1.063g/mL. Overall, there was a 
small but significant decrease in the total cholesterol: 
protein(w/w) ratio from 1.72(sd 0.20) to 1.53(0.26),p<0.05.
The plasma decay curves and urinary radioactivities of the
125 131native( I-labelled) and cyclohexanedione-modified( I-
labelled) LDL were used to estimate fractional catabolic
rates(as described in chapter 6) before and after drug
therapy. In one patient, before drug therapy, there was a
131very rapid early decay of the I tracer which was 
probably due to denaturing of the protein during the 
modification procedure. For this patient, only the decay 
of the unmodified tracer was analysed giving a value for 
the total LDL fractional catabolic rate.
The changes in the apoLDL pool sizes, production rates and 
fractional catabolic rates for total, receptor-mediated and 
receptor-independent pathways are illustrated for each 
subject in figure 7.5. The mean values before and after 
treatment are shown in table 7.3. Five patients exhibited
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increases in the total FCR while the rest were unchanged or 
fell slightly. Overall, the mean changes were not 
significant. Similarly, the FCR for the receptor-mediated 
pathway did not alter consistently in all 7 subjects 
although again a majority(5/7) demonstrated an increase in 
this parameter. The effect of drug therapy on the 
contribution of the receptor-independent pathway showed 
great variation among subjects(figure 7.5f) although the 
mean values before and after treatment were similar. 
Absolute apoB production rates were decreased in four 
subjects, unchanged in three and rose in one.
The amount of TCA-precipitable radioactivity in urine was 
used to estimate urinary losses of intact LDL. This varied 
widely from <1% to 14% of the daily turnover of LDL(taken 
as the average of 14 days) both among and within 
individuals. The mean values were lower than in the 
previous study(chapter 6). This was attributed to a more 
rigorous washing of the precipitate to remove any free 
radioiodide. The values quoted for the FCR's are corrected
for the % of protein-bound urinary radioactivity. The
125 131average value for both I and I was used since there 
did not seem to be any consistent difference between the 
two tracers.
Plasma lathosterol concentrations fell in all eight 
subjects from a mean value of 127(sd 59) to 61(sd 23)ug/mg
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cholesterol. The average decrease was 48%. There was no 
association between the decrease in lathosterol and changes 
in plasma cholesterol, LDL cholesterol, apoB pool size or 
kinetic parameters.
7.4 Discussion
Efficacy and tolerability
A number of recent studies have reported on the use of HMG 
CoA reductase inhibitors in nephrotic hyperlipidaemia(table 
7.4). Reductions of 27-36% have been achieved in total 
cholesterol and of 27-45% in LDL-cholesterol. These 
reductions were compared favourably to the effect of 
cholestyramine by Rabelink(12 5). Plasma triglyceride and 
VLDL-cholesterol concentrations were also generally reduced 
and there was a trend towards an increased HDL-cholesterol 
concentration. All these studies reported minimal side- 
effects in short term use and, in one report(117), longer 
term therapy(48 weeks) satisfactorily controlled plasma 
cholesterol and was associated with reductions in 
proteinuria. The results of the current study are broadly 
in keeping with these previous reports with substantial 
falls in total and LDL-cholesterol and plasma apoB 
concentrations. Triglyceride and HDL-cholesterol both 
showed modest improvements and there was a significant 
increase in the cardioprotective HDL2 subfraction. These
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results confirm the utility of this group of drugs in 
reducing nephrotic hyperlipidaemia.
However, two serious adverse events were witnessed during 
this study, one of which resulted in a permanent 
disability. Although it is not certain that the drug 
therapy was causal in these adverse events, both of these 
side-effects have been previously reported for this group 
of drugs. An early inhibitor of cholesterol synthesis 
(triparanol) was associated with alopecia and lens 
opacities when used in clinical trials in the 1960's 
(193,194). This was attributed to the accumulation of 
toxic sterol metabolites late in the cholesterol 
biosynthetic pathway. For this reason, newer inhibitors of 
cholesterol synthesis have been extensiviely tested in 
animals with particular reference to possible lens 
toxicity. Large doses of both simvastatin and lovastatin 
(2 0-50x the equivalent dose in man) have been shown to 
cause an increased incidence of subcapsular lens opacities 
in dogs(195). The mechanism is thought to relate to the 
avascular nature of the lens combined with relatively high 
requirements for cholesterol for the differentiation and 
growth of lens epithelial and fibre cells. The lens has a 
high rate of cholesterol synthesis to compensate for its 
inability to utilise circulating cholesterol. Although 
little active drug will also reach the lens, even small 
decreases in cholesterol synthesis may be critical.
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However, double-blind controlled studies in man have failed 
to show any increased incidence of opacity formation when 
compared to placebo or other lipid-lowering agents and the 
doses used in dogs to induce minor lens changes are much 
greater than would be used in clinical practice.
Muscle problems are also a recognised complication of this 
group of drugs. Asymptomatic rises in creatine kinase and 
vague muscle tenderness or weakness have been reported with 
a frequency of approximately 1%(196). More severe cases of 
myopathy and rhabdomyolysis have also been recorded(197). 
There appears to be an increased risk of muscle problems 
when used in conjunction with fibrates, cyclosporin A and 
nicotinic acid. Recently, it has been proposed(198) that 
the muscle toxicity results from depletion of mitochondrial 
ubiquinone stores. Ubiquinone is a product of mevalonate 
(see figure 7.1) and, although serum levels are not reduced 
by HMG CoA reductase inhibitors, mitochondrial supplies may 
be impaired(199).
These adverse events sound a note of caution amidst growing 
enthusiasism for the use of these drugs in renal disease. 
Careful monitoring of biochemical indices and 
ophthalmological review is advisable until more experience 
of HMG CoA reductase inhibitors in nephrotic syndrome is 
available.
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Mechanism of plasma cholesterol lowering by HMG CoA 
reductase inhibition
Only one previous study has investigated the kinetic 
mechanisms underlying the reductions of plasma lipoproteins 
by this group of drugs in nephrotic syndrome(69). In 3 
patients, radioiodinated VLDL/IDL(d<l.019g/mL) and 
LDL(d=l.019-1.063g/mL) tracers were used to follow apoB 
metabolism. Both increases in fractional catabolism and 
decreases in apoB production were observed in response to 
lovastatin therapy. A similar heterogeneity of response 
was found in the current study. Baseline results confirmed 
the low fractional catabolic rate of LDL(see chapter 6) in 
the nephrotic syndrome, mainly attributable to a decrease 
in receptor-mediated clearance. Despite consistent and 
substantial falls in apoLDL pools in all patients, the 
changes in apoLDL kinetics underlying these reductions were 
variable. A majority of subjects had increased catabolism 
by the receptor-mediated pathway in keeping with increased 
expression of LDL receptors. However, in four patients 
there were falls in apoLDL production of 23-51% and this 
was reduced by 13% on average. There were no apparent 
distinguishing factors between those who responded with an 
increase in receptor-mediated catabolism or those with 
decreased apoLDL production in terms of underlying renal 
disease, severity of nephrotic syndrome, apoE phenotype or 
fall in plasma lathosterol.
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The relative importance of synthetic and catabolic 
processes in determining the steady state levels of plasma 
lipoproteins was considered in chapters 1 and 6. There is 
considerable evidence(31) that the major determinant of 
steady state plasma LDL concentrations is the rate of LDL 
receptor-mediated catabolism. This is controlled by the 
intrahepatic sterol pools which when depleted(e.g. by 
inhibiting cholesterol synthesis) results in increased 
synthesis of LDL receptors, increased LDL catabolism and 
reduction in plasma concentration. It is generally held 
that the plasma cholesterol lowering effect of HMG CoA 
reductase inhibitors is due to increased removal of LDL 
from plasma by the liver. Studies by Shepherd et al.(200) 
previously demonstrated this for cholestyramine where 
interruption of the enterohepatic bile salt circulation 
depleted hepatic sterol pools and increased the fractional 
catabolic rate of LDL by the receptor-mediated route.
Early work in dogs confirmed that a similar mechanism 
existed in vivo for lovastatin(188). Although this paper 
is often quoted in support of this theory, this 
interpretation may be unjustified. The dosages of 
lovastatin used(10 and 25mg/kg/day) are much larger than 
would be used in clinical practice in man and at the lower 
dose the main cause of the fall in plasma cholesterol was a 
reduced apoLDL production rate. Although there was an 
increase in the number of receptors expressed on hepatic 
membrane preparations, there was no increase in the
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fractional catabolic rate of radioiodinated human LDL. At 
the higher dose, these workers did demonstrate an increased 
fractional catabolic rate of LDL and increased high 
affinity binding of LDL to hepatic membrane preparations. 
Studies in humans have demonstrated the ability of these 
drugs to increase fractional catabolism of LDL in both 
heterozygous familial hypercholesterolaemia(190) and, more 
recently, in normal volunteers(201). Further support for 
this hypothesis is also available from in vitro studies of 
LDL receptors expressed on monocyte-derived macrophages 
(202) and circulating lymphocytes(203) from subjects 
treated with these drugs and by a recent elegant study by 
Reihner et al.(189). In this latter study, treatment of 
patients with lovastatin prior to elective cholecystectomy 
led to an increase in the amount of LDL receptor mRNA and 
high affinity LDL binding sites expressed on liver biopsy 
samples compared to controls.
However, apoB kinetic studies in other dyslipidaemias 
treated with lovastatin or pravastatin have not confirmed 
that increased catabolism of LDL is the principal cause of 
the lipid lowering effect. In two studies of patients with 
primary moderate hypercholesterolaemia(i.e. total 
cholesterol >6.5mmol/L), Vega and Grundy(204,205) 
documented increases in fractional catabolic rates of LDL 
in only 9/21 patients despite similar reductions in LDL- 
cholesterol and protein. In a majority of patients, the
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kinetic explanation for the falls in apoLDL pool size was a 
reduced production rate. Studies in small numbers of 
patients with type III dysbetalipoproteinaemia(206) and in 
cholesterol ester storage disease(207) have produced 
similar findings. A recent study of lovastatin in familial 
combined hyperlipidaemia also concluded that the main 
metabolic change was a decreased LDL apoB production rate, 
specifically a decrease in the production of LDL which was 
not derived from VLDL(2 08).
Vega and Grundy(204,205) have attempted to explain the dual 
effects of HMG CoA reductase inhibitors on LDL metabolism 
by postulating the presence of a nascent pool of rapidly 
metabolised VLDL particles. Following drug therapy, these 
lipoproteins were removed by receptor-mediated clearance 
thus decreasing the amount of apoB available for transfer 
to LDL. Why "up-regulation" of LDL receptors leads to 
increased removal of precursors in some patients and 
enhanced LDL removal in others has not been satisfactorily 
explained. An alternative explanation is that decreased 
cholesterol availability due to inhibition of synthesis may 
reduce secretion of apoB-containing lipoproteins from the 
liver. The consistent reductions in plasma lathosterol 
concentrations(34-71%) suggest that hepatic cholesterol 
synthesis was significantly reduced in all these patients 
but the effect of this on LDL turnover is not clear. There 
is surprisingly little experimental work which has
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investigated the effects of alterations of hepatic sterol 
metabolism on the assembly and secretion of lipoproteins. 
This has not been studied directly in man by methods 
examining synthesis directly(i.e. incorporation of 
radioactive or stable isotopes into VLDL apoB).
Indirect measures derived from studies with radioiodinated 
VLDL and LDL in rabbits(209) and miniature pigs(210,211) 
suggest that the cholesterol-lowering effect of lovastatin 
is achieved by inhibiting direct secretion of LDL by the 
liver. There is great debate about the existence of a 
pathway for direct hepatic LDL production in man(see ref 
208 for a full discussion). The discrepancy between LDL 
apoB production and flux from VLDL identified by some 
workers in animals and in man may be due to one of two 
mechanisms:-
(i)direct secretion of LDL particles by the liver
(ii)a rapidly metabolised pool of nascent particles which 
are converted to the LDL density range in the hepatic 
sinusoids or in the circulation possibly by binding to 
lipoprotein lipase binding sites during "first pass"
The present study does not differentiate between reduced 
hepatic VLDL production, changes in flux of apoB from VLDL 
to LDL or variation in direct LDL secretion by the liver in 
these patients. However, the results presented in chapter 
5 do not suggest that direct hepatic secretion of LDL is a
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major metabolic pathway in nephrotic hyperlipidaemia. A 
recent study of VLDL-triglyceride metabolism in nephrotic 
rats treated with pravastatin showed that limitation of 
hepatic sterols may normalise VLDL synthetic rates(212). 
However, the results of this experiment must be interpreted 
with caution as the failure of the drug to reduce plasma 
cholesterol and apoB concentrations in control or nephrotic 
animals illustrates the fundamental differences in 
lipoprotein metabolism between rats and man.
Finally, at least part of the cholesterol-lowering effect 
of simvastatin is achieved by depleting low density 
lipoproteins of cholesterol with a decrease in the 
cholesterol:protein ratio. This has been shown previously 
by other investigators(204).
Further studies are required in man to fully elucidate the 
kinetic mechanisms underlying the reductions in cholesterol 
in these subjects. One approach would be to study the 
effects on VLDL apoB metabolism using the methods in 
chapter 5. However, a more useful and direct assessment of 
the relationship between secretion of apoB-containing 
lipoproteins and alterations of cholesterol metabolism 
could be gained by utilising stable isotopes to look at 
synthesis of apolipoproteins and lipids directly.
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TABLE 7.3 - CHANGES IN apoLDL KINETIC PARAMETERS FOLLOWING 
SIMVASTATIN THERAPY
PRE POST SIGNIFIGANCE
(paired t test)
apoLDL pool size 
(mg)
5158(947) 3376(510) p<0.001
LDL cholesterol: 
protein ratio(w/w)
1.72(0.25) 1.48(0.24) p<0.05
plasma lathosterol 
(ug/mg chol)
127(59) 61(23) p<0.005
total FCR 
(pools/day)
0.196(0.053) 0.252(0.076) ns
receptor-mediated 0.077(0.040) 
FCR
0.111(0.051) ns
receptor- 0.126(0.023)
independent FCR
0.140(0.063) ns
absolute turnover 
rate(mg/kg/day)
984(218) 871(343) ns
values are means and standard deviations
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FIGURE 7.3a - PLASMA CHOLESTEROL CHANGES ON SIMVASTATIN
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FIGURE 7.5 - EFFECT OF SIMVASTATIN ON apoLDL METABOLISM
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CHAPTER 8 LIPOPROTEINURIA IN NEPHROTIC SYNDROME
8.1 Introduction
Increased urinary excretion of lipids is well-recognised 
in the nephrotic syndrome and has been included by some in 
the definition of the clinical syndrome. However, the 
nature and quantity of urinary lipids has been infrequently 
investigated. Urinary lipids may exist in four discrete 
physico-chemical forms(213):-
1.Cell membrane phospholipids
2.Large lipid droplets composed of cholesterol ester which 
are visible as oval fat bodies under the light microscope 
and as "Maltese crosses" under polarised light.
3.Small quantities of cholesterol monohydrate in solution 
4.Lipoprotein particles
The aim of this study was to characterise and quantify 
urinary excretion of lipoproteins in relation to 
proteinuria. No attempt was made to investigate losses of 
the first three categories of lipid. A few previous 
studies have demonstrated excretion of lipoprotein 
particles, particularly HDL, in the nephrotic syndrome 
(53,119). HDL apolipoproteins have also been demonstrated 
in the urine of both normal and nephrotic subjects. This 
is probably due to filtration of apolipoproteins
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circulating free of lipoprotein complexes(214). The 
finding of small but significant quantities of protein- 
bound radioactivity in the urine of patients with nephrotic 
syndrome undergoing radioiodinated LDL turnovers(chapter 6) 
stimulated further investigations designed to confirm that 
this was due to urinary losses of LDL particles. The 
molecular weight(approximately 2.3 x 10 d) , size(18-25nm) 
and net negative charge of LDL particles should retard 
glomerular filtration.
8.2 Subjects and methods
Lipoproteins were isolated from urine by concentrating 
large volumes of fresh, timed urine collections using a 
combination of ultrafiltration and ultracentrifugation. 
Fasting blood and 24 hour urine collections were collected 
from eleven patients with nephrotic syndrome. The 
patients studied were selected at random and included 
patients with several distinct glomerular diseases, 
proteinuria from 3.3 to 24.2g/day and a range of plasma 
lipid concentrations. Fasting lipids and lipoprotein 
cholesterol, serum creatinine and albumin and urine total 
protein and creatinine were measured as described in 
chapter 2.
Urine samples were collected with thymol or sodium azide as 
a preservative. The urine was concentrated 20-50 fold
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using an ultrafiltration system within hours of the end of 
the collection period. An Amicon HIP 100-2 0 hollow fibre 
cartridge with a nominal MW cut-off of 100,000d(source: 
Amicon, Stonehouse, Gloucester, UK) was employed. Using 
this system, it was possible to concentrate urine samples 
(l-31itres) to a final volume of approximately 20-50mL over 
a period of several hours. The concentration factor was 
calculated from careful measurement of the volumes of the 
initial urine collection and the final concentrate. A 
membrane with a high molecular weight cut-off was 
deliberately chosen to remove most of the albumin and 
other small proteins from the concentrate while retaining 
lipoproteins. This helped to maintain the ultrafiltration 
rate during concentration and reduced the risk of albumin 
contamination of lipoprotein fractions. Studies with 
radioiodinated LDL and HDL showed that 60% of the 
radioactivity was recovered in the retentate and 
approximately 10% in the ultrafiltrate. The rest was 
assumed to have bound to connecting tubing or the 
filtration membrane. No correction was made for recovery 
in these experiments and the lipoprotein masses recovered 
represent a minimum estimate of urinary losses.
The retentate was further concentrated(x2) and fractions 
corresponding to IDL/LDL(1.006-1.063g/mL) and HDL 
(1.063-1.21g/mL) obtained by sequential flotation 
ultracentrifugation at the appropriate density. To
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ascertain the background density of the solution, a 
preliminary ultracentrifugation step was performed where 
6mL aliquots of the retentate were subjected to 
ultracentrifugation at 39,000rpm in a Ti 40.3 rotor for 16 
hours at 4°C. The top lmL was aspirated and its density 
measured in a densitometer(source: Anton Parr KG, Graz, 
Austria). The remaining 5mL aliquot was then adjusted to a 
density of 1.063g/mL by the addition of solid sodium 
bromide according to the formula:-
v (d2 - d )
M =
1 - Vsd2
where v = volume of initial solution
M = mass of sodium bromide in grams 
Vg= partial specific volume of salt at relevant 
temperature and concentration 
d2= 1.063g/mL
d1= initial density of background solution
The solution was then made up to a final volume of 6mL by 
overlaying with d=1.063g/mL solution. A fraction 
corresponding to LDL was recovered in a volume of 2mL by 
careful aspiration after further ultracentrifugation.
Solid NaBr was then added to bring the density to 1.210g/mL 
for isolation of HDL.
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The lipoprotein fractions obtained were analysed for 
cholesterol, triglyceride and phospholipid content as 
outlined in chapter 2. Protein content was measured by 
Bradford's method(215). The minimum concentration of 
protein detectable was equivalent to excretion of 
approximately 5mg/day of lipoprotein. Values below this 
were considered too small to quantify accurately although 
small amounts of lipid were often measurable. Total 
lipoprotein concentration(mg/dL) was calculated from the 
sum of these concentrations and the daily excretion 
calculated from the urine volume and the concentration 
factor. To confirm the presence of intact lipoprotein 
particles, selected samples were subjected to non­
denaturing gradient gel electrophoresis(216) and electron 
microscopy of preparations(217) negatively stained with 
phosphotungstate.
8.3 Results
Lipoproteins were detected in the urine of all eleven 
patients studied although in some this was too small to 
quantify accurately. In six primary hypercholesterolaemic 
patients with normal renal function, a small quantity of 
HDL was recovered from the urine in only one patient. The 
presence of "intact" lipoprotein particles was confirmed by 
direct visualisation of particles by electron microscopy 
where preparations of both HDL and LDL revealed circular
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particles consistent with lipoproteins(figure 8.1). The 
estimated size of these(up to 50nm) was larger than 
predicted but this may be an artefact resulting from the 
extensive processing required to isolate the lipoproteins 
and the tendency for these particles to flatten and 
spread-out on EM grids. Further confirmation was obtained 
from gradient gel electrophoresis where both HDL particles 
over a range of sizes and LDL particles(occasionally in 
discrete subfraction bands) were identified(figures 8.2 & 
8.3) .
HDL was found in all eleven patients and could be 
accurately quantified in nine with values ranging from 
29.3-107.Omg/day. Significant quantities of LDL were found 
in 6 patients varying from 11.1-57.8mg/day. Of those with 
no measurable LDL in the urine, four had the lowest levels 
of total protein excretion(3.3-6.2g/day). The fifth had 
the highest quantitative proteinuria at 24.2g/day. This 
discrepancy may be explained by a continuing degree of size 
selectivity even at this larger particle size since this 
patient had steroid-responsive, minimal change disease and 
would be predicted to have "selective" proteinuria.
Overall, there was a significant correlation between
2
urinary losses of total protein and HDL(r =55.2%, p=0.005)
- figue 8.4d. The numbers with LDL in urine are too 
small to draw any firm conclusions but there was a trend to
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increased LDL in those with higher levels of proteinuria. 
There was no relationship between plasma LDL or HDL 
cholesterol concentrations and the urinary excretion of 
these lipoproteins(figures 8.4a and b).
8.4 Discussion
These results confirm that measurable quantities of both 
HDL and LDL are present in the urine of many nephrotic 
subjects. These particles have similar physical 
characteristics to their plasma counterparts. Glomerular 
filtration is the most likely route of entry into the urine 
as the quantity of lipoprotein generally mirrors total 
protein losses. A degree of selectivity occurs as 
demonstrated by the absence of urinary LDL in the patient 
with minimal change disease despite the highest total 
protein losses and the highest plasma LDL-cholesterol 
concentration. This raises fundamental questions about the 
nature and size of the defects in the glomerular capillary 
wall in glomerular disease. Current theories favour a 
model consisting of a membrane bridged by water-filled 
pores(218). Estimates of the size of these pores in normal 
subjects ranges from 4.5-5.5nm. In nephrotic syndrome, it 
is postulated that there is heterogeneity in the size of 
these pores. The area of the glomerular capillary wall 
covered by a subset of larger pores is increased at the 
expense of a decrease in number of smaller pores favouring
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the filtration of larger molecules(e.g. albumin) to water 
and salt. The size of these larger pores is uncertain but 
these results suggest a few at least must approach the 
diameter of LDL particles. It is possible that these 
particles are deformable and may be able to migrate through 
smaller pores. Alternative theories consider the 
glomerular basement membrane to be similar to a thixotropic 
gel(219) which when subjected to physical stress(e.g. 
haemodynamic forces) becomes less viscous and allows the 
migration of larger particles to the urinary space.
Lipoproteins may reach the urinary space by processes other 
than filtration. There may be breaks or defects along the 
glomerular basement membrane allowing direct leakage of 
plasma constituents into the urinary space. A similar 
mechanism may explain the appearance of red blood cells of 
glomerular origin in the urine. There is evidence that 
filtered lipoproteins are catabolised and altered by 
tubular cells(53,119) and it is unlikely that tubular cells 
could assemble and secrete lipoproteins.
Although the presence of lipiduria in nephrotic syndrome 
has been known for many years, surprisingly few studies 
have attempted to characterise and quantify these losses. 
The oval fat body is perhaps the best recognised form of 
urinary lipid. This consists of an accumulation of 
cholester ester in cellular debris or casts. It has a
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typical appearance under the microscope. However, the 
precise mechanism of the formation of these collections of 
fat is not known. Only a few reports have confirmed the 
presence of lipoprotein particles by a combination of 
chemical and physical methods(119,220,221,53) although 
there presence was predicted by earlier workers(222) and by 
the identification of apolipoproteins in urine. Jungst et 
al.(221) also identified a macromolecular protein/lipid 
complex in both normal and nephrotic urine. This accounted 
for most of the lipid in normal urine and a substantial 
fraction in nephrotic urine. Although thought to be a 
membrane derived complex, it contained significant 
quantities of albumin, possibly as a contaminant. 
Interestingly, it floated at a density between l.l-1.3g/mL 
raising the possibility that it could be mistaken for HDL.
There are several important consequences of these findings. 
Firstly, as discussed above it raises important questions 
about the nature of the defect in the glomerular capillary 
wall in nephrotic syndrome. Second, it gives credence to 
the theory(107) that filtered lipoproteins may be capable 
of damaging tubular cells. Finally, it is important in the 
context of metabolic studies of radiolabelled lipoproteins 
in nephrotic subjects since losses of the magnitude 
measured here would represent up to 5% of HDL and up to 3% 
of LDL protein turnover each day. Since almost certainly 
these are underestimates due to losses during processing of
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samples, the total urinary excretion may account for a 
significant fraction of daily apolipoprotein flux 
justifying attempts to correct for this in these studies.
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CHAPTER 9 GENERAL DISCUSSION
This final section considers the contribution of the 
preceding studies to current understanding of lipoprotein 
metabolism in nephrotic syndrome and highlights possible 
directions for further study. Three main areas are 
discussed:-
9.1 The relationship between hyperlipidaemia and nephrotic 
syndrome. This explores the prevalence and nature of 
hyperlipidaemia in the nephrotic syndrome and the effect of 
increasing severity of renal disease(chapters 3 & 8).
9.2 Lipoprotein metabolism in nephrotic syndrome. This 
is the main topic of this thesis and addresses the 
underlying abnormalities of lipoprotein metabolism and 
their possible causes(chapters 4-6).
9.3 Treatment of nephrotic hyperlipidaemia. The 
continuing uncertainty surrounding if, when and how to 
treat this complication of proteinuric disease is 
discussed(chapter 7).
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9.1 THE RELATIONSHIP BETWEEN HYPERLIPIDAEMIA AND NEPHROTIC
SYNDROME
Although hyperlipidaemia is a very common complication of 
nephrotic syndrome(41-48,53,223), its precise incidence has 
been poorly documented. Few studies have adequately 
defined their population base and have reported on a 
selected series of patients in whom hyperlipidaemia, often 
severe, has been identified. With two exceptions(47,53), 
it is not clear in these surveys whether all nephrotic 
subjects seen in a given time period were included. Other 
factors which hamper interpretation and comparisons of 
studies include the absence of well-defined "normal” plasma 
lipid and lipoprotein levels, differences in the analysis 
and classification of hyperlipidaemia, variations in the 
severity of nephrosis and the influence of co-existent 
factors on plasma lipids(e.g. systemic disease, drugs, 
renal failure).
The current investigation confirms previous surveys 
documenting the main lipid and lipoprotein abnormalities. 
Established nephrotic syndrome with heavy proteinuria, 
hypoalbuminaemia(<30g/L) and oedema is complicated by 
hyperlipidaemia in nearly all cases. Plasma cholesterol 
and LDL-cholesterol are invariably increased and, in more 
severe disease, plasma triglycerides and VLDL-cholesterol 
also rise and may become the dominant abnormality. In
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these cases, plasma cholesterol may reach as high as 
30mmol/L. However, in less severe cases with proteinuria 
>3g/day but well-maintained serum albumin, plasma 
cholesterol may be only modestly elevated or even 
"normal"(i.e. <6.5mmol/L). The studies presented here
also demonstrate that, although lower levels of proteinuria 
are not associated with significant rises in cholesterol 
compared to controls, there is a weak but continuous 
relationship between these two variables. Further 
evidence(146) is presented confirming the significant 
elevations of plasma lipoprotein(a) concentrations and a 
strong relationship was demonstrated with the inverse of 
serum albumin.
Abnormalities of lipoprotein composition have been 
described in nephrotic subjects(42,49) but the consistent 
increases in free cholesterol in the VLDL and IDL 
subfractions demonstrated here are at variance with these 
previous reports. Gherardi et al.(42) reported an increase 
in the esterified cholesterol and phospholipid content of 
VLDL but the subjects in this study were all children which 
may go some way to explaining the discrepancy. Muls(49) 
identified two peaks in the LDL density range in some 
nephrotic subjects with the presence of higher density, 
cholesterol- and protein-rich particles. These findings 
were not confirmed by compositional changes over the whole 
LDL range. However, preliminary results of LDL
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subfractionation by density gradient ultracentrifugation 
and gradient gel electrophoresis(224) in the Glasgow 
Royal Infirmary lipid research laboratory have consistently 
shown the presence of a denser species of LDL(LDL-III) in 
these subjects. A similar finding has been reported in 
patients with proven coronary artery disease(224). These 
particles are thought to be formed in the presence of 
hypertriglyceridaemia where slowly removed VLDL species are 
remodelled by lipases activity to produce small dense LDL 
particles.
Most studies of nephrotic hyperlipidaemia have emphasisied 
the relationship between the degree of hyperlipidaemia and 
the severity of renal disease as measured by 
hypoalbuminaemia or quantitative proteinuria. The three 
largest series(41,46,48) have found the closest association 
to be between plasma cholesterol and the inverse of serum 
albumin. No significant relationship was demonstrated with 
quantitative proteinuria in the two more recent studies
(46,48). The data presented here shows serum albumin to be 
inversely related to LDL-cholesterol, only very weakly to 
total cholesterol and not at all to triglycerides. 
Relationships with all three parameters were found for 
proteinuria. Extending the study to subjects with lower 
levels of proteinuria(quantified accurately by urinary 
albumin assay) revealed that this relationship with 
cholesterol concentrations existed even at lower levels of
180
protein excretion. This may be important in view of 
reports suggesting microalbuminuria may predict a higher 
risk of future cardiovascular disease(149,150).
It has been postulated that the relationships between 
hyperlipidaemia and both hypoalbuminaemia and proteinuria 
are causal. Increased hepatic synthesis of lipoproteins 
has been shown in a variety of animal models. In man, 
lowered serum albumin levels may stimulate a general 
increase in hepatic protein synthesis resulting in 
elevated plasma concentrations of lipoproteins and other 
larger proteins(e.g. IgM, alpha-2-macroglobulin, 
fibrinogen). This may be mediated directly by albumin or 
by plasma oncotic pressure(47). The studies of Baxter and 
others(73,74) which demonstrated the ability of infusions 
of albumin, dextrans and other oncotic agents to ameliorate 
the lipid abnormalities provide strong support for this 
theory. However, recent work in man and animal models 
(38,225) has demonstrated a divergence between albumin 
synthetic rates and hyperlipidaemia. Others have proposed 
that the loss of a "liporegulatory" substance in the urine 
is responsible for the reduced catabolism of very low 
density lipoproteins and that proteinuria is the best 
predictor of hyperlipidaemia. ApoCII was an obvious 
candidate but although detectable in nephrotic urine it 
does not appear to be depleted in plasma. Staprans et 
al.(84) isolated a glycosaminoglycan co-factor from
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nephrotic urine and this may yet prove to be very 
important. However, it seems certain that more than one 
mechanism accounts for the hyperlipidaemia and this is 
considered in more detail below.
Further studies
There have been relatively few studies of the 
apolipoproteins in patients with nephrotic syndrome(44). 
Further work is required to document the quantity and 
distribution of apolipoproteins among lipoprotein 
subfractions. Disturbances of apolipoproteins may explain 
some of the defects of lipoprotein metabolism in this 
condition. It is increasingly realised that the protein 
moieties of lipoproteins play a crucial role in determining 
their metabolic fate(226).
9.2 LIPOPROTEIN METABOLISM IN NEPHROTIC SYNDROME
The kinetic studies presented in this thesis were designed 
to elucidate the metabolic abnormalities underlying 
nephrotic hyperlipidaemia. The conclusions will be 
considered separately for triglyceride-rich(chylomicrons/ 
VLDL) and low density lipoproteins.
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9.2.1 Triglyceride-rich lipoproteins
Despite a number of animal studies demonstrating a defect 
in chylomicron metabolism in nephrosis(166-168), there is a 
paucity of data on humans. Few studies have carefully 
evaluated the presence of fasting hyperchylomicronaemia in 
nephrotic syndrome. The available evidence is conflicting
(46,48). Difficulties in separating chylomicrons from 
large, triglyceride-rich VLDL species may be resolved by 
newer specific assays of apoB48.
Using the technique of a vitamin A-loaded, standardised fat 
meal followed by serial measurements of triglyceride and 
retinyl palmitate in the d<1.006g/mL fraction, no overall 
difference in post-prandial lipaemia was demonstrated 
between a group of patients with nephrotic-range 
proteinuria and a control group. However, this summary 
statistic masks the fact that in both groups there was 
substantial inter-individual variation in the duration and 
magnitude of post-prandial lipaemia. Subjects with an E2 
allele were shown to have a persistence of retinyl 
palmitate at 24 hours consistent with impaired removal of 
chylomicron remnants(158). However, the most abnormal 
lipaemic response was seen in a nephrotic patient with an 
E4/E3 phenotype and the reason for the delayed clearance in 
this case is unclear. Post-heparin LPL and HTGL activities 
were not significantly different between the two groups.
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This contrasts with the significant decrease in the removal 
of two species of VLDL in nephrotic subjects shown in 
chapter 5. This is consistent with studies in rats(63,64) 
and in man(66,69). In Vega's study(69) using a similar 
technique, the average transit time for VLDL apoB was 
increased 3x above normal in four nephrotic subjects. In 
contrast, a preliminary report by Moorhead(70) suggested 
that the half life of VLDL apoB was no different from 
controls although there was a very wide spread of results 
in the nephrotic group. The discrepancy between the 
catabolism of chylomicrons and VLDL in the current studies 
may be due to compositional changes in VLDL which are not 
seen in chylomicrons in nephrotic syndrome in man. This is 
supported by the normal lipase activities. Compositional 
analysis of the apoB-containing lipoproteins fractionated 
by DGUC showed an increase in the free cholesterol content 
of these lipoproteins. This compositional changes has been 
shown to decrease the rate of lipolysis of triglyceride- 
rich lipoproteins(227). Chylomicrons were not specifically 
separated from VLDL species in the fat load tests. 
Therefore, no clear conclusions can be drawn regarding the 
composition of these particles. However, the small 
increases in free and esterified cholesterol resulting in a 
higher cholesterol:phospholipid ratio at baseline 
disappeared six hours after a fat meal suggesting that, in 
contrast to those of hepatic origin, the composition of 
lipoproteins of intestinal origin is not altered in
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nephrosis. In neither study was the apolipoprotein content 
of the triglyceride-rich lipoproteins determined and it is 
possible that changes in the absolute or relative amounts 
of apoC's and apoE may influence the catabolic potential of 
these particles. This is certainly worthy of further study 
although simple, accurate and precise assays of individual 
apolipoproteins are not readily available.
Although catabolic defects of triglyceride-rich 
lipoproteins have been recognised in nephrotic syndrome, 
most workers have emphasised the importance of increased 
hepatic lipid, protein and lipoprotein synthesis as the 
main cause of the hyperlipoproteinaemia. The data in 
chapter 5 show that in nephrotic patients the rates of apoB 
synthesis vary widely from normal to 4x normal. Overall, 
there was no significant difference between the two groups 
although there was a consistent increase in the production 
of VLDL2 apoB. This suggests apoB production is increased 
relative to triglyceride with the elaboration of smaller, 
triglyceride-poor VLDL species. These results are in 
accord with those of Vega(69) who found an average apoB 
production rate in VLDL of 10.7mg/kg/day(range 6.0-18.5). 
However, Moorhead's study(70) had much higher apoB 
production rates(mean 75.Omg/kg/day). These differences 
may reflect the heterogeneity of the nephrotic population 
since Moorhead's patients may have been more severely 
nephrotic as judged by their higher plasma lipid
185
concentrations than the patients in the current study. In 
this relatively small group of subjects, there was no 
association between apoB production rates and serum albumin 
or proteinuria and the reason for the wide variation in 
apoB production rates is not clear. *
9.2.2 LDL Metabolism
Elevations of LDL-cholesterol are the earliest and most 
consistent lipid abnormality found in nephrotic syndrome.
In chapter 6, evidence is presented that both catabolic and 
synthetic defects of apoLDL turnover are responsible.
There was a highly significant reduction in the fractional 
catabolic rate of LDL, mainly due to decreased activity of 
the receptor-mediated pathway. Possible mechanisms for 
this were discussed. It was hypothesised that disturbances 
of mevalonate metabolism may stimulate hepatic cholesterol 
synthesis and thereby reduce apo B/E receptor activity 
(73). However, further work on mevalonate metabolism in 
human nephrotic syndrome is required to confirm the animal 
studies.
Three previous studies of LDL metabolism in nephrotic 
syndrome have been published over the last twenty years 
although none of these differentiated between the two 
pathways for LDL catabolism. Early work by Scott et al.
(67) showed a modest decrease in apoLDL FCR compared to
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controls but this was not statistically significant. Two 
more recent studies(48,69) have found virtually normal 
FCR's although in both the FCR's of the control groups were 
relatively low(0.30 and 0.33pools/day respectively) 
compared to the controls reported here(0.38pools/day) and 
other studies(180). None of these studies took account of 
urinary loss of LDL which would have led to a small 
overestimate of the true FCR but would not alter the 
results significantly. Other possible reasons for these 
discrepancies were discussed in chapter 6. In the further 
studies described in chapter 7, the low apoLDL FCR's were 
confirmed and this does appear to be a consistent finding 
in these subjects using the methods presented here.
All three previous studies of LDL metabolism in nephrotic 
syndrome have concluded that increased LDL production is 
the main cause of the elevated plasma level. In the 
current work, there was a very strict relation between 
apoLDL production and quantitative proteinuria and only 
those with >10g/day clearly had increased synthesis.
These studies demonstrate that both decreased catabolism 
and increased production of LDL are responsible for the 
hyperlipidaemia and that reduced receptor-mediated 
catabolism is the earliest detectable and, perhaps, most 
important metabolic defect. The cause of this has not been 
determined.
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These results offer new insights into lipoprotein 
metabolism in the nephrotic syndrome but need to be 
qualified by the limitations of the techniques employed. 
Firstly, these subjects are investigated in a new steady 
state, a prerequisite for these studies. The changes in 
lipoprotein turnover which initiate the
hyperlipoproteinaemia could conceivably be different from 
those which maintain it. The metabolic changes which occur 
at the onset of nephrosis in man are not known and would be 
difficult to study even in patients with frequently 
relapsing nephrotic syndrome. Secondly, the limitations of 
radiolabelled autologous tracers need to be considered. 
These were discussed earlier but it should be stressed that 
the fractional catabolic rate is the only kinetic parameter 
measured directly(from the slope of the plasma decay 
curve). Production rates are derived from the product of 
pool size and FCR on the assumption of a steady state. 
Furthermore, the rationale of these investigations is that 
the plasma lipid and lipoprotein concentrations are 
governed by changes in metabolic parameters and not vice 
versa. The evidence for this stems from the classical 
studies of Langer et al.(139) who demonstrated a reduced 
LDL FCR in familial hypercholesterolaemia which was 
subsequently shown to be due to a well-defined defect of 
the LDL receptor. Other work by Thomson et al.(177) has 
shown that acute reductions in the LDL pool size by 
plasmapheresis during a LDL turnover did not change the FCR
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measured by the urine:plasma ratio. If lipoprotein levels 
rise above the maximum capacity of a catabolic route, this 
will inevitably lead to a decline in the FCR of that 
particle. This has been considered in some detail in 
animals by infusing lipoproteins to alter steady state 
levels and repeating kinetic studies(178). In the studies 
presented above, the maximum capacity of the various 
metabolic pathways has not been determined. However, the 
reductions in fractional catabolism of VLDL^ apoB were seen 
even in subjects with only slightly expanded VLDL^ apoB 
mass and normal production rates indicating that reduced 
catabolism was the primary defect.
Further studies
Considerably more work needs to be done before the sequence 
and importance of the various metabolic disturbances in 
nephrotic syndrome can be identified. The use of stable 
isotopes detected by mass spectroscopy offers new 
opportunities for research into lipoprotein metabolism in 
the next decade. These isotopes will permit safe and 
repeated measures of synthesis of apolipoproteins and 
lipids. The relationship with synthesis of other proteins, 
particularly albumin, could be assessed relatively easily 
and subjects, including children, could be studied in 
relapse and in remission. These studies may be seen as 
complementary to the use of radiolabelled tracers.
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The effect of changes in composition of VLDL and LDL 
species on their metabolic fate might be investigated by 
crossover studies in man(initially performed in 1958 by 
Gitlin) where lipoprotein tracers prepared from both normal 
and nephrotic subjects labelled with different isotopes are 
administered to both to compare their plasma decay.
However, there are considerable practical and ethical 
difficulties in ensuring that the donors are not harbouring 
infective agents and, at present, these have not been 
considered feasible.
9.3 TREATMENT OF HYPERLIPIDAEMIA IN NEPHROTIC SYNDROME
The arguments concerning the risk:benefit ratio of lipid 
lowering therapy in nephrotic subjects were considered in 
chapter 1. In the absence of well-conducted, controlled, 
prospective studies, a number of workers have advocated an 
individualised approach to lipid-lowering therapy(228,229). 
Initially, all other modifiable cardiovascular risk factors 
should be corrected with special attention to smoking and 
blood pressure control. Where the nephrotic syndrome is 
persistent, renal function is well-preserved and 
hyperlipidaemia is present, specific measures to reduce 
plasma and LDL-cholesterol are probably worthwhile. A low 
cholesterol diet(<300mg/day) with a polyunsaturated: 
saturated fat ratio of approximately 1.0 is advisable 
although by itself is unlikely to lower plasma cholesterol
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to the "normal" range. The decision to add drug therapy is 
entirely empirical. Total cholesterol levels above 
7.8mmol/L may well justify treatment and some would 
advocate a threshold of 6.5mmol/L or even lower for drug 
therapy. In all cases, the patients overall coronary risk 
profile may influence a decision to start therapy - where 
other factors are present a lower threshold may be adopted.
The study presented in chapter 7 and other published 
work(125,128,129) indicate that inhibitors of HMG CoA 
reductase are very effective in reducing plasma and 
LDL-cholesterol although not always to "normal" levels. In 
these and longer term(117) studies of small numbers of 
nephrotic patients, there have been few significant 
side-effects. However, in the series of patients presented 
here, the rapid progression of a posterior capsular lens 
opacity in one patient shortly after starting therapy 
warrants further study. Careful follow-up with 
ophthalmological assessment is advisable until more data is 
available. Serum creatine kinase levels also need careful 
monitoring.
The mechanism whereby HMG CoA reductase inhibitors reduce 
plasma and LDL-cholesterol appears to differ among 
individual patients(chapter 7). This is in accord with 
studies of some other hyperlipidaemias, particularly 
primary moderate hypercholesterolaemia(204,205). These
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studies challenge the contention that inhibition of 
cholesterol biosynthesis reduces intra-hepatic cholesterol 
pools, increases apoB/E receptor expression and accelerates 
catabolism of LDL. This is an oversimplification of the 
action of these drugs on the complex metabolic processes 
involved in the assembly, secretion, interconversion and 
removal of circulating lipoproteins.
Experience with other lipid-lowering agents was considered 
in chapter 1. There are relatively few studies of there 
use although gemfibrozil(12 3) seems to be a safe fibric 
acid derivative and may have the advantage of raising HDL- 
cholesterol and lowering triglyceride(103). There is no 
data however on the potential atherogenicity of 
hypertriglyceridaemia in the nephrotic syndrome nor do 
these subjects appear to be at risk from pancreatitis.
The role of lipid-lowering therapy in the progression in 
renal disease has recently received considerable attention 
(230). Several authors(107,108) have hypothesised on the 
possible mechanisms of lipid nephrotoxicity. There are a 
number of studies in animal models of renal disease which 
have demonstrated the ability of lipid lowering drugs to 
ameliorate some measures of renal damage(230,115). As yet, 
there is no evidence to prove that such treatment is 
effective in man.
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Further study
The indications for lipid-lowering therapy in nephrotic 
syndrome will only be clearly defined by prospective, 
double-blind controlled studies. There are two possible 
end-points of such studies - cardiovascular morbidity/ 
mortality and progression of renal failure. At a 
conservative estimate, these studies would require 250-500 
subjects to be recruited and followed-up for 3-5years. 
Nephrotic syndrome in adults has an annual incidence of 
1/100000. If only newly-presenting patients were eligible, 
this would entail recruiting all new patients in the UK to 
finish recruitment in one year! The logistical problems 
are therefore formidable and may preclude such studies. At 
present, some nephrologists have adopted an individualised 
approach to therapy as described above while others do not 
actively attempt to correct the lipid abnormalities.
9.4 Conclusion
Investigations of hyperlipidaemia in human nephrosis may 
lead to advances in our understanding of both normal and 
abnormal lipoprotein metabolism and the complex 
pathophysiological changes that accompany proteinuria. The 
results of the studies presented here detail some of the 
changes found in the kinetics of circulating lipoproteins. 
There is considerable heterogeneity among nephrotic
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subjects and the precise basis of these kinetic alterations 
remains to be established.
Drugs are now available which can substantially reduce the 
hypercholesterolaemia of this condition. However, their 
place in routine practice will only be proven by 
appropriate, controlled trials and longer term experience.
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Metabolism of apolipoprotein B-containing lipoproteins in 
subjects with nephrotic-range proteinuria
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Metabolism of apolipoprotein B-containing lipoproteins in subjects with 
nephrotic-range proteinuria. Although hyperlipidemia is a well recog­
nized complication of the nephrotic syndrome, the precise disturbances 
of lipoprotein metabolism which cause the elevated plasma lipid and 
lipoprotein concentrations have not been clearly defined in humans. 
This study examines the metabolism of apolipoprotein B-containing 
lipoproteins in patients with nephrotic-range proteinuria and in healthy 
controls. Two radioiodinated tracers of very low density lipoproteins 
(VLDLj, Sf 60 to 400, and VLDL2, Sf 20 to 60), were used to trace the 
metabolism of apolipoprotein B through the cfelipidation cascade from 
very low density lipoproteins (VLDL) to low density lipoproteins 
(LDL). The data from the apoB specific radioactivity curves and the 
pool sizes of apoB in four subfractions were analyzed by a multicom- 
partmental modeling procedure using the SAAM 30 program. The main 
findings in the nephrotic group were: 1.) a consistent decrease in the 
fractional rate of apoB transfer from V L D L ^V L D L ^ (median val­
ues—nephrotic 0.92 pools/day vs. controls 3.66, P  < 0.02) and from 
VLDLj-frlDL (1.49 vs. 2.74, P  <  0.05); 2.) increased secretion of apoB 
into VLDL2 (14.5 mg/kg/day vs. 4.2, P  < 0.02); 3.) a trend towards 
decreased removal of IDL and LDL attributable to a defect in LDL  
receptor-mediated removal as previously shown (M etabolism  39:187- 
192, 1990). These findings suggest that catabolic defects of the apo 
B-containing lipoproteins are as important as increased hepatic synthe­
sis in the pathogenesis of nephrotic hyperlipidemia in humans.
Hyperlipidemia has long been recognized as a complication 
of human nephrotic syndrome. However, the metabolic 
changes which result in the elevations of plasma lipids and 
lipoproteins have not been satisfactorily established [1, 2], 
Evidence from experimental animal models of nephrotic syn­
drome has demonstrated increased hepatic lipoprotein secre­
tion as the major cause of the hyperlipoproteinemia with some 
contribution from delayed lipoprotein catabolism [3]. It is not 
certain, however, that these findings can be extrapolated to 
humans. In recent years a considerable body of information 
regarding normal and abnormal lipoprotein metabolism has 
been obtained from techniques which employ radiolabeled 
tracers to follow the fate of lipoprotein particles in vivo [4], 
Despite a number of early studies in nephrotic syndrome [5—8], 
these methods have not been widely employed to investigate 
this form of secondary hyperlipidemia.
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Hyperlipidemia in nephrotic syndrome may take various 
forms [1]. The most common finding is an elevation of low 
density lipoprotein (LDL) cholesterol levels. In more severe 
cases with heavy proteinuria and severe hypoalbuminemia, 
hypertriglyceridemia and elevated very low density lipoprotein 
(VLDL) cholesterol levels may become the dominant abnor­
malities [9, 10]. High density lipoprotein (HDL) cholesterol 
levels have been variously recorded as high, low or normal [11, 
12], The main abnormalities therefore involve the apolipopro­
tein B-containing lipoproteins. In the general population this 
pattern is associated with an increased risk of coronary ather­
osclerosis. Patients with nephrotic syndrome and/or renal fail­
ure are considered to have an increased incidence of ischemic 
heart disease [13], although this has been challenged by some 
[14] and the benefits of lipid-lowering therapy have not been 
clearly shown. Recent interest has also focused on the possible 
role of hyperlipidemia in the progression of many renal diseases 
[15, 16]. A clearer understanding of the pathophysiological 
disturbances of lipoprotein metabolism may allow more precise 
targeting of future therapeutic efforts to reduce the hyperlipi­
demia.
The kinetic characteristics of very low and low density 
lipoproteins can be followed by trace-labeling of the apoB 
moiety. Each particle contains one molecule of apoB which is 
integral to its structure and remains with the lipoprotein during 
its lifetime in the circulation. Radiolabeled apoB can therefore 
be used to follow the metabolic fate of lipoprotein particles. 
Recent reports have examined LD L apoB kinetic studies in 
patients with nephrotic syndrome and hypercholesterolemia 
[17,18]. In our own study of the condition we concluded, on the 
basis of experiments using dual tracer methods, that the main 
reason for an increased LD L apoB pool in nephrotic syndrome 
was a reduced clearance (that is, fractional catabolic rate) of 
LD L by the receptor-mediated pathway [19]. Synthetic rates 
were increased only in those patients with proteinuria in excess 
of 10 g/day. There is little data on the metabolism of apoB in 
VLDL. In a recent report of four nephrotic subjects Vega and 
Grundy found delayed catabolism of V LDL with normal pro­
duction rates [17]. However, these workers used a tracer of a 
wide density range which included both V LDL and IDL parti­
cles. Since there is considerable heterogeneity in the metabo­
lism of VLDL particles, more precise information may be 
obtained by using tracers with well-defined flotation character­
istics [20].
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Table 1. Clinical characteristics of nephrotic group3
Subject Sex
Age
years
Weight
kS
Body mass 
index
kg/m2 Histology
Duration of 
disease 
months Treatment
CM M 60 77 26.3 FGSb 310 Nifedipine, mctoprolol, 
£}'ranitidinc ^
AP M 55 98 30.9 Membranous 42 Fruscmide, atenolol, nifedipine
WS M 58 75 27.9 Membranous 55 Atenolol, cnalapril, warfarin
JH M 53 90 29.4 IgA 10 Digoxin, bumctanide, warfarin
JG M 48 57 24.1 Membranous 420 Nifedipine, atenolol, fruscmide
MD F 28 49 19.4 MCGNC II 159 Phenobarbitone
RG M 66 80 25.0 Membranous 31 Nifedipine
CF F 34 61 22.6 MCGN II 66 Fruscmide
3 Control group: N  =  5, M:F = 3:2, age 36 to 46 years, weight 71 to 89 kg 
3 Focal glomerulosclerosis 
3 Mesangiocapillary glomerulonephritis
Table 2. Renal function tests
Subject
Serum
creatinine
nmol/liter
Scrum
albumin
g/liter
Creatinine 
clearance ml/ 
min/1.73 m 2
Quantitative
proteinuria
g/day
CM 310 33 19 6.6
AP 190 36 35 10.8
WS 160 33 43 6.1
JH 100 38 58 3.3
JG 4203 32 18 9.6
MD 90 33 90 6.2
RG 250 27 40 8.3
CF 70 31 89 4.5
Values represent mean of repeated measures over the study period. 
3 Serum creatinine rose from 370 to 450 /unol/liter over the study 
period.
The aim of this study was to investigate the metabolism of the 
apoB moiety of very low density lipoproteins in patients with 
nephrotic syndrome. Quantitative assessments of apoB produc­
tion, catabolism and flux through the delipidation cascade from 
VLDL to LD L were derived from multicompartmental analysis 
of apoB pool sizes and plasma decay/appearance curves.
Methods
Patients
Patients were recruited from the outpatient clinic of the renal 
unit at Glasgow Royal Infirmary according to the following 
selection criteria: 1.) quantitative proteinuria > 3.0 g/day; 2.) 
serum creatinine < 400 /imol/liter; 3.) plasma cholesterol > 7 
mmol/liter. All patients had a primary glomerular disease 
proven by renal biopsy. Diabetes mellitus, thyroid disorders, 
liver disease, pregnancy, amyloid and neoplasia were exclusion 
criteria. Treatment with corticosteroids was also considered an 
exclusion criterion although patients on diuretic and/or antihy­
pertensive therapy were included. Clinical details of the pa­
tients are given in (Tables 1 and 2. A group of five normolipi- 
demic volunteers was also studied. They were recruited from a 
coronary screening program and were selected because of 
homozygosity for the E3 polymorphism of apolipoprotein E. 
This is the most common apo E phenotype, and since apo E 
polymorphisms may influence apo B metabolism [20] these 
subjects were selected as normal controls. Throughout the 
studies patients were asked to follow their normal diets. None
of the proteinuric group had been prescribed a specific diet. The 
study was approved by the Ethics Committee of Glasgow Royal 
Infirmary.
The technique for performing apoB kinetic studies has been 
described previously [21, 22]. Briefly, subjects were asked to 
attend fasting and approximately 200 to 250 ml of plasma was 
removed by plasmapheresis. Oral potassium iodate (170 mg 
twice a day) was started and continued for four weeks to 
suppress thyroidal uptake of radioiodide. V LDL (daily < 1.006 
g/ml) was recovered from the plasma by ultracentrifugation in a 
Beckman Ti60 rotor (18 hr, 39000 rpm, 10°C). Total V LDL was 
removed by aspiration of the top 2 to 4 ml from each 25 ml tube 
and diluted with the infranatant salt solution to achieve a 
lipoprotein concentration equivalent to a plasma triglyceride 
level of 1.5 mmol/liter (for example, triglyceride 3 mmol/liter — 
dilute 1:2). This minimises carryover of V LDL, to VLDLj 
during preparative ultracentrifugation. The solution density was 
then raised to 1.118 g/ml by the addition of solid sodium 
chloride (0.171 g/ml). Six 2 ml aliquots were subjected to 
cumulative flotation ultracentrifugation on a discontinuous salt 
gradient in a SW 40 rotor as adapted from Lindgren, Jensen and 
Hatch [23]. VLDL, (Sf 60 to 400) and V LDL2 (Sf 20 to 60) were 
isolated by this method and aliquots (2 ml) were then labeled 
with I31I and 125I, respectively, as previously described [24], 
Free radioiodide and salt were removed by gel filtration on a 
PD10 column (Pharmacia, Uppsala, Sweden) followed by ex­
tensive dialysis against 0.15 m  NaCl pH 7.4. Three days after 
plasmapheresis the subjects returned, having fasted for more 
than 12 hours, and approximately 50 p.C\ of each tracer was 
administered intravenously. The tracers were sterilized by 
passage through a 0.45 micron filter (Acrodisc; Gelman Sci­
ence, Northampton, UK) immediately prior to injection. Blood 
samples were collected at 10 minutes and then frequently over 
the first 10 hours, after which a low fat meal was allowed. 
Further samples were taken at 14 and 24 hours and then daily 
fasting samples were obtained for 12 days. Each plasma sample 
was subjected to ultracentrifugation as above to isolate four 
fractions: V LDLj, V LDLj, IDL (Sf 12 to 20) and LD L (Sf 0 to 
12). ApoB was precipitated [25] from each fraction by the 
addition of an equal volume of freshly-distilled 1,1,3,3-tetra- 
methylurea (TMU). The pellet was then delipidated and the 
apoB specific activity calculated from the protein content of the 
precipitate redissolved in 0.5 m  NaOH (measured by a modified
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Lowry assay [26]), and the radioactivity counted in a twin 
channel gamma counter (Canberra Packard, Pangbourne, UK).
The plasma concentration of each lipoprotein fraction was 
estimated from the sum of the concentrations of lipids and 
protein in each fraction isolated from pooled plasma. Total 
cholesterol, free cholesterol, triglyceride and total phospholip­
ids were measured by enzymatic colorimetric assays (Boehr- 
inger Mannheim, Lewes, East Sussex, UK). Protein was mea­
sured by the Lowry method [26]. The mass of each fraction was 
corrected for ultracentrifugai losses by comparing the total 
cholesterol recovered in the four fractions obtained by cumu­
lative flotation ultracentrifugation with the cholesterol content 
of the non-HDL cholesterol measured by routine beta-quanti- 
fication [27]. Recovery varied from 82 to 92% and the calculated 
lipoprotein masses were each corrected by this factor. This 
assumes that each fraction was lost in similar amounts and that 
the different components of the lipoproteins were also lost in 
equal proportion.
Apo B concentration was measured in aliquots of each 
fraction by precipitating apoB with TM U and measuring the 
protein content in the supernatant solution [25]. ApoB concen­
tration was derived from the difference between total and 
TMU-soluble protein. Intravascular pool sizes of apoB were 
obtained from the product of apoB concentration and plasma 
volume estimated from the dilution of the V LD L, tracer at ten 
minutes. Steady state conditions of lipoprotein metabolism 
were confirmed by measurements of plasma lipid and lipopro­
tein levels at regular intervals over the study period. The 
coefficient of variation for each patient’s plasma cholesterol 
level was < 10%. The figure for plasma triglyceride ranged up to 
20%. Apolipoprotein E phenotyping was performed by isoelec­
tric focusing [28, 29].
Kinetic analysis
The radioactivity in apoB in each lipoprotein fraction was 
obtained by multiplying the specific activity (cpm/mg) at each 
time point by the pool size (mg apoB) of the appropriate 
fraction. All radioactivities were then expressed as a percentage 
of the total apoB activity present in the 10 minute sample 
calculated from the sum of radioactivity in V LD Ll5 V LDL2, 
IDL and LDL. Plasma decay curves and pool sizes w ere then 
analyzed by a multicompartmental model using the SAAM/ 
CONSAM 30 program [30, 31]. The rate constants and esti­
mated compartmental masses were used to derive fractional 
transfer and catabolic rates, production rates for apoB in 
V LD Lj, V LDLj and, where necessary, LD L and flux rates 
between compartments. Production and flux rates are ex­
pressed as mg apoB/kg body weight/day. Fractional transfer 
and catabolic rates are presented as pools/day.
The model used to analyse apoB metabolism in very low 
lipoproteins has been described previously [22, 32]. In sum­
mary, it consists of two parallel pathways from large and small 
VLDL (VLDL! and V LDLj, respectively) through IDL to 
LDL. The transfer of apoB along this chain is thought to be 
dependent on stepwise delipidation mediated by lipase activity. 
Direct input of apoB occurs both at VLDLj and V LD L,. Where 
the calculated mass in LDL derived from these precursors falls 
significantly short (>10%) of the measured mass, direct synthe­
sis of LD L is invoked. Removal of apoB occurs at each level of 
the pathway. This model, however, did not allow an adequate
fit of the data from the proteinuric group in that the calculated 
pool mass for V LDLX was underestimated in a number of these 
subjects who had an expanded V L D L t pool. Several subjects 
also demonstrated a biexponential decay of V LD Lj, suggesting 
the presence of an additional slowly metabolized component 
within this fraction. A revised model was therefore developed 
for the nephrotic subjects^(Fig. IF The numbering of these 
compartments reflects the evolution of the mathematical model 
and is presented in the form used in these studies. In this 
version, VLDL! is composed of'three compartments with input 
to and direct removal from two parallel pathways one of which 
does not feed into the delipidation chain and contribute to the 
mass of other lipoprotein fractions. These extra compartments 
(29 and 26) were not required for the analysis of the control 
subjects.
S ta tis tic a l a n a lysis
Non-parametric methods were used because of the small 
numbers and the wide spread of results in the nephrotic group. 
Results are shown as medians and ranges. Differences between 
nephrotic and control groups were tested by the Mann-Whitney 
U test and correlations by Spearm an’s rank test. The plots 
comparing the specific activities of the two tracers between the 
groups are shown as mean and standard deviations. The com­
positional data for both groups were of comparable variance 
and were analyzed by a two-sample r-test.
Results
This group of patients with moderate to heavy proteinuria 
demonstrated v ariable rises in plasma cholesterol and triglyc­
eride (Tab]£_3). Serum albumin was remarkably well maintained 
even when quantitative proteinuria approached 10 g/day, and 
the inverse relationship between serum albumin and plasma 
cholesterol often seen in nephrotic syndrome did not exist. 
LD L cholesterol was moderately elevated in seven patients 
with one patient (JG) having a very high level of 10.0 mmol/liter. 
V LDL cholesterol was high in three patients who all demon­
strated a relatively high VLDL cholesterol/plasma triglyceride 
ratio. One of these patients (WS) possessed an E2 allele of the 
apoE polymorphism. The increased plasma lipid levels were 
reflected in increased concentrations ofVLDL^, IDL and LDL. 
V LD LX was not significantly increased (Fig. 2). There were no 
significant differences in the relative composition of all four 
lipoprotein fractions between controls and proteinuric subjects 
(data not shown).
Kinetic studies
/F igure 3 compares the metabolism of apoB from each tracer 
in the four subfractions by plotting the mean radioactivity at 
each time point for both proteinuric and control groups. The 
results of the kinetic analysis are presented in Tables 4A to D.
VLDLj
The !;nI V LDLX apoB tracer was cleared more slowly in the 
nephrotic group than in controls primarily due to a consistent 
reduction in the fractional transfer of V LD LX apoB to VLDLj 
^median 0.92; range 0.22 to 3.31 vs. 3.66; 2.48 to 5.16, P < 0.02; 
T able 4A). Both nephrotic and control groups showed wide 
variation in the fraction of the VLDLj apoB pool which was 
catabolized directly from the plasma compartment. In the
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,25I-VLDL2
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\
,31I-VLDL1
VLDL1 
S f 60-400
U26
26
T
U12
VLDL2 
Sf 20-60
IDL 
Sf 12-20
LDL 
S f 0-12
Fig. 1. M odel o f  lipoprotein metabolism used fo r  multicompartmental 
analysis. This model has been built up over several years from apoB 
kinetic studies in various dyslipidemic conditions. ApoB production 
occurs in both VLDL, and in VLDLj, which is shown as U29/U26 and 
U12, respectively. Parallel pathways are shown for apoB derived from 
the two VLDL species. ApoB is transferred along a delipidation chain 
or removed from the system according to the arrows. The metabolic 
pathways are considered to be unidirectional and to follow first order 
kinetics.
proteinuric group, the VLDL! apoB pool size varied from 
normal to eight times normal and this was related to plasma 
triglyceride level (Table 3). The calculated rate of apoB flux 
from the large triglyceride rich V LDL, to smaller V LD Lj was 
reduced significantly (1.9 mg/kg/day; 1.1 to 2.9 vs. 2.7; 1.8 to 
5.1, P < 0.05) even in those patients with normal pool sizes 
(CF, MD, RG, JG). There was wide variation in the secretion of 
apoB into VLDLj (2.6 to 64.8 mg/kg/day) in the proteinuric 
group. Although four patients had very high production there 
were no statistically significant differences between the groups.
VLDL2
The V LDLj apoB tracer was also cleared from the plasma of 
the nephrotic group at a slower rate than normal. This was seen 
with both tracers, that is, directly labeled V LD Lj and the 
material transferred from V LDL, (Fig. 3B and 3E). Again this 
was attributable to a reduced delipidation rate to IDL (or LDL 
by pathways 12—>21 and 4—>-20; Table 4B). Direct removal of 
V LDLj apoB from plasma was highly variable and not signifi­
cantly different between the two groups. The V LD Lj apoB pool 
was expanded in the proteinuric group (2 to 3 x normal) mainly 
due to a marked increase in de novo synthesis of apoB in 
V LD Lj (14.5 mg/kg/day; 5.1 to 32.2 vs. 4.2; 2.9 to 8.8, P < 
0.02). Reduced catabolism made a relatively smaller contribu­
tion to the expansion of the pool size. The larger V LDLj pool 
led to a modest increase in the amount of IDL apoB formation, 
although this was not statistically significant (10.4 mg/kg/day; 
4.4 to 17.2 vs. 5.8; 2.7 to 8.7; P  = 0.12). This occurred despite 
the reduced fractional transfer rate from IDL to LDL.
IDL
The mean plasma radioactivity curves for l25I and I31I 
reached comparable peak values in IDL at similar times for 
both groups (Fig. 3 C and F). Thereafter, the curves diverged 
with the normals, showing an initial more rapid decay that was 
due to direct catabolism of the lipoprotein (Table 4C). There 
was no obvious difference in the rate at which both groups of 
subjects accumulated 125I and 131I in LDL apoB, indicating a 
similar degree of IDL to LDL conversion (Table 4C). The 
expansion of the IDL apoB pool in nephrotics was due to a 
combination of increased synthesis from V LD Lj and dimin­
ished direct removal. This had the net effect of channeling an 
increased amount of apoB from IDL to LDL (Table 4D).
LDL
The appearance curves for 125I and 131I apoB radioactivity in 
LDL were similar for control and nephrotic groups (Fig. 3 D 
and G). Peak values were achieved at a later time in the latter 
group but the extent of transfer from V LDLj and V LD Lj was 
approximately the same. The most pronounced difference in the 
curves was delayed clearance of both tracers from the LDL of 
nephrotic subjects. Normal subjects had a biphasic LDL decay 
curve consisting of a relatively rapid catabolism up to 120 
hours, and then a slower terminal phase. Visual inspection of 
the averaged data from the patients with nephrotic syndrome 
indicated a lack of the early rapid phase of LD L degradation. 
The observed fractional catabolic rate for LDL should be 
corrected for urinary loss of whole lipoprotein. This is not 
possible to determine from urine collections during a VLDL 
turnover because a high proportion of injected radioactivity is
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Table 3. Plasma lipid and lipoprotein concentrations
Subject
E/E
phenotype Cholesterol Triglyceride
VLDL-cholesterol
mmol/liter LDL-cholcsteroI HDL-cholesterol
VLDL-cholesterol: 
plasma triglyceride 
ratio
apoB pool* 
size 
m g
Nephrotic
CM 4/3 9.4 4.5 3.0 5.4 1.1 0.67 4306
AP 4/3 8.6 3.5 1.6 6.0 1.0 0.46 5718
WS 3/2 8.6 3.4 3.0 4.8 0.8 0.88 5061
JG 3/3 12.8 3.1 2.1 10.0 0.8 0.68 4848
JH 3/3 8.3 2.8 1.1 6.0 0.9 0.38 3181
MD 3/3 7.3 1.9 0.9 4.9 1.5 0.47 2038
RG 3/3 7.3 1.6 0.6 5.4 1.3 0.38 4796
CF 4/3 7.6 1.2 0.6 5.4 1.7 0.46 2640
Controls
NC 3/3 5.0 1.7 0.8 3.1 1.0 0.46 1970
CD 3/3 6.2 2.6 1.0 4.1 1.4 0.40 2860
MF 3/3 5.8 1.1 0.6 4.0 1.2 0.56 3000
EK 3/3 5.0 1.0 0.4 2.8 1.9 0.37 1450
MM 3/3 5.6 2.2 1.0 3.7 1.2 0.45 2270
Sum of apo B pools in the four lipoprotein fractions
800 i
600 -
400 -
200 -
I •
VLDL1 VLDL2 IDL LDL
Fig. 2. Plasma concentrations o f  lipoprotein 
subfractions prepared by cumulative flotation 
ultracentrifugation calculated from the sum o f  
the compositional analysis. Open circles (C) 
represent nephrotic subjects and closed circles 
controls ( • ) .  P  values represent comparisons 
between control and nephrotic groups:
VLDL, P  = NS; VLDL, P  < 0.03; IDL P  < 
0.01; LDL P  < 0.02.
present in components other than apoB (that is, apolipoproteins 
C and E and lipids). In a previous study of trace-labeled LD L in 
nephrotic syndrome [19], we estimated the average urinary 
excretion of undegraded lipoprotein as 7% of total urine radio­
activity; the values in Table 4D overestimate the true FCR by 
this proportion. The LDL FCR was subnormal in m ost of the 
disease group, but three (CM, WS and CF) showed normal or 
even high values, and overall there was no significant difference 
from controls even when corrected for estimated urinary losses. 
Likewise, there was a variable expansion of the LD L apoB 
pool. Its size ranged from normai to twice normal. The produc­
tion of LD L from VLDL 2  and IDL was significantly increased 
in the nephrotic group compared to normal.
Discussion
Hyperlipidemia is common in nephrotic syndrome. Despite 
this its origins remain unexplained. Most investigators have
considered that the major pathogenic mechanism is increased 
hepatic synthesis and secretion of lipoproteins [33]. The stim­
ulus for this may be decreased serum albumin, either directly or 
indirectly via changes in plasma oncotic pressure [34] or vis­
cosity. It has been suggested that there is a non-specific 
increase in hepatic protein synthesis in response to these 
factors. However, recently Kaysen et al [35] have examined the 
relationship between hyperlipidemia and albumin synthetic 
rates. By replacing a high protein with a low protein diet in 
patients with nephrotic syndrome, mean albumin synthetic 
rates were reduced from 17.60 to 12.61 g/1.73 m2/day, which is 
in the low/normal range. Although lipoprotein synthetic rates 
were not measured directly, hyperlipidemia persisted in the 
face of normal albumin synthetic rates.
Reduced lipoprotein catabolism has also been described in 
nephrotic syndrome. Several lines of evidence suggest that 
catabolic defects are present along the V LD L—»IDL—»LDL
,AME: KID. INTER.-JULY 91 PAGE: 6 SESS: 8 OUTPUT: Tue Apr 9 14:00:37 1991
i/302/team6/kid/kid—jul91/3336—323
/
Warwick e t al:. ApoB metabolism in nephrotic syndrome
100 i
10 -
1 -
MiSj-*i
A 131l VLDL1 apoB
5 10
Tim e, hours
15
VLDL2 apoB100 i. 100VLDL2apoB
>
10 -10 - >
oCDOT3!U0C
0 20 40 60 80 100 120 140140
Tim e, hours T im e, hou rs
100
L** • i i
C 131l LDL apoB  
10 12
.1
H
50 100
Tim e, hours
150
100 IDL apoB
>-
>
o<nOT3CD0C
1501000 50
T im e, hou rs
LDL apoB100 n LDL apoB 100-1
>
1 0 ->
o(Oo
200 300100300 0200100
T im e, hours Time, h ou rs
Fig. 3A-G. Plots o f  mean radioactivity fo r 1251 and 
I3iI apoB tracers in each subfraction. Open circles 
(O) represent nephrotic-subjects and closed circles 
controls ( • ) .  Error bars are one standard deviation.
delipidation cascade. Early work by Gitlin et al [5] demon­
strated a delay in the catabolism of radioiodinated Sf 100 to 400 
lipoproteins. More recently Vega and Grundy [17] have shown 
reduced clearance of a combined VLDL and IDL tracer (daily 
< 1.019 g/ml) in four nephrotic subjects compared to controls. 
The delipidation of V LDL is catalyzed by endothelium-bound 
lipases in hepatic and extra-hepatic tissues (skeletal muscle and 
adipose tissue). Decreased activities of these enzymes have 
been reported in this disorder [36-39], although this finding has 
not always been confirmed [40-42]. Our own study of LDL 
metabolism in nephrotic syndrome [19] emphasized the de­
creased catabolic rate of the lipoprotein as the major contribu­
tor to the elevated plasma levels in the majority of subjects 
investigated. These observations imply that the metabolic dis­
turbances in the lipoprotein transport system in this condition 
are complex. This led us to undertake the present detailed 
investigation of apoB kinetics in the nephrotic syndrome.
The eight subjects studied had persistent heavy proteinuria
and had been followed up for a period varying from 10 months 
to 35 years (Table 1). They had moderate hyperlipidemia except 
for JG who had a markedly elevated LDL cholesterol level. 
Plasma triglyceride levels varied from low normal (1.2 mmol/ 
liter) to high (4.5 mmol/liter), emphasizing the heterogeneous 
nature of the study group. Previous larger, cross sectional 
studies of the incidence of hyperlipidemia in nephrotic syn­
drome [9, 10] have generally reported relationships between 
hyperlipidemia and severity of nephrotic syndrome (hypoalbu- 
minemia or proteinuria). These associations were not found in 
this study, but this probably reflects the small numbers which 
can be practically studied in lipoprotein kinetic investigations. 
When apoB-containing lipoproteins w ere fractionated by cumu­
lative flotation ultracentrifugation significant increases were 
seen in plasma levels of VLDL 2 , IDL and LD L (Fig. 3). The 
composition of all four lipoprotein fractions was normal, indi­
cating that there was no substantial accumulation of cholesterol 
ester-rich VLDL remnants in the VLDLj and IDL density
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Table 4A. Kinetic parameters of apo B metabolism in VLDLi Table 4C. Kinetic parameters of apo B metabolism in IDL
Fractional catabolism Fractional
Production Pool size poolslday catabolism
Subject mg!kg/day mg Direct to VLDL, Production poolslday
from VLDLj Pool size To
Nephrotic
CM 25.3 413 4.54 0.22
Subject mgikg/day m g Direct IDL
AP 11.9 297 3.11 0.85 Nephrotic
WS 7.8 210 1.74 1.02 CM 11.9 730 0.02 1.2
JG 64.8 117 30.6 1.05 AP 8.1 1131 0.01 0.69
JH 2.8 195 0.58 0.74 WS 17.2 1122 0.58 0.56
MD 34.5 83 19.5 0.70 JG 12.0 595 0.09 1.15
RG 23.0 87 20.1 1.01 JH 4.4 554 0.0 0.71
CF 2.6 46 0.04 3.33 MD 5.5 322 0.08 0.75
Median 17.5 156 3.83 0.93 RG 8.5 754 0.02 0.88
Controls CF 11.7 527 0.21 1.13
NC 8.8 67 4.17 5.16 Median 10.4 663 0.05 0.82
CD 6.1 52 5.75 4.49 Controls
MF 14.5 97 10.8 2.48 NC 8.7 241 0.76 1.80
EK 11.5 47 14.7 2.71 CD 5.8 408 0.18 1.02
MM 14.7 106 6.91 3.66 MF 5.8 358 0.26 1.17
Median 11.5 67 6.91 3.66 EK 2.7 174 0.37 0.68
P NS NS NS <0.02 MM 5.1 351 0.33 0.76
Median 5.8 351 0.33 1.02P  value by Mann-Whitney companng groups. Significance taken as P P NS <0.05 <0.05 NS
< 0.05.
P  value by Mann-Whitney comparing groups. Significance taken as P
< 0.05.
Table 4B. Kinetic parameters of apo B metabolism in VLDLi
Production mg/kg/day
Fractional 
• catabolism 
pools/day
Table 4D. Kinetic parameters of apo B metabolism in LDL
Production mg/kg/day Pnn| Frat, finnal Tntal ano R
Subject Direct From VLDLt
Pool size 
m g Direct
To
IDL Subject
From VLDL2 
Direct and IDL
size
mg
catabolism
poolslday
production
mg/kg/day
Nephrotic
CM 14.6 1.2 642 0.44 1.43
Nephrotic
CM 4.8 11.9 2623 0.49 44.8
AP 15.7 2.6 714 1.40 1.11 AP 0.0 8.0 3617 0.22 27.6
WS 14.5 2.9 570 0.03 2.26 WS 4.7 8.4 3187 0.32 27.2
JG 11.2 2.2 488 0.0 1.54 JG 0.0 12.4 3426 0.21 76.1
JH 5.1 1.6 336 0.61 1.18 JH 0.0 4.6 2247 0.18 8.0
MD 32.2 1.2 162 8.44 1.66 MD 0.0 4.9 1315 0.18 66.7
RG 17.3 1.1 505 1.55 1.36 RG 0.0 8.4 3129 0.22 40.3
CF 9.8 2.5 233 0.12 3.12 CF 0.0 10.0 -1842 0.33 12.3
Median 14.6 1.9 • 497 0.53 1.49 Median 0.0 8.4 2876 0.22 33.9
Controls
NC 4.2 4.9 160 0.18 3.88
Controls
NC 0.0 6.1 1433 0.30 11.4
CD 8.8 2.7 231 2.14 2.14 CD 2.7 4.9 2505 0.26 13.7
MF 5.6 2.7 199 0.92 2.81 MF 0.1 5.2 2044 0.23 13.4
EK 2.9 1.8 69 2.14 2.74 EK 2.6 1.7 1160 0.26 14.3
MM 3.7 5.1 218 1.15 1.93 MM 2.0 4.0 1620 0.28 14.9
Median 4.2 2.7 199 1.15 2.74 Median 2.0 4.7 1620 0.26 13.7
P <0.02 <0.05 <0.02 NS <0.05 P NS NS NS NS NS
P  value by Mann-Whitney comparing groups. Significance taken as P  
< 0.05.
ranges despite high plasma triglyceride/VLDL cholesterol ra­
tios in some patients.
Three significant perturbations of apolipoprotein B metabo­
lism w ere noted in the nephrotic subjects. First, the rates of 
transfer of V LDL1 apoB to V LD L, and of V L D L , apoB to IDL 
were reduced. This was true even in normotriglyceridemic 
nephrotic subjects (MD, RG, CF in Table 4A) who had normal 
V LD LX apoB pool sizes. Thus the delayed clearance could not 
be due simply to saturation of the delipidation mechanism. 
These metabolic steps are believed to involve the action of 
lipoprotein lipase and, to some extent, hepatic triglyceride
lipase [22]. As noted above, a number of studies in both human 
and experimental nephrotic syndrome have examined post- 
heparin plasma lipase activities with contradictory results. 
Chan and co-workers [39], using a substrate-specific method, 
documented a decrease in lipoprotein lipase with normal he­
patic triglyceride lipase activity, while Oetliker et al [42] could 
not find any significant difference compared to controls for 
either enzyme using a more standard immunoinhibition method. 
In vitro, nephrotic serum appears to be able to inhibit lipase 
activity [39]; a similar finding has been reported in uremia. 
However, the degree of inhibition did not correlate with reduc-
uv\ .
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tions in lipase activity in the patients. Several hypotheses have 
been advanced to explain the possible reduced lipase activity. 
Apolipoprotein CII, an important activator of lipoprotein li­
pase, has been isolated from nephrotic urine. However, esti­
mates of total plasma levels have not confirmed a reduced 
concentration although recently Kashyap et al [43] have re­
ported that the absolute amount associated with V LD L is 
reduced. Alterations of the apolipoprotein composition of 
V LDL may alter its catabolic potential, and account for a 
recent report that VLDL from nephrotic rats has a reduced 
clearance rate in normal animals and is more resistant to 
lipolysis in vitro [44]. Two other explanations have been 
proposed. Staprans and co-workers [45] isolated a separate 
lipase co-factor from the urine of nephrotic patients which they 
identified as a glycosaminoglycan, and Bernard [1] has re­
viewed the possibility that in hypoalbuminemic states de­
creased removal of free fatty acids which are normally protein- 
bound may impair lipolysis.
Second, the synthesis of apoB in the density interval of 
V LD Lj was increased several-fold on average. This effect was 
more consistent than the highly variable values seen for VLDLi 
apoB synthesis in the nephrotic subjects. The increased direct 
synthesis (Table 4B) more than compensated for the reduced 
flux from VLDLi. This in turn led to overproduction of IDL and 
LDL (Table 4 C and D). Thus, hepatic oversynthesis of apoB 
was a feature of this group and contributed to the expansion of 
the VLDL 2 , IDL and LDL pools. As discussed above, hepatic 
oversynthesis of apoB-containing lipoproteins is a feature of 
animal models of nephrotic syndrome [33, 45-49] and has also 
been reported in humans [50]. In the latter study [50], markedly 
increased rates of apolipoprotein B production were found in a 
group of severely hyperlipidemic nephrotic patients, although 
the full details of these subjects have not been reported. The 
stimulus to overproduction is unclear. However, in the current 
study, the finding that triglyceride-poor VLDL^ rather than 
VLDLi overproduced suggests that increased hepatic apo­
lipoprotein rather than triglyceride synthesis was responsible 
for the elevation in plasma VLDL. This contrasts with the 
kinetic changes that underly the hypertriglyceridemia of non­
insulin-dependent diabetes mellitus [51]. In this condition 
larger, lipid-rich VLDLi particles are secreted in excessive 
amounts but insulin therapy results in a decrease in VLDLj 
production and an increase in V LDL,. This is thought to reflect 
limitation of carbohydrate and free fatty acid flux to the liver, 
which in the insulin-deficient state stimulates hepatic triglycer­
ide synthesis and production of V LD Lt .
The third abnormality observed in nephrotic subjects was a 
reduced clearance rate (FCR) for both ID L and LDL (Table 4 C 
and D). The reduction was consistent and significantly different 
from normal for IDL, whereas the LD L FCR varied from 
subnormal values in five patients (AP, JG , JH , MD and RG) 
through normal (WS and CF) to an elevated level in CM. 
Overall there was a trend towards lower LD L catabolic rates in 
the nephrotic group in keeping with previous studies [17, 19], 
although there was no statistically significant reduction. We 
believe that patient selection may have contributed to the lack 
of a significant reduction in the LD L FCR compared to the 
control group,, since the present group did not exhibit as severe 
hypercholesterolemia as our previous study (mean LD L cho­
lesterol 6.0 mmol/liter vs. 7.5 mmol/liter). In addition, there are
methodological differences between the two studies. LD L 
studied using the cumulative flotation ultracentrifugation tech­
nique often displays a lower FCR compared to LDL prepared 
by rate zonal ultracentrifugation or fixed angle centrifugation. 
Indeed, the values obtained for the control group are lower than 
published data utilizing radiolabeled apoLDL as a tracer.
Synthesis of LD L apoB was found to be higher than normal, 
but unlike Vega and Grundy [17], we did not require a signifi­
cantly increased level of direct LDL apoB synthesis. In most 
subjects all of the apoB in LD L of nephrotics could be ac­
counted for by delipidation of V LDL and IDL.
The results of this study expand our current knowledge of the 
abnormalities in lipoprotein metabolism in the nephrotic syn­
drome. Increased hepatic synthesis of apoB-containing lipopro­
teins at the level of V LD Lj was a feature of the syndrome, and 
this together with a diminished capacity to catabolize IDL and 
LD L led to the hypercholesterolemia observed in these sub­
jects. Elevation of plasma triglyceride was associated with high 
concentrations of the large triglyceride-rich VLDLj which 
derived again from a combination of overproduction and a 
reduced delipidation rate. It should be noted that this group of 
patients studied was atypical in some respects with well- 
maintained serum albumin despite heavy proteinuria. The ex­
planation for this is not clear; it is unusual but not unknown for 
patients with moderately heavy proteinuria to maintain serum 
albumin > 35 g/liter. Hypoalbuminemia has been most closely 
correlated with hyperlipidemia in this condition. The absence of 
severe hypoalbuminemia in our patients is reflected in the 
relatively modest elevations of plasma and LD L cholesterol and 
of LDL apoB pools. On the basis of our previous study we 
predict that an increase in LDL to a level more commonly 
found in nephrotic syndrome would be accompanied by further 
reduction in the fractional catabolic rate of the lipoprotein.
Renal failure is associated with a different spectrum of lipid 
and lipoprotein abnormalities than is found in the nephrotic 
syndrome. Elevations of plasma triglycerides, reduced HDL- 
cholesterol and normal or marginally elevated LDL-cholesterol 
concentrations are the typical findings, and some of these 
changes have been reported with mild renal impairment [52]. 
We attem pted to minimize the effect of renal failure by restrict­
ing this study to patients with only modestly elevated serum 
creatinine concentrations. One patient studied did have serum 
creatinine > 400 /xmol/liter, but had a lipoprotein profile typical 
of the nephrotic syndrome with markedly raised LDL. Al­
though this patient had a high rate of apoB synthesis in V LDL^ 
other kinetic parameters did not show any systematic differ­
ences from those with well-maintained renal function.
Further studies comparing well defined groups of nephrotic 
subjects on the basis of proteinuria, serum albumin, renal 
function and lipoprotein patterns together with comparisons of 
patients in relapse and remission of minimal change disease 
would be useful. The advent of methods involving stable 
isotopes [53] will permit more extensive and repeated applica­
tions of these techniques.
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Appendix 1. Rate constants K(i) pools/day
(0,1) (1,29) (2,1) (0,26) (4,2) (6,2) (0,6) (0,4) (13,4) (20,4) (17,4) (0,12) (15,12) (21,12) (0,15) (21,15) (0,13) (20,13) (0,17) (0,21) (0,20)
Subject
CM 0 24.0 4.73 4.8 1.21 0.06 0.28 14.74 24.0 0 0 0.45 1.57 0 0 1.31 0.24 0.61 0.17 0.50 0.33
AP 3.6 29.14 0.98 1.22 1.63 0.43 0.71 1.15 1.07 0 0 1.97 1.63 0 0.01 0.72 0 0.54 9.93 0.21 0.32
WS 2.66 34.46 2.50 1.23 0.94 0.08 0.60 0 1.04 0 0 0 7.72 0 0.62 0.61 0.44 0.39 0.20 0.31 0.35
JG 0 24.0 5.59 39.74 0.58 0 0 0 24.0 8.72 24.0 0 2.33 0 0 1.40 0.01 0.41 2.66 0.21 0.21
JH 2.82 1.65 3.59 13.34 2.59 0.49 0.53 0.78 1.39 0.09 0 0.72 1.66 0.07 0 0.75 0 0.57 0.39 0.17 0.29
MD 2.37 36.0 4.13 24.0 2.31 0.41 0.95 8.06 4.78 0 0 10.44 1.97 0 0.09 0.80 0.06 0.40 0 0.18 0.29
RG 0 29.0 8.03 24.0 2.07 0.22 0.39 7.75 3.62 1.36 0 1.65 1.49 0 0 0.94 0.30 0.10 0 0.22 0.16
CF 0.31 4.06 21.76 36.0 2.53 0.05 0.60 1.67 7.85 0.98 0 0 3.89 0 0.23 1.98 0.19 0.25 0.70 0.37 0.19
Median 1.34 26.5 4.43 18.7 1.85 0.15 0.57 1.41 4.20 0.05 0 0.59 1.82 0 0.01 0.87 0.13 0.40 0.40 0.21 0.29
Controls
NC 4.17 5.16 0 6.22 0.03 0.56 0 5.76 0 0.90 0.56 5.45 0 0 4.09 1.65 2.04 0.52 0.42 0.21
CD 5.75 4.49 0 7.16 0.02 0.41 1.92 2.22 0 0.60 2.72 2.42 0 0 1.39 0.80 1.10 0.32 0.30 0.15
MF 10.79 2.48 0 6.96 0.13 0.76 0 3.14 0.68 0 1.87 3.23 0 0 1.58 0.61 0.70 0.37 0.28 0.16
EK 14.73 2.71 0 7.03 0.10 0.90 0.33 10.35 0 0 3.65 1.56 0 0 0.80 1.21 1.39 0.24 0.28 0.25
MM 6.91 3.66 0 8.92 0.09 0.63 1.63 2.19 0.08 1.26 1.24 2.37 0 0 1.44 0.49 0.44 0.38 0.32 0.23
Median 6.91 3.66 0 7^3 0 ■ *,3 0.33 3.14 0 0.60 1.87 2.42 0 0 1.44 0.80 1.10 0.37 0.30 0.21
Notes to appendices:
1). Controls were analyzed with a model containing a rate constant (17,6). This accounted for a very small percentage of apoB flux to IDL and 
for comparisons with nephrotic subjects this material has been moved to (0,6).
2). Minor discrepancies in flux rates in and out of compartments are due to the effect of rounding up or down the compartment masses and rate 
constants.
3). U29 and U1 are equivalent inputs into the system. The control subjects did not require an extra delipidation step and apoB production was 
considered to occur directly into compartment 1.
Appendix 2. Calculated masses and inputs
M(l) M(26) M(29) M(2) M(4) M(6) M(12) M(13) M(15) M(17) M(20) M(21) U(26) U(29/l) U(12)
Subject
CM 19 391 3 70 2 16 555 62 668 0 115 1743 1877 72 1121
AP 256 1 40 122 90 74 428 176 955 0 305 3312 1 1166 1541
WS 86 111 13 210 190 29 141 239 883 0 263 1756 134 446 1090
JG 22 90 5 212 2 0 274 121 455 19 325 3101 3577 120 638
JH 40 0 155 46 53 43 194 128 426 0 265 1982 0 256 462
MD 14 66 3 22 4 9 127 41 281 0 57 1258 1584 108 1576
RG 11 73 3 37 6 21 441 54 700 0 85 3044 1752 87 1385
CF 7 0 39 60 15 5 153 258 269 0 405 1437 0 158 595
Median 21 70 9 65 11 19 234 125 562 0 264 2716 859 139 1106
Controls
NC 67 0 0 56 52 3 50 81 66 94 793 640 0 625 301
CD 51 0 0 32 48 3 148 56 256 95 417 1206 0 522 761
MF 97 0 0 34 62 6 98 148 199 11 920 1124 0 1288 500
EK 47 0 0 18 11 6 39 42 76 56 231 219 0 1120 203
MM 106 0 0 43 99 2 70 231 114 5 485 606 0 819 280
Median 67 0 0 34 52 3 70 81 76 56 485 640 0 819 301
1990 and at the European Dialysis and Transplantation Association in 
Vienna, Austria on 5-8 September, 1990.
Reprint requests to Dr. Graham L. Womack, Renal Unit, Royal 
Infirmary, Glasgow G4 OSF, Scotland, United Kingdom.
References
1. B e r n a r d  DB: Metabolic abnormalities in nephrotic syndrome: 
Pathophysiology and complications, in Contemporary Issues in 
Nephrology, (vol 9, Nephrotic Syndrome) edited by B r e n n e r  BM, 
S t e i n  JH, New York, Churchill Livingstone, 1982, pp 85-120
2. K e a n e  WF, K a s i s k e  BL: Hyperlipidemia in the nephrotic syn­
drome. N  Engl J  Med 323:603-604, 1990
3. M a r s h  JB: Lipoprotein metabolism in experimental nephrosis. J  
Lipid Res 25:1619-1923, 1984
4. F i s h e r  WR: Apolipoprotein B  kinetics in man: Concepts and 
questions, in Lipoprotein Kinetics and Modeling, edited by B e r -
m am  M, G r u n d y  SM, H o w a r d  BV, London, Academic Press, 
1982, pp 43-68
5. G i t l i n  D, C o r n w e l l  DG, N a k a s a t o  D, O n c l e y  JL, H u g h e s  
WL J r ,  J a n e w a y  CA: Studies on the metabolism of plasma 
proteins in the nephrotic syndrome. II. The lipoproteins. J  Clin 
Invest 37:172-184-, 1958
6. M c K e n z i e  IFC, N e s t l e  PJ: Studies on the turnover of triglyceride 
and csterified cholesterol in Subjects with nephrotic syndrome. J  
Clin Invest 47:1685—1695, 1968
7. K e k k i  M, N i k k i l a  EA: Plasma triglyceride metabolism in the 
adult nephrotic syndrome. E urJ  Clin Invest 1:345-351, 1971
8 . S c o t t  PJ, W h i t e  BM, W i t n e r b o u r n  CC, H u r l e y  PJ: Low 
density lipoprotein metabolism in nephrotic syndrome: A compar­
ison with patterns observed in other syndromes characterised by 
hyperlipoproteinemia. A ust Ann M ed 1:1-15, 1970
9. B a x t e r  JH, G o o d m a n  H, H a v e l  RJ: Scrum lipids and lipoprotein 
alterations in nephrosis. J  Clin Invest 39:455^165, 1960
10. N e w m a r k  SR, A n d e r s o n  CF, D o n a d i o  JV, E l l e f s o n  RD:
nn
KID. IN T E R .-JU J L Y  91 
:eam6/kid/kid -  j u!91/3336 -  323
P A G E : 10 S E S S: 8 O U T P U T : T ue A pr 9 14:00:37 1991
10 Warwick e t al: ApoB metabolism in nephrotic syndrome
Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 50:359— 
364, 1975
11. S o k o l o v s k a y a  IV, N i k i f o r o v a  NV: High-density lipoprotein 
cholesterol in patients with untreated and treated nephrotic syn­
drome. Nephron 37:49-53, 1984
12. J o v e n  J, R u b i e s - P r a t  J, E s p i n e l  E, R a s  MR, P i e r a  L: High- 
density lipoproteins in untreated idiopathic nephrotic syndrome 
without renal failure. Nephrol Dial Transplant 2:149-153, 1987
13. M a l l i c k  NP, S h o r t  CD: The nephrotic syndrome and ischemic 
heart disease. Nephron 27:54-57, 1981
14. W a s s  VJ, J a r r e t  RJ, C h i l v e r s  C, C a m e r o n  JS: Does the 
nephrotic syndrome increase the risk of cadiovascular disease? 
Lancet 2:664-667, 1979
15. M o o r h e a d  JF, C h a n  MK, E l - N a h a s  M, V a r g h e s e  Z: Lipid 
nephrotoxicity in chronic progressive glomerular and tubulo-inter- 
stitial disease. Lancet 2:1309-1311, 1982
16. D ia m o n d  JR, K a r n o v s k y  MJ: Focal and segmental glomerulo­
sclerosis: Analogies to atherosclerosis. Kidney Int 33:917-924, 1988
17. V e g a  GL, G r u n d y  S M : Lovastatin therapy in nephrotic hyperlip­
idemia: Effects on lipoprotein metabolism. Kidney Int 33:1160- 
1168, 1988
18. J o v e n  J, V i l l a b o n a  C, V i l l e l a  E, M a s a n a  L, A l b e r t i  R, 
V a l l e s  M : Abnormalities of lipoprotein metabolism in patients 
with the nephrotic syndrome. N  Engl J  M ed 323:579-584, 1990
19. W a r w i c k  GL, C a s l a k e  M J, B o u l t o n - J o n e s  J M , D a g e n  M , 
P a c k a r d  C J, S h e p h a r d  J: Low-density lipoprotein metabolism in 
the nephrotic syndrome. Metabolism  39:187—192, 1990
20. D e m a n t  T, S h e p h e r d  J, P a c k a r d  CJ: Very low density lipopro­
tein apolipoprotein B metabolism in humans. Klin Wochenschr 
66:703-712, 1988
21. J a m e s  RW, M a r t i n  B, P o m e t t a  D , F r u c i i a r t  JC, D u r i e z  P , 
P u c h o i s  P, F a r r i a u x  JP, T a c q u e t  A ,  D e m a n t  T , C l e g g  RJ, 
M u n r o  A ,  O l i v e r  MF, P a c k a r d  CJ, S h e p h e r d  J: Apolipoprotein 
B metabolism in homozygous familial hypercholesterolemia. J  
Lipid Res 30:159-169, 1989
22. D e m a n t  T, C a r l s o n  LA, H o l m q u i s t  L, K a r p e  F, N i l s s o n -  
E h l e  P , P a c k a r d  C J , S h e p h e r d  J: Lipoprotein metabolism in 
hepatic lipase deficiency: Studies on the turnover of apolipoprotein 
B and on the effect of hepatic lipase on high density lipoprotein. J  
Lipid Res 29:1603-1611, 1988
23. L i n d g r e n  FT, J e n s e n  C L , H a t c h  FT: The isolation and quanti­
tative analysis of serum lipoproteins, in Blood Lipids and Lipopro­
teins: Quantitation, Composition and M etabolism, edited by N e l ­
s o n  GJ, New York, Wiley Interscience, 1972, pp 241-245
24. B i l h e i m e r  DW, E i s e n b e r g  S, L e v y  RI: The metabolism of very 
low density lipoprotein protein. I. Preliminary in vitro and in vivo 
observations. Biochim Biophys Acta  260:212-221, 1972
25. K a n e  JP, S a t a  T, H a m i l t o n  RL, H a v e l  RJ: Apoprotein compo­
sition of very low density lipoproteins of human serum. J  Clin 
Invest 56:1622-1634, 1975
26. L o w r y  OH, R o s e b r o u g h  NJ, F a r r  AL, R a n d a l l  RJ: Protein 
measurement with the Folin phenol reagent. J  Biol Chem 193:265- 
275, 1951
27. Lipid Research Clinic Program: Manual o f  Laboratory Operations. 
US DHEW publication no. NIH 75-628, Washington DC, US 
Government printing office, 1975
28. M e n z e l  HJ, U t e r m a n n  G: Apolipoprotein E phenotyping from 
serum by Western blotting. Electrophoresis 7:492-495, 1986
29. H a v e k e s  LM, d e  K n u f f  P , B e i s i e g e l  U, H a v i n g a  J, S m it  M, 
K j l a s e n  E: A rapid micromcthod for apolipoprotein E phenotyping 
directly in serum . J  Lipid R es  28:455-463, 1987
30. B e r m a m  M, W e is s  MF: SAAM  Manual. Washington DC, US 
DHEW publication no. NIH 1978, pp 78-180
31. B e r m a n  M, B e l t z  WF, G r i e f  PC, C h a b a y  R, B o s t o n  RC: 
Consam User’s  Guide. US Department of Health and Human 
Services, 1983
32. S h e p h e r d  J, P a c k a r d  CJ, S t e w a r t  JM, A t m e h  RF, C l a r k  RS, 
B o a g  DE, C a r r  K, L o r i m e r  AR, B a l l a n t y n e  D, M o r g a n  HG, 
L a w r i e  TDV: Apolipoprotein A  and B  ( S f  100-400) metabolism 
during bezafibrate therapy in hypertriglyceridemic subjects. J  Clin 
Invest 74:2164-2177, 1984
33. M a r s h  JB, D r a b k i n  DL: Experimental reconstruction of meta­
bolic pattern of lipid nephrosis: Key role of hepatic protein synthe­
sis in hyperlipidemia. Metabolism  9:946-955, 1960
34. A p p e l  GB, B lu m  CB, C h i e n  S, K u n is  CL, A p p e l  AS: The 
hyperlipidemia of the nephrotic syndrome: Relation to plasma 
albumin concentration, oncotic pressure and viscosity. N  Engl J  
M ed  312:1544—1548, 1985
35. K a y s e n  GA, G a m b e r t o g l i o  J, F e l t s  J, H u t c h i s o n  FN: Albu­
min synthesis, albuminuria and hyperlipemia in nephrotic patients. 
Kidney Int 31:1368-1376, 1987
36. Y a m a d a  M, M a t s u d a  I: Lipoprotein lipase in clinical and exper­
imental nephrosis. Clin Chim A cta  30:787-794, 1970
37. H y m a n  LR, W o n g  PWK, G r o s s m a n  A: Plasma lipoproteins in 
children with idiopathic nephrotic syndrome. Pediatrics 44:1021- 
1024, 1969
38. G a r b e r  DW, G o t t l i e b  BA, M a r s h  JB, S p a r k s  CE: Catabolism, 
of veiy  low density lipoproteins in experimental nephrosis. J  Clin 
Invest 74:1375-1383, 1984
39. C h a n  MK, V a r g h e s e  Z, P e r s u a d  JW, M o o r h e a d  JF: Post­
heparin hepatic and lipoprotein lipase activity in nephrotic syn­
drome. A ust NZ J  M ed 14:841-847, 1984
40. R o s e n m a n  RH, B y e r s  SO: Lipoprotein lipase metabolism in 
experimentally nephrotic rats. Proc Soc Exp M ed Biol 103:31-36, 
1960
41. C a l a n d r a  S, G o t t a r d i  E, T a r u g i  P: Plasma post-heparin lipo­
lytic activity in rats with nephrotic syndrome. Horm M etabol Res 
15:361, 1983
42. O e t l i k e r  OH, M o r d a s i n i  R, L u t s c h g  J, R i e s e n  W: Lipoprotein 
metabolism in nephrotic syndrome in childhood. Pediatr Res 14: 
64-66, 1980
43. K a s h y a p  ML, S r i v a s t a v a  LS, H y n d  BA, B r a d y  D, P e r i s u t t i  
G, G l u e c k  CJ, G a r t s i d e  PS: Apolipoprotein CI1 and lipoprotein 
lipase in human nephrotic syndrome. Atherosclerosis 35:29-40, 
1980
44. F u r u k a w a  S, H i r a n o  T, M a m o  JCL, N a g a n o  S, T a k a h a s h i  T: 
Catabolic defect of triglyceride is associated with abnormal very- 
Iow-dcnsity lipoprotein in experimental nephrosis. Metabolism  
39:101-107, 1990
45. S t a p r a n s  I, A n d e r s o n  CD, L u r z  FW, F e l t s  JM: Separation of 
a lipoprotein lipase co-factor from the alpha-1 acid glycoprotein 
fraction from the urine of nephrotic patients. Biochim Biophys Acta  
617:514-523, 1980
46. S h a f r i r  E, B r e n n e r  T: Lipoprotein lipid and protein synthesis in 
experimental nephrosis and plasmapheresis. 1: Studies in rat in 
vivo. Lipids 14:695-702, 1979
47. B r e n n e r  T, S h a f r i r  E: Lipoprotein lipid and protein synthesis in 
experimental nephrosis and plasmapheresis. II: Perfused rat liver. 
Lipids 15:637-643, 1980
48. C a l a n d r a  S, G h e r a r d i  WE, F a i n a r u  M, G u a i t a n i  A, B a r -  
t o s e k  I: Secretion of lipoproteins, apolipoprotein A-I and apolipo­
protein E by isolated and perfused liver of rat with experimental 
nephrotic syndrome. Biochim Biophys Acta  665:331-338, 1981
49. R a d d i n g  CM, S t e i n b e r g  D: Studies on the synthesis and secre­
tion of serum lipoproteins by rat liver slices. J  Clin Invest 39:1560— 
1569, 1960
50. M o o r h e a d  JF, W h e e l e r  DC, V a r g h e s e  Z: Glomerular struc­
tures and lipids in progressive renal disease. Am  J  M ed  87(suppl): 
5-12N, 1989
51. T a s k i n e n  M-R, P a c k a r d  CJ, S h e p h e r d  J: Insulin therapy 
changes the metabolic fate of apolipoprotein B (apoB) containing 
lipoproteins in non-insulin dependent diabetes. Diabetes 39:1017- 
1027, 1990
52. G r u t z m a c h e r  P, M a r z  W, P e s c h k e  B, G r o s s  W, S c h o e p p e  W: 
Lipoproteins and apolipoproteins during the progression of renal 
disease. Nephron 50:103-111, 1988
53. C r y e r  DR, M a t s u s h im a  T, M a r s h  JB, Y u d k o f f  M, C o a t e s  
PM, C o r t n e r  JA: Direct measurement of apolipoprotein B syn­
thesis in human very low density lipoprotein using stable isotopes 
and mass spectrometry. /  Lipid Res 27:508-516, 1986
Low-Density  Lipoprotein Metabol ism in the Nephrotic Syndrome
Graham L. W arwick, Muriel J. Caslake, J. Michael Boulton-Jones, Morag Dagen, Christopher J. Packard,
and James Shepherd
Hyperlipidemia is a consisten t feature of th e  nephrotic syndrom e. In this study, low -density lipoprotein (LDL) m etabolism  
has been investigated in nine patients w ith nephrotic syndrom e and varying degrees of proteinuria. In subjects with  
m oderate proteinuria (less than 10 g /d ), total plasma cholesterol values w ere elevated to  approxim ately 160% of normal 
due mainly to an increase in circulating LDL cholesterol. M etabolic studies show ed that a defect in LDL clearance via the  
receptor pathway w a s responsible for its accum ulation. The total amount of LDL apolipoprotein catabolized by this 
m echanism  w as only 55% of the value seen  in controls; 60% more LDL w as channelled into alternative, receptor- 
independent, catabolic pathw ays. Heavier proteinuria w a s associated  with substantial increases in plasma triglyceride and 
very-low -density  lipoprotein (VLDL) levels. The d efect in LDL catabolism  w as aggravated by oversynthesis of the  
lipoprotein, which expanded the plasma LDL pool to 250% of normal. T hese observations indicate that the hyperlipidemia of 
the nephrotic syndrom e is multifactorial in origin. The altered catabolism  of LDL may be important in predisposing th ese  
subjects to prem ature atherosclerosis.
© 1990 b y  W.B. Saunders Com pany.
HYPERLIPIDEMIA is a consistent feature of the ne­phrotic syndrome. Individuals with persistent nephro­
sis have elevated plasma cholesterol levels that are consid­
ered to contribute to the accelerated atherosclerosis prevalent 
in this condition.1'3 More recently it has been proposed that 
hyperlipidemia is an important factor in the progression of 
chronic renal failure'* and this is currently the subject of 
much research. However, the mechanisms responsible for the 
hyperlipidemia in the nephrotic syndrome remain poorly 
understood.
Characteristically, total and low density lipoprotein (LDL) 
cholesterol are elevated in all subjects, while those with 
heavier proteinuria or marked hypoalbuminemia often dem­
onstrate significant increases in triglyceride and very-low- 
density lipoprotein (VLDL) cholesterol.5,6 The “cardiopro­
tective” high density lipoprotein (HDL) fraction has variously 
been reported to be increased, decreased, or normal.5'8
The regulation of plasma LDL level is complex—both 
synthetic and catabolic mechanisms playing important mod­
ulatory roles. Much of our present understanding of the 
cellular metabolism of LDL stems from the work of Gold­
stein and Brown.9 They identified the specific, high affinity, 
LDL receptor on cell membranes, which plays a central role 
in controlling the delivery and uptake of cholesterol by cells. 
In normal individuals, this receptor pathway accounts for 
about half of LDL catabolism while in familial hypercholes­
terolemia, deficient or absent receptor activity is associated 
with raised plasma LDL cholesterol levels and a substan­
tially increased risk of premature atherosclerosis. In the 
presence of diminished receptor-mediated LDL removal, 
excessive amounts of the lipoprotein are channelled into 
alternative and, as yet, poorly defined, receptor-independent 
pathways that may involve the phagocytic system.9
The pathophysiological disturbances responsible for the 
hyperlipidemia of the nephrotic syndrome have not been 
clearly elucidated. Work on animal models10' 12 has indicated 
that increased hepatic lipoprotein synthesis may be the major 
metabolic abnormality but considerable differences in lipopro­
tein metabolism between species make direct comparison 
with human nephrotic syndrome difficult. However, some 
studies in humans have also suggested that oversynthesis is
the most important disturbance in generating the hyper­
lipidemia.7,13
The aim of this study was to determine whether the 
accumulation of LDL in the nephrotic syndrome was a result 
of hepatic oversynthesis or decreased catabolism of the 
lipoprotein. In addition, the relative contributions of the two 
pathways responsible for LDL catabolism (receptor-medi­
ated and receptor-independent) were examined as this may 
have important implications both for the pathogenesis of the 
hyperlipidemia and in assessing cardiovascular risk.
MATERIALS AND M ETHODS
S u bjects
Nine patients (seven male, two female), aged between 30 and 66 
years, gave informed consent to this study. They were recruited from 
the outpatient population attending the Renal Unit of Glasgow 
Royal Infirmary according to the following criteria; (1) serum 
creatinine < 300 ^mol/L, (2) quantitative proteinuria consistently > 
5 g/d, (3) total plasma cholesterol > 7 mmol/L.
Subjects suffering from other diseases or on treatment that might 
significantly alter plasma lipids were excluded. These included 
neoplastic and untreated endocrine disorders, diabetes mellitus, 
amyloidosis, systemic lupus erythematosis, or corticosteroid therapy. 
Women of child-bearing age were also excluded. Treatment with 
diuretics or antihypertensives was not considered an exclusion 
criteria. All subjects had an established histological diagnosis and 
were under regular renal review. No patient had a family history of 
premature vascular disease and there were no external stigmata of 
hyperlipidemia.
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Part o f this work was presented at the Scottish Society for 
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Table 1. Clinical Details of Nephrotic Subjects
Age Weight Body Mass Renal Follow-up
Patient Sex (yr) (kg) Index (kg/m2) Histology (yr) Treatment
RG M 54 77 2 4 .0 M embranous 1 Bendrofluazide
J J M 51 71 2 3 .2 FSGS 6 Frusamide, enalapril
MM F 55 70 28 .8 MCGN type II 7 Frusemide, enalapril
BT M 52 59 19.7 M embranous 1 Frusemide
RM M 30 107 3 1 .8 M embranous 0 .5 None
Frusemide, nifedipine.
DE M 53 70 25.1 Membranous 1 spironolactone
MJ F 65 49 2 2 .7 M embranous 1 Frusemide
EA M 66 96 3 9 .4 M embranous 1 Frusemide, isosorbide
JB M 3 0 63 20 .9 Membranous 1 Frusemide
Mean(SD) 51(13) 74(18)
Controls (all male, n =  8) 26(6) 71(12)
Abbreviations; FSGS, focal segm ental glomerulosclerosis; MCGN, mesangio-capillary glomerulonephritis.
The clinical and biochemical features of the study subjects are 
listed in Tables 1 and 2. Eight normal volunteers were also studied. 
The study conformed to the requirements of the Ethical Committee 
of Glasgow Royal Infirmary.
P rotocol
LDL apolipoprotein metabolism was examined in the nephrotic 
subjects according to previously published procedures.1415 Briefly, 
blood was withdrawn after an overnight' fast and used to produce 
LDL (1.030 < d < 1.050 g/mL) by rate zonal ultracentrifugation.
Table 2. Biochemical Features of Nephrotic Subjects
P a tie n t
S eru m
C rea tin in e
(/im ol/L )
C rea tin in e
C le a ran ce
(m L /m in)
S e ru m
A lbum in
(g/L)
Q u a n ti ta t iv e
P ro te in u ria
(g /d )
RG 122 (9.5) 8 6 .0  (5.7) 23 6.1 (1.0)
J J 2 2 4  (8.4) 3 9 .3  (3.9) 25 5 .2  (1.3)
MM 123 (10.0) 4 5 .0  (6.0) 3 0 6 .6  (1.3)
BT 106 (8.5) 6 3 .0  (11.0) 25 5 .4  (1.5)
RM 107 (4.2) 11 5 .0  (18.5) 3 4 9 .7  (3.4)
DE 95  (9.3) 8 4 .0  (14.0) 2 0 15.3  (4.3)
MJ 2 39  (14.0) 17.6 (2.1) 18 11.9 (2.1)
EA 127 (7.2) 7 5 .0  (8.0) 28 12 .0  (2.3)
JB 102 (4.6) 8 4 .8  (5.6) 21 18 .0  (6.0)
Mean(SD) 138 (54) 6 7 .7  (29.7) 25  (5) 10 .0  (4.6)
Controls (n =  8) 100 (5.7) 10 2 .4  (7.1)
NOTE. Serum albumin w as determ ined a t s ta rt of study. Other values 
represent m ean (SD) of daily m easures throughout the  study period.
This was then dialyzed against 0.15 mol/L N aC l/0.01 % Na2EDTA/ 
0.01 mol/L Tris, pH 7.4, and divided into two aliquots that were 
labeled16 with m I and l2SI. Unbound iodide and glycine buffer were 
removed by gel filtration.15 After this maneuver, more than 98% of 
the radioactivity was covalently bound to apolipoprotein LDL. The 
l3lI-LDL tracer fraction was then treated with 1,2-cyclohexanedione 
(CHD), which blocks the arginyl residues of apolipoprotein B of 
LDL and prevents receptor binding.17 The modified LDL is other­
wise indistinguishable from native LDL and is handled as such by 
other metabolic pathways. Twenty-five f id  of each isotope were 
administered intravenously (IV) to their respective donors after 
sterilization through a 0.22 micron filter (Millipore UK, London). 
Exact weighing of syringes before and after injection permitted 
calculation of the dose administered. A blood sample was drawn at 
10 minutes and then daily for 14 days. Subjects collected all their 
urine and the completeness of each day’s collection was checked by 
measuring creatinine excretion. Two-milliliter aliquots of plasma 
and urine samples were stored for counting in a scintillation counter 
(Packard Instruments, Oberlin, OH) at the end of the study period. 
Urine samples were treated with trichloroacetic acid (1 vol urine;3 
vol 20% TCA) to precipitate undegraded LDL lost directly into the 
urine and the radioactivity in the precipitate measured.
Studies were performed on outpatients eating a normal West of 
Scotland diet. None had been prescribed a specific diet as a result of 
their renal disease. Plasma lipid and lipoprotein levels were checked 
serially and did not alter significantly (ie, within 10% of mean value) 
over the study period indicating apolipoprotein B metabolism was in 
a steady state. Plasma cholesterol, triglyceride, and lipoprotein
Table 3. Plasma Lipid and Lipoprotein Concentrations in Control and Nephrotic Subjects
T o ta l VLDL LDL HDL
C h o le s te ro l T rig lyce ride  C h o le stero l C h o le s te ro l C h o le ste ro l
(m m ol/L ) (m m ol/L ) (m m ol/L ) (m m ol/L ) (m m ol/L )
RG 8.5  (0.2) 2.1 (0.1)
J J 7 .5  (1.0) 3.1 (0.7)
MM 8 .4  (0.4) 2 .2  (0.1)
BT 10.3 (0.2) 2 .9  (0.5)
RM 9 .4  (0.1) 2 .2  (0.1)
DE 14.1 (0.7) 4 .3  (0.5)
MJ 12.1 (0.4) 5 .5  (0.8)
EA 9.6  (0.4) 5 .6  (0.2)
JB 16.7 (1.8) 4 .9  (0.6)
Mean(SD) 10.7 (3.0) 3 .6  (1.4)
Controls 5 .2  (1.0) 1.2 (0.5)
1.1 (0.1) 6 .3  (0.2) 1.2 (0.1)
1.8 (0.6) 4 .8  (1.3) 0 .9  (0.1)
1.1 (0.1) 6.1 (0.4) 1.3 (0.2)
1.4 (0.3) 7 .5  (0.4) 1.5 (0.1)
0 .9  (0.2) 7 .0  (0.3) 1.4 (0.1)
2 .5  (0.9) 10.2  (0.6) 0 .9  (0.1)
2 .8  (0.4) 8 .5  (0.7) 0 .8  (0.1)
4 .2  (0.2) 4 .6  (0.3) 0 .7  (0.1)
2 .9  (0.9) 12.9 (1.1) 0 .9  (0.2)
2.1 (1.1) 7 .5  (2.7) 1.1 (0.3)
0 .6  (0.2) 3.1 (0.6) 1.6 (0.3)
NOTE. Values are mean(SD) of three separate determ inations over the study period.
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Fig 1. Relationships between plasma cholesterol, LDL choles­
terol, plasma triglyceride, and proteinuria in the nephrotic syn­
drome. All three lipid parameters showed positive correlations 
with daily protein loss. Linear regression analysis gave the follow­
ing relationships: (A) plasma cholesterol versus proteinuria, y =  
4.84 + 0.59x, r =  .90, P < .0005; (B) plasma triglyceride versus 
proteinuria, y =  1.39 + 0.22x, r =  .72, P < .01; (C) LDL 
cholesterol versus proteinuria, y =  3.07 + 0.45x, r=  .77, P < 
.002.
cholesterol were measured according to the Lipid Research Clinic’s 
standard procedures.18 Plasma LDL apolipoprotein levels were 
determined from the compositional analysis of the 1.019 to 1.063 
g/mL LDL fraction.15
Kinetic Analysis
The plasma and urine radioactivity were used to calculate the 
plasma fractional catabolic rate (FCR)— ie, the fraction of the 
intravascular LDL pool catabolized per day— using the SAAM  
compartmental modeling program.19 A two-compartmental model 
containing intra- and extravascular pools was used, together with
two urinary excretion pathways—one for loss of intact or partially 
degraded LDL (ie, TCA-precipitable) and the other for degraded 
radioactivity. Both the native and the CHD-modified LDL fractional 
catabolic rates were corrected in this manner.
Native LDL acts as a tracer for total LDL catabolism while the 
modified LDL is cleared by receptor-independent mechanisms. The 
difference between the two clearance rates is, therefore, a measure of 
receptor-mediated clearance. From a knowledge of the intravascular 
apolipoprotein B pool size (calculated from apoLDL plasma concen­
tration and plasma volume derived from the dilution of the injected 
LDL at 10 minutes) the absolute catabolic rate was obtained. In a 
steady state, this is equal to the production rate and this is 
conventionally expressed as milligram of apoLDL per kilogram of 
body weight per day.
Statistical analyses were performed using Student’s t test to 
compare differences between groups. Correlations were performed 
by linear regression analysis.
RESULTS
The patients in this study had marked elevations of total 
cholesterol and triglyceride (Table 3) in accord with previous 
reports in the nephrotic syndrome.5 :o'23 Plasma LDL choles­
terol was elevated in all nine subjects. Triglyceride levels and 
VLDL cholesterol were only marginally increased compared 
with controls in those subjects with moderate proteinuria (5 
to 10 g/d), whereas in the group with heavier proteinuria 
(DE, MJ, EA, JB) much higher values were found. HDL 
levels tended to be lower in the latter group and overall were 
significantly lower compared with normals. Urinary protein 
loss was positively correlated with total cholesterol, LDL 
cholesterol, and triglyceride (Fig 1).
There were differences in the composition of LDL between 
controls and subjects with nephrotic syndrome. Protein, 
phospholipid, and esterified cholesterol content were un­
changed but LDL triglyceride was increased (11.4% SD 
3.1% v 7.8% SD 1.2%, P < .01) while free cholesterol fell 
(6.9% SD 2.1% v 12.1% SD 1.2%, P < .001).
LDL Apolipoprotein Kinetics
There was a significant reduction in the FCR of LDL in 
nephrotic subjects compared with controls (0.219 SD 0.061 v
0.384 SD 0.057 pools/d, P < .001; Table 4). This was almost 
entirely due to a reduction in the activity of the receptor- 
mediated clearance pathway. Clearance by this route was 
reduced by 70% in the nephrotic subjects (0.050 SD 0.026 
pools/day v 0.165 SD 0.051, P < .001). There was a smaller 
reduction in the receptor-independent FCR (0.169 SD 0.043 
v 0.219 SD 0.039 pools/day, P < .05; Table 4). The FCRs 
were corrected for measured urinary losses of “ intact” LDL, 
ie, TCA-precipitable. This accounted for a small proportion 
(1% to 5%) in four subjects but was a potentially significant 
source of error (5% to 16%) in the remainder. The percentage 
urinary loss of TCA-precipitable radioactivity was similar 
for both l25I-native LDL and l3lI-CHD modified LDL. The 
mean value is given in Table 4. This adjustment, therefore, 
did not alter the balance between receptor-mediated and 
receptor-independent clearance.
Overall, the mean absolute catabolic rate (ACR) was 
increased but this was not a uniform finding in the study 
group. Those patients with moderate proteinuria -(patients
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Table 4. Kinetic Parameters Describing apoLDL Turnover in Control and Nephrotic Subjects
Plasma
apoLDL
(mg/dL)
% Urinary* 
Loss
Fractional Catabolic Ratef 
(pools/d)
Absolute Clearance Rate$ 
(mg/kg/d)
Total
Receptor
Independent
Receptor
Mediated Total
Receptor
Independent
Receptor-
Mediated
Patient
RG 2 2 4 2 .0 0 .1 8 8 0 .1 4 5 0 .0 4 3 18.1 14.0 4.1
JJ 118 .1.2 0 .2 9 2 0 .2 1 0 0 .0 8 2 12.8 9 2 3 .6
MM 2 1 5 15.7 0 .1 6 3 0 .1 3 7 0 .0 2 6 12.0 10.5 2 .2
BT 2 4 4 6 .9 0 .1 4 0 0 .1 2 0 0 .0 2 0 14.0 12.0 2 .0
RM 2 38 7.5 0 .2 3 7 0 .2 1 9 0 .0 1 8 19.5 18.0 1.5
DE 347 4 .5 0 .181 0 .1 2 7 0 .0 5 4 2 9 .6 20 .8 8 .8
MJ 279 4 .4 0 .2 4 2 0 .1 7 7 0 .0 6 5 2 7 .2 19.9 7.3
EA 171 8 .0 0 .3 2 5 0 .2 3 6 0 .0 8 9 2 2 .2 16.1 6.1
JB 427 12.6 0 .2 0 0 0 .1 4 8 0 .0 5 2 3 5 .3 2 6 .2 9.1
Mean 251 6 .9 0 .2 1 9 0 .1 6 9 0 .0 5 0 2 0 .7 16.3 4 .9
(SD) (92) (4.7) (0 .061) (0 .043) (0.026) (8.3) (5.5) (3.0)
Controls
Mean 93 0 .3 8 4 0 .2 1 9 0 .1 6 5 14.2 8.1 6.2
(SD) (12) (0 .057) (0 .039) (0.051) (2.3) (1.1) (2.1)
P§ < .001 < .0 0 1 < .0 5 < .001 < .0 2 < .0 5 NS
•Percentage of urinary radioactivity precipitated with trichloroacetic acid.
■(■Data is corrected for m easured urinary losses of protein-bound radioactivity.
J  Absolute clearance is the product of fractional clearance rate and plasm a pool size expressed per kilogram of body weight. 
§P  values represent differences betw een nephrotic and control groups.
RG, JJ, MM, and BT) cleared the same amount of LDL 
each day as controls while in those with urinary protein losses 
of greater than 10 g/d, this amount was substantially 
increased. There was a strong positive correlation between 
the level of proteinuria and the overall ACR (Fig 2, r =  .929, 
P < .00005). Since in steady state conditions catabolism and 
synthesis are equal, this implies that apoLDL synthesis is 
directly related to proteinuria.
DISCUSSION
High levels of plasma lipids are found in individuals with 
the nephrotic syndrome. The development of this secondary 
hyperlipidemia appears to be independent of the underlying 
renal disease but directly related to the degree of proteinuria 
and/or hypoalbuminemia. Previous investigations of the
lipid and lipoprotein profiles of nephrotic patients have 
revealed a pattern of abnormalities5,20,21 that was also present 
in our subjects. Mild to moderate proteinuria (generally with 
serum albumin greater than 20 g/L ) is primarily associated 
with hypercholesterolemia due to raised LDL levels and its 
degree is proportional to measured urinary protein loss. 
Heavier proteinuria (in excess of 10 g/d) is associated with 
an increase in VLDL cholesterol and triglyceride levels, 
further rises in LDL, and a decrease in plasma HDL 
cholesterol. Several reports20"23 recorded falls in a specific 
HDL sub-fraction—HDL2 (d =  1.063 to 1.125 g/m L)—but 
this is not a universal finding.24 Clearly, the alterations in 
lipoprotein transport caused by the nephrotic syndrome are 
complex and multiple mechanisms are involved in their 
etiology.
40 n
30-
20-
quantitative proteinuria (g/day)
Fig 2. Correlation between apoLDL syn­
thetic rate and daily urinary protein loss. 
Linear regression analysis provided the fol­
lowing relationship: y =  4.44 -f 1.68x, r =  
.93. P < .00005.
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The precise nature of the pathophysiological disturbances 
responsible for the hyperlipidemia of the nephrotic syndrome 
remains uncertain. Work on a rat model, using isolated liver 
perfusion and rat liver slices,10,11 has demonstrated a rise in 
lipoprotein synthesis. However, differences in lipoprotein 
metabolism between species make extrapolation to the hu­
man condition unreliable.
Early studies of triglyceride turnover6,25 and cholesterol 
synthesis6 in humans have suggested that hepatic overproduc­
tion of these lipids is a feature of the disease. Few metabolic 
investigations have followed the turnover of apolipoprotein 
B, the major protein component of VLDL and LDL, and the 
only constituent that is integral to both particles throughout 
their lifetime in the plasma. Pioneering work by Scott et al26 
and Gitlin et al27 suggested that human LDL catabolism was 
decreased in nephrotic syndrome. Scott et al reported values 
of 0.224 pools/d compared with 0.308 pools/d in normal 
subjects. However, this difference was not significant due to 
the wide variation in the control population (0.21 to 0.35 
pools/d) and these investigators were led to invoke increased 
synthesis as the main contributor to the high LDL levels in 
nephrotics. No corrections were made in their measurements 
for loss of intact or partially degraded LDL in the urine. 
Small amounts of LDL were found in the urine of these 
patients using an immunoassay method. In addition, the 
injected tracer contained 2% to 9% nonprotein bound iodide. 
Both these factors may have falsely increased the FCR of the 
lipoprotein. Two more recent studies of small groups of adult 
nephrotics13,28 reported virtually normal FCRs for radiola­
beled LDL and concluded that the most important change 
was increased synthesis of this lipoprotein. However, the 
investigators again did not correct for urinary loss of protein- 
bound radioactivity which, if as extensive as we have found 
(up to 16%), would cause a substantial overestimate of the 
FCR from the plasma compartment. The level of proteinuria 
in their subjects was comparable with that of our group. The 
most consistent finding in the present study was an overall 
reduction in the mean FCR for apoLDL (0.219 SD 0.061 v 
control values of 0.384 SD 0.057 pools/day) although the 
range is wide and encompasses most of the results seen in the 
previous studies.13,26,27 The reduced clearance rate was prima­
rily due to a fall in catabolism via the LDL receptor pathway 
(0.050 v 0.165 pools/day in normals, Table 4). Indeed, the 
values seen in these nephrotics are similar to those observed 
in heterozygous familial hypercholesterolemia.14,29,30
Several mechanisms might result in suppression of LDL
receptor activity in the nephrotic syndrome. Golper et al31 
have shown that, in experimental nephrosis in the rat, 
reduced renal clearance of plasma mevalonate led to in­
creased hepatic cholesterol synthesis from this precursor. 
Expansion of the intrahepatic sterol pool (as suggested by 
animal studies11) would reduce LDL receptor activity. An 
alternative explanation is that nephrosis modifies the binding 
capability of LDL by altering the conformation of apoB on 
the particle’s surface as has been reported in patients with 
chronic renal failure maintained on dialysis.32 Certainly, in 
other situations, LDL with an increased triglyceride content 
binds less well to fibroblast receptors in vitro.33
In the four subjects with moderate proteinuria (RG, JJ, 
MM and BT) reduced LDL clearance was the main cause of 
the elevated plasma level (Table 4). The synthetic rate of the 
lipoprotein (mean value 14.4 m g/kg/d) was not significantly 
different from normals. Subjects with heavier proteinuria 
(DE, MJ, EA, and JB) exhibited a higher than normal 
apoLDL synthetic rate in addition to a lower FCR. As a 
group they also showed higher triglyceride and VLDL 
cholesterol levels suggesting that this additional apoB came 
via the VLDL-LDL delipidation cascade. The remaining 
subject (RM) showed an intermediate pattern.
The present study together with earlier work on lipopro­
tein patterns at different stages of the nephrotic syndrome5 
suggests that the hyperlipidemia is caused by at least two 
independent mechanisms. At moderate levels of proteinuria 
(less than lOg/d), LDL catabolism is impaired either due to 
reduced receptor activity or defective ligand-receptor interac­
tion. Above a proteinuria threshold of about 10 g/d, in­
creased LDL (and possibly VLDL) synthesis aggravates the 
hyperlipidemia and triglyceride levels rise, often to become 
the dominant abnormality. The factors that precipitate the 
increase in synthesis are uncertain, although there is some 
evidence to suggest that a decrease in circulating albumin or 
plasma oncotic pressure may be responsible by stimulating a 
general increase in hepatic protein synthesis.34 Finally, the 
effect of altered rates of lipoprotein synthesis and catabolism 
in nephrotic syndrome may be modified by postsecretory 
changes in lipoprotein particles.35 Reduced activity of lipo­
lytic and other enzymes has been recorded in nephrosis.36,37
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SUMMARY
Urinary albumin excretion was measured in a group of 141 otherwise 
healthy subjects attending a lipoprotein clinic to determine whether primary 
hyperlipidaemia was associated with evidence of early renal dysfunction. 
There was no evidence of increased urinary albumin concentrations or 
albumin:creatinine ratios when compared with data for normal controls. 
There were no differences in these parameters when the values for the 
upper and lower quartiles of the cholesterol distribution were compared and 
no relationship existed between plasma cholesterol and albuminuria. A 
weak association was shown between plasma triglyceride and urinary 
albumin concentration after log transformation of the data. We conclude that 
hyperlipidaemia per se is not associated with renal disease as measured by 
sensitive assays of albuminuria.
key words - hyperlipidaemia, lipoproteins, microalbuminuria 
running title - hyperlipidaemia and albuminuria
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INTRODUCTION
The factors responsible for the progressive nature of chronic renal 
disease have not been clearly elucidated. Recently it has been postulated 
that the hyperlipidaemia which accompanies proteinuric renal disease may 
play a role in the progressive decline in glomerular filtration rate (1). Studies 
in a number of experimental animal models of nephrotic syndrome and renal 
failure have shown that cholesterol feeding increases proteinuria and 
glomerulosclerosis and accelerates loss of GFR (2,3). Treatment of the 
hyperlipidaemia ameliorates these measures of renal damage. In man, an 
anecdotal report has suggested plasma cholesterol lowering may reduce 
proteinuria(4). Furthermore, renal disease has been documented in the rare 
familial lecithin cholesterol acyl transferase deficiency® and in association 
with morbid obesity®. Other primary hyperlipidaemias do not appear to 
impair renal function although this has not been studied in a comprehensive 
fashion. To assess the potential nephrotoxicity of hyperlipidaemia we have 
looked at urinary albumin excretion in a group of patients with primary 
hyperlipidaemia attending a lipoprotein clinic.
METHODS
The patients studied were attending routine appointments at the 
lipoprotein clinic at Glasgow Royal Infirmary between October 1989 and 
January 1990. Patients were excluded if there was evidence of other 
diseases associated with increased albuminuria. These were:- 
hypertension or recorded blood pressure above 170/95 mmHg , diabetes 
mellitus, thyroid disease or abnormal thyroid function tests, renal disease or 
raised serum creatinine, history of malignancy, pregnancy, rheumatoid 
arthritis or connective tissue disease and treatment with non-steroidal anti­
inflammatory drugs. Random urine samples were collected into empty sterile 
containers and stored at 4° C. Specimens were assayed between 4 and 10 
weeks following collection. Fasting blood samples were obtained for plasma 
lipid and lipoprotein levels and renal function was checked if this had not 
been done previously.
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Cholesterol and triglyceride were assayed using enzymatic 
colorometric methods on a Hitachi 717 discrete autoanalyser. Urinary 
albumin was assayed by a modification of the radioimmunoassay method 
described by Hutchison (7). The imprecision of this assay at a 
concentration of 12mg/L has been reported as <5%(within batch) and 
6.7%(between batch). For these studies the working lower limit of detection 
was taken as 1mg/L. Urinary creatinine estimation was carried out on a 
Hitachi 704 discrete autoanalyser using the Jaffe reaction.
Statistical analysis was performed using the Minitab microcomputer 
package. Urinanry albumin concentrations, urinary albumin:creatinine ratios 
and plasma triglyceride concentrations all demonstrated a markedly skewed 
distribution which became Gaussian on log transformation of the data.The 
relationships between plasma lipids and urinary albumin concentrations 
were tested by linear regression. A two-sample t test was used to compare 
albumin excretion in the upper and lower quartiles for plasma cholesterol 
concentrations.
RESULTS
Urine and plasma specimens were collected from 141 patients. 
Fasting plasma cholesterol levels for this group ranged from 4.15 to 
13.3mmol/l with a mean value of 7.73mmol/l. The distribution of urine 
albumin concentrations is shown in figure 1 and is highly skewed. The 
median urinary albumin concentration was 5.95mg/l (range <1.0- 48.5) and 
median albumin/creatinine ratio was 0.79mg/mmol (range <0.5 - 4.1). The 
normal range of urinary albumin excretion is difficult to define because of 
differences in methods of urine collection, subject preparation and inter­
assay variation. However, Watts et al(8) have quoted 29.6mg/L as the upper 
95% confidence limit for urinary albumin concentrations in untimed 
collections in ambulant subjects and only 2(ie 1.4%) of our results lie outwith 
this range. Similarly only 4/90(4.4%) had an albumin:creatinine ratio greater 
than the 95% confidence limits quoted in the same paper(0.1-2.3mg/mmol).
There was no relationship between plasma cholesterol and log 
transformed values of urinary albumin(figure 2) concentration or 
albumin/creatinine ratio (r2=0.9, p=0.9). Fasting triglyceride values also
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showed a markedly skewed distribution and after log transformation a weak 
relationship was demonstrated between triglyceride and urinary albumin 
concentration (figure 3). There was only a very weak correlation between 
albumin concentrations in urine and the urinary albumin:creatinine ratio 
(r2=5.7%; p=0.022) in contrast to Hutchison’s group of diabetic patients(7). 
There was however a clear relationship between these variables when we 
considered a group with high albumin concentrations in patients who were 
excluded on the basis of hypertension(data not shown).
Finally there was no difference in the urinary albumin concentrations 
(after log transformation) between the upper and lower quartiles of the 
plasma cholesterol distribution (0.735 SD 0.374 v 0.802 SD 0.286; p=0.4).
DISCUSSION
Increased urinary albumin excretion(’microalbuminura’) has been 
shown to predict the development of renal failure in diabetes mellitus(9).
The precise mechanisms responsible for the rise in urinary albumin levels 
are unclear. Increased glomerular filtration, decreased tubular reabsorption 
or both may occur. Elevated urinary albumin excretion rates have been 
found in a number of other conditions including hypertension(10), 
postoperatively(11) and psoriasis(12) and are thought to be an early 
indicator of renal dysfunction.
There has been recent interest in the role of lipids in the development 
of glomerulosclerosis or tubular injury(1-3). Hyperlipidaemia secondary to 
proteinuria or renal failure following an initial renal insult may be capable of 
promoting progressive renal injury. The precise mechanism is unknown 
although an increase in glomerular permeability due to neutralisation of 
anionic sites, mesangial cell accumulation of lipoproteins and tubular cell 
toxicity from filtered lipoproteins have all been proposed(1).
Most workers have used models where an initial renal injury is 
induced by toxic, immunological or surgical measures and investigated the 
role of hyperlipidaemia on the subsequent course of the disease. Little data 
exists on renal function in primary hyperlipidaemias. There are no reports of 
renal disease in familial hypercholesterolaemia or in the animal model of 
this disease, the Watanabe rabbit. However there are a number of primary
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disorders of lipid metabolism which have been associated with renal 
disease. Glomerulosclerosis develops in the spontaneously hyperlipidaemic 
obese Zucker rat(2)and has been reported in morbid obesity in man(6). We 
hypothesised that if hyperlipidaemia per se was capable of inducing renal 
damage in man then this might first be manifested as an increase in urinary 
albumin excretion.
We were unable to show any correlation between serum cholesterol 
concentrations and albumin excretion nor did we find a higher mean 
albumin excretion in the hypercholesterolaemic group. Mean values for 
albumin excretion compare closely to those obtained by other authors in 
normal patients using random or timed samples(8,13). Data for random 
urine samples are limited. They may produce elevated results in patients 
with orthostatic proteinuria or following exercise particularly in the diabetic 
patient and are therefore not ideal for prognostic use in this group(13). There 
is no evidence that they may produce low results. The absence of an 
association between albumin concentration and albumin:creatinine ratio 
contrasts with previous studies and our own observations on subjects 
excluded from the current study. This can most probably be explained by the 
consistently low levels of albuminuria. The albumin:creatinine ratio is 
consequently dependent to a greater degree on the urinary creatinine 
concentration than in those with higher albumin concentrations.
The signifigance of the weak relationship between the log 
transformed values of plasma triglyceride and urinary albumin concentration 
is uncertain. This may reflect variability in other factors(eg obesity, blood 
pressure) which may influence albumin excretion.
We conclude that primary hyperlipidaemia is not associated with 
increased urinary albumin excretion. If hyperlipidaemia has a role in the 
progression of renal disease this must be as a secondary permissive effect 
following renal injury rather than an initiating factor.
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LEGENDS
Figure 1: The frequency distribution of urinary albumin concentration in 
study population(n=141).
Figure 2: The relationship between plasma cholesterol and log urinary 
albumin concentration (r2=0.9%, p=0.91).
Figure 3: The relationship between the log transformed values of plasma 
triglyceride and urinary albumin concentration(r2=3.1%, p<0.05)
8
urinary 
album
in 
concentration(m
g/L)
o
coo
o
cn
o
• • • •
• • • •
CM
O
• •
00
• •
• ••
CO
oCM
uoi}BJ}U0Ouoo uiiunqiE Ajeuun 6o|
pl
as
m
a 
ch
ol
es
te
ro
l(
m
m
ol
/l
)
log 
plasm
a 
triglyceride
log urinary albumin concentration
o
cn
o
o • •
• ••
• ••
In
